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ABSTRACT 
Despite the existence of vaccinations, diagnostic tools and treatments, tuberculosis 
(TB) prevalence is increasing because of the circulation of people and misuse of 
antibiotics, giving rise to growing numbers of drug resistant strains of 
Mycobacterium tuberculosis. There is therefore a pressing need to look for new 
strategies against TB, in the hope of finding new drugs with novel mechanisms of 
anti-tubercular action or ways to potentiate the activity of already existing drugs and 
reduce treatment duration.  
This thesis explores the employment of peptides in anti-tuberculosis therapy. The 
project was initiated by the identification of a novel therapeutic target in M. 
tuberculosis: murein peptide ligase (Mpl, Rv3712), an enzyme involved in the 
bacterial peptidoglycan recycling process. The aim is to synthesise its putative 
natural substrates (peptidoglycan peptide fragments) to characterise its activity and 
synthesise sequence analogues. These analogues were tested on the whole-cell 
and will be evaluated for inhibitory activity on the recombinant Mpl enzyme and 
eventually could be used in combination with existing or new drugs to see whether 
they increase anti-tubercular potency and thus combat resistance. Attainment of the 
putative substrate required the synthesis of mDAP, an unusual amino acid unique to 
peptidoglycan. Its synthesis was successfully completed and it was incorporated in 
the tripeptide Mpl putative substrate. 
Solid-phase synthesis has been used successfully and proved effective for rapid 
synthesis of multiple short peptide analogues in parallel. In addition it was used to 
synthesise anti-tuberculosis lasso peptides, lariatins A and B, lassomycin and 
analogues, to evaluate the structural requirements for biological activity. 
The method for the heterologous expression and purification of recombinant Mpl 
from M. tuberculosis has been confirmed as successful, and the enzyme is available 
for future target-based evaluation using the synthesised mDAP-containing tripeptide 
and eventually for other mDAP-containing PG fragments and analogues.  
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1. INTRODUCTION 
1.1 The burden of infectious diseases 
After the onset of the antibiotics golden era, the world witnessed a surge in the 
discovery and development of such compounds; nonetheless the past couple of 
decades has seen a decline in antimicrobial production rate (1). Oddly this has 
coincided with the widespread use and misuse of antibiotics in previous years, 
which triggered the development of bacterial resistance to those agents. The drugs 
provided microorganisms with selective pressure, challenging their ability to survive 
the inhospitable conditions created by the use of antibiotics and rewarding those 
that evolved accordingly. The rate of appearance of resistant mutants has been 
steadily increasing, and in this light the unlikelihood of such drugs bringing profit in 
the long term and especially the financial and time resources needed to bring them 
to market seems to have driven most major pharmaceutical companies to reduce 
their investment in antibiotic R&D departments (1). This is counterproductive as the 
urgent need for new antimicrobial agents has actually increased proportionally. 
Major infectious diseases such as tuberculosis (TB) and the ones caused by 
‘ESKAPE’ pathogens have become extremely detrimental to human health and 
wellbeing. This acronym, coined by the Infectious Diseases Society of America 
(IDSA), refers to Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter 
spp. (1). These organisms are widespread and common causes of nosocomial 
infections, but, as they are able to escape antibiotic action and became pan-
resistant, they represent a mounting clinical burden for the future, especially for 
immunocompromised patients (2). Mycobacterium tuberculosis also poses a serious 
threat as it is still one of the major deadly diseases in the world (3). It is in this 
perspective that the quest for investigating multiple ways of dealing with infections 
and bacterial resistance becomes fundamental.  
1.1.1 Tuberculosis   
TB is an ancient disease that, despite an important decrease (47%) in mortality 
between 1990 and 2014, is still one of the biggest global health threats (3). WHO 
estimated 9.6 million new cases in 2014 and the yearly death toll is still well above 1 
million (3). M. tuberculosis, identified as the tuberculosis causative agent in 1882 by 
Robert Koch, is a slow growing acid-fast bacterium. Despite the absence of an outer 
membrane, it does not retain the typical crystal violet dye used to differentiate Gram 
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negative and positive organisms. This happens as a result of a layer of mycolic 
acids and other complex lipids that covers the outer surface of the bacterium, 
conferring upon it a waxy consistency. The alternative Ziehl-Neelsen stain is very 
specific towards mycobacteria (and some Protozoa). The carbol fuchsin component 
of the stain penetrates and stains red any cell, but after the use of a destaining 
solution, only the “acid-fast” bacteria are able to retain it due to their mycolic acid 
layer. The latter is one of the peculiar features of mycobacteria. The extra layer, and 
the relatively lower peptidoglycan (PG) content (similarly to that found in Gram 
negative organisms) are characteristics of this bacterium. 
 
Figure 1.1 Mycobacterium sp. (1000x) stained following Ziehl-Neelsen staining 
protocol  
TB is an air-borne disease of bacterial origin, transmitted through the aerosol 
droplets exhaled by an individual with active pulmonary disease, while sneezing, 
coughing or talking. There have been a limited number of cases reported in which 
transmission occurred through infected milk from cattle (4). 
After entering the body via the respiratory system the bacteria settle in the lungs, 
which generally become the primary site of the infection. The bacteria then multiply, 
causing the initiation of an immune response from the host (5,6). Activated 
macrophages, deputed to kill and digest pathogens, ingest the bacteria, then 
fibroblasts are recruited that envelope the phages causing the formation of 
tubercles. However M. tuberculosis is often able to survive and multiply inside the 
macrophage, resisting the low pH and the oxidative species produced by the 
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phagocytes (7). This appears to happen as a result of the cell-wall glycolipids, which 
are able to absorb hydroxyl radicals and superoxide anions. The ability of M. 
tuberculosis to enter a dormant state with a lower metabolic activity, allows it to 
survive under difficult conditions and reactivate later, making TB a disease 
particularly prone to relapses. In individuals with a low resistance, such as children, 
elderly people and immunocompromised patients, therefore, the multiplication of the 
bacteria is uncontrolled, leading to an acute pulmonary infection that causes 
extensive destruction of lung tissue and the spread of the infection to other parts of 
the body (extra-pulmonary TB), typically ending in death. Despite this possibility, 
generally the infection remains localised and unapparent. In most cases an initial 
infection is sufficient to cause hypersensitisation of the individual to the bacteria and 
their products, subsequently altering the response in the case of further post-primary 
infections by M. tuberculosis (5). In general, cell-mediated immunity is a lifelong 
protection, although there is still the possibility of reinfection from other sources or 
due to reactivation of dormant bacteria in the lungs’ macrophages (6,8,9). The 
typical clinical symptoms of the disease are chronic cough with blood-tinged sputum, 
fever, sweats, decreased appetite and weight loss. Given the role played by the 
immune system it is easy to imagine why immunocompromised patients such those 
infected with HIV are the biggest risk group. In fact TB is one of the main causes of 
death among these individuals (3). 
If untreated, TB infection can lead to death. It is important to note how almost 90% 
of new cases occur in South-East Asia, Western Pacific countries and Africa (3) – 
countries affected by social and geographical (humid tropical weather) conditions 
that lead to low levels of hygiene, greater difficulties in accessing therapy, poor 
compliance and support. A larger pool of HIV cases also makes these countries 
more susceptible to TB burden. 
1.1.2 Current treatment of tuberculosis 
The current standard treatment for patients that have never been previously treated 
– and therefore initially assumed to be infected with a susceptible strain – consists 
of two months’ therapy with isoniazid 1 (INH), ethambutol 2, pyrazinamide 3 (PZA) 
and rifampicin 4. The continuation phase consists of four further months of isoniazid, 
rifampicin and ethambutol treatment. The doses have to conform to international 
recommendations.  
Isoniazid 1, a prodrug, and ethambutol 2 inhibit cell-wall synthesis, the former by 
interfering with the biosynthesis of mycolic acids, the latter by inhibiting the enzyme 
arabinosyl transferase, which contributes to the synthesis of arabinolactan (10). 
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Rifampicin 4, an ansamycin, acts differently, inhibiting RNA synthesis by binding to 
the β-subunit of DNA-dependent RNA polymerase therefore inhibiting the elongation 
of mRNA (11,12). 
Pyrazinamide 3 is a prodrug activated intracellularly by pyrazinamidase PncA, which 
hydrolyses the primary amide to give the carboxylic acid derivative pyrazinoic acid 
(POA). It is the only drug active against non-replicating persisters; its effect on the 
growing bacilli is negligible and it works with maximum efficacy at acidic pH and low 
metabolic conditions. Its exact mechanism of action is not clear.  
 
 
Figure 1.2 First-line anti-TB drugs 
One hypothesised mechanism suggested the inhibition of fatty acid synthetase I 
(FAS I), involved in the elongation of mycolic acids, but this has been recently 
questioned (13). A model suggested by Zhang et al. 2014 (13) considers the main 
mechanism of action to be the acidification of the cytoplasm leading to the inhibition 
of the correct functioning of certain cellular enzymes (13,14). In this model, PZA 
passively enters the cell where PncA activates it to POA, which gets ejected by an 
efflux system; once outside, at acidic pH, POA gets protonated to HPOA and re-
enters the cell. There it releases protons, acidifying the intracellular environment, 
and being then in anionic form can only be ejected through efflux pumps. The 
inward permeation rate of HPOA is greater than the efflux of POA, which causes 
accumulation of the active drug inside the cell. This seems to be rendered possible 
because of an efflux system deficient in M. tuberculosis, this seemingly being the 
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reason for which other mycobacteria species are not susceptible to PZA (15). The 
intracellular acidification and accumulation of POA together with the energy expense 
to fuel the efflux pump, eventually causes cell death,  via disruption of the 
membrane potential and inhibition of essential enzymes (13). This model is 
supported by the fact that PZA works against M. tuberculosis only and other 
Mycobacteria contain altered forms of PncA (12). Intracellular POA seems to inhibit 
RpsA (ribosomal protein S1), which regulates trans-translation. 
These four compounds in Fig. 1.2 constitute the first-line drugs against TB and they 
were all discovered in the early days of anti-TB research. Their positive impact on 
global health, together with the introduction of the BCG vaccine, has been huge and 
had brought the world close to the eradication of TB. Unfortunately a surge in the 
number of cases was witnessed throughout the 1980s and then again in the 2000s, 
especially in those so-called high burden countries and in HIV-positive patients (16). 
This is due to human movement across countries, low adherence and access to 
therapy (poor countries) and resistance development. 
  
 
Figure 1.3 Different mechanisms of action of existing anti-TB drugs (modified from (17)) 
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Figure 1.4 Second-line anti-TB drugs 
The World Health Organisation has tried to improve the outcome of TB treatment by 
introducing DOT (Directly Observed Therapy) for the treatment of tuberculosis. This 
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procedure prescribes that a trained health care professional or other provides a 
standardised treatment with supervision and patient support. This is especially 
critical in the case of HIV-positive and drug-resistant patients. The patient is given 
the medication and has to take it in front of the supervisor (13).  
Second-line drugs include molecules with quite different mechanisms of action (Fig. 
1.3): D-cycloserine 5 inhibits cell-wall PG synthesis, ethionamide 6, a prodrug, 
possibly disrupts the mycolic acid layer while another prodrug, para-aminosalicylic 
acid 7, inhibits dihydrofolate reductase (18,19). Fluoroquinolones such as 
levofloxacin 8 (20,21), ciprofloxacin 9 (22), moxifloxacin 10 and gatifloxacin 11 (23), 
inhibit DNA gyrase and type II topoisomerase IV therefore interfering with cell 
division, while aminoglycosides such as kanamycin 12, amikacin 13 and 
streptomycin 14  are protein synthesis inhibitors.  
Since the discovery of the TB aetiological agent in 1882, a number of different anti-
TB drugs have been discovered and exploited (Fig. 1.5). Streptomycin was one of 
the first agents used but resistance soon arose. A few years later the development 
of INH fuelled great expectations as the molecule was found to be ten times more 
active than any other previous one and highly selective for mycobacterial cells thus 
being free of major side effects. Unfortunately resistance rapidly occurred and for 
this reason nowadays it is used only in combination with the other first-line drugs 
(24). It is interesting to note that essentially all of the drugs in current routine use 
were developed within 20 years, but beyond that, little further progress has been 
made in the subsequent 50 years. Of course those initial 20 years represent the age 
of pioneering antibiotic research, with many new agents being discovered, and 
resistance had not at that time developed to the extent that is has now.                 
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Figure 1.5 TB drugs discovery timeline 
1
approved by FDA for active and latent TB treatment in combination with isoniazid; 
2
approved by FDA 
for treatment of MDR-TB, currently in phase II clinical trials 
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Furthermore, following the finding that multidrug therapy was effective against 
susceptible TB, cases decreased impressively and not much effort was invested into 
finding alternatives. In the light of the current resurgence of TB, it is becoming 
increasingly evident that looking for better treatment options is necessary. Ideally, 
more effective drug therapy would be of shorter duration with a lower number of 
drugs (realistically two drugs would be best, as monotherapy more easily incurs the 
risk of resistance). This would greatly improve compliance, which would likely result 
in a reduced need for accessibility and control (DOT), leading to even better 
compliance and adherence. That would, in turn, limit the spread of the disease and 
of resistance. The other pillar of the TB fight is prevention, through education, 
sanitised environments and BCG vaccination. Early detection is also fundamental as 
undiagnosed cases can be source of contagion.  
1.1.3 Resistance  
The first line of intrinsic resistance to antibiotics in Mycobacteria is represented by 
the mycolic acids layer, which naturally confers low permeability to many molecules. 
M. tuberculosis expresses β-lactamases (encoded by blaC and blaS), conferring 
resistance to β-lactam antibiotics (25). Furthermore efflux pumps promptly eject 
tetracycline, fluoroquinolones, aminoglycosides and other antibacterials. Depletion 
of porins (MspA in M. smegmatis (26) and Rv1698 in M. tuberculosis), which have 
been associated with the diffusion of hydrophilic compounds into the bacterial cell, is 
another general mechanism of resistance in Mycobacteria (12). 
Resistance in M. tuberculosis typically occurs via single point mutations of 
chromosomal genes. In the case of INH, the main cause of resistance is due to 
mutations of katG, which encodes for the enzyme responsible for the activation of 
the prodrug, leading to partial or total loss of katG catalase/peroxidase activity (12). 
Rifampicin-resistant strains in most cases show mutations of rpoB, the gene 
encoding for the RNA polymerase subunit where the drug binds. The production of a 
slightly modified target lowers the affinity for the drug, leading to the development of 
resistance. Interestingly the vast majority of these strains show some degree of 
resistance against other antibiotics, mainly INH (12). Similarly, pyrazinamide 
resistance is generally found in strains with mutated pncA, the gene encoding for the 
enzyme responsible for the conversion of the prodrug into its active form (12). It was 
found that 50% of ethambutol-resistant strains show mutations of embB, encoding 
for an arabinosyl transferase, an enzyme involved in cell-wall assembly. The 
reasons for resistance in the remaining strains are under investigation and suggest 
the existence of other mechanisms of action of ethambutol (27). 
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The term MDR-TB (multi drug-resistant tuberculosis) has been coined to describe 
the situation in which two of the first-line drugs, generally isoniazid and rifampicin, 
are no longer effective. MDR-TB is caused by a multi-step process in which the 
accumulation of mutations on different resistance genes leads to a bacterium better 
adapted for survival (28). In these cases patients have to be treated with second-line 
drugs, which take longer to act, are more expensive and present more side effects. 
When resistance to any fluoroquinolone and to at least one of the second-line 
injectable drugs also occur, the disease is described as extensively drug-resistant 
tuberculosis (XDR-TB) (3). In this eventuality, the treatment options are seriously 
limited. Furthermore, in recent years “totally drug-resistant” (TDR) cases have been 
reported (29,30). This term, which has not been recognised by the WHO, is used to 
represent strains that are resistant to all the first-line and second-line drugs in vitro 
(31,32). MDR and XDR tuberculosis strains are not responsive to the standard six-
month treatment and generally take two years or more to be treated; cases of TDR 
are being considered untreatable at the moment, with some cases having been 
treated for more than four years without any improvement (32). It is therefore of 
primary importance to develop new anti-TB drugs while controlling the spread of 
resistant strains of tuberculosis. 
1.2 CELL-WALL PEPTIDOGLYCAN 
1.2.1 Cell-wall as an antibacterial target 
The cell-wall is a unique and essential feature of the bacterial cell providing extra 
protection from the external environment, therefore being an ideal target for therapy. 
Its structure is fairly complicated and comprises different molecular components with 
various functions that can be exploited as targets. All bacteria have a cell-wall but 
differences in composition are apparent (Fig. 1.6).  
30 
 
 
Figure 1.6 Different cell-walls: PG – peptidoglycan; LPS – lipopolysaccharides; MAGP – mycolyl-
arabinogalactan-peptidoglycan complex 
The mycobacterial cell-wall is comprised of a lower and upper segment. The lower 
segment lies directly beyond the membrane and it is made of cross-linked 
peptidoglycan covalently bound to arabinogalactan (AG). This is then esterified by 
mycolic acids, a group of complex branched-chain hydroxylated lipids, which consist 
of one long meromycolate and one short alpha-alkyl branch (Fig. 1.7), The 
meromycolate branch can include cyclopropane, methyl, methoxy and carbonyl 
groups; unsaturations along the chain have been found in M. tuberculosis mycolic 
acids.  
 
Figure 1.7 Schematic representation of mycolic acid meromycolate and alpha branch 
This mycolyl-arabinogalactan-peptidoglycan complex (MAGP) is considered the cell-
wall core. This is the portion of the cell-wall that appears to be essential for the 
viability of the cell. The upper segment, on the other hand, is made of free lipids with 
variable fatty acid chain length. In between are phthiocerol containing lipids, 
phosphatidyl inositol mannosides, lipomannan, lipoarabinomannan and cell-wall 
proteins (33,34) . 
PG is a fundamental component of the cell-wall as it gives structural strength to the 
cell, it counteracts the osmotic pressure and provides anchoring support for other 
molecules that enrich this structure, and it takes part in cell division (35). It is 
particularly abundant in Gram positive bacteria, while in Gram negative organisms it 
constitutes a thinner layer. It is a large polymer made of repeating disaccharide-
pentapeptide units (36,37). Each of these is made of alternating β(1→4)-linked N-
31 
 
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) residues, the 
latter of which has a pentapeptide attached through its D-lactyl moiety. Each strand 
of the peptidoglycan is predisposed for cross-linking to a maximum of three 
neighbouring peptidoglycan strands, even though not all strands have to be cross-
linked (38).  
For most Gram positive bacteria the pentapeptide (15) growing sequence is L-Ala, γ-
D-Glu, L-Lys, D-Ala, D-Ala, but for Gram negative bacteria and in few Gram positive 
organisms, including Mycobacterium tuberculosis, meso-2,6-diaminopimelic acid 
(mDAP) is substituted for L-lysine in the peptide chain of the peptidoglycan (Fig 1.8) 
(37,39). This type of bacterium also shares the larger intermembrane space found in 
Gram negative bacteria, but characterised by the presence of mycolic acid lipids, 
which are found only in mycobacteria and some species belonging to 
Corynebacteriales (40). 
 
Figure 1.8 Structure of the mycobacterial pentapeptide, highlighting the mDAP residue (red) 
Different bacterial genera and species showcase peculiarities in their PG structures. 
There is a higher frequency (75%) of cross links in M. tuberculosis PG compared to 
that of E. coli (41). These are mainly 4→3 linkages, between D-Ala and mDAP, but 
about one third is constituted of 3→3 linkages, between two mDAP residues (41–44). 
The latter are the result of L,D-transpeptidase activity and are found in E. coli solely 
during the stationary phase under stress conditions, such as nutrient depletion (45). 
In M. tuberculosis they are also present during the growth phase but their content 
increases up to 80% during the stationary and dormant phases (46,47). 
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1.2.2 Peptidoglycan: biosynthesis, degradation and recycling 
1.2.2.1 Biosynthesis of the peptidoglycan  
The building blocks of the peptidoglycan are sequentially assembled in the 
cytoplasm by Mur ligases (or synthetases). They are a family of bacterial enzymes 
responsible for the synthesis (and recycling) of peptidoglycan. They have recently 
become the centre of increasing interest in the potential development of PG 
inhibitors with activity against different pathogens (M. tuberculosis, M. leprae (48,49), 
Chlamydiaceae (50), H. influenza (51), S. pneumoniae, S. aureus (52)), as they are 
essential for the survival of the bacterial cell. They are highly specialised enzymes 
that generally have high substrate specificity. The initial conversion of UDP-GlcNAc 
to UDP-MurNAc is performed by MurA and MurB: MurA, a transferase, catalyses the 
transfer of enolpyruvate from phosphoenolpyruvate to UDP-GlcNAc; MurB, a 
reductase, transforms enolpyruvate to D-lactate, producing UDP-MurNAc (Scheme 
1.1) (53).  
 
Scheme 1.1 MurA and MurB convert UDP-GlcNAc to UDP-MurNAc 
Subsequently the addition of the five amino acids of the pentapeptide is catalysed 
by a series of essential ATP-dependent Mur ligases. Each step requires the 
hydrolysis of ATP, releasing ADP and inorganic phosphate (39,54); interaction of the 
UDP-precursor with ATP generates an acyl phosphate. The amino group of the 
incoming amino acid attacks the carbonyl carbon atom, producing a tetrahedral 
intermediate, which leads to the elimination of the phosphate group to give a peptide 
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bond (53,55). These enzymes sequentially attach amino acids to the PG 
disaccharide formed by UDP-GlcNAc-UDP-MurNAc to form the peptide stem of the 
PG monomer. Their activity in M. tuberculosis is illustrated in Scheme 1.2. The 
sequence similarities among these enzymes are limited to the highly conserved 
regions corresponding to the active site: the ATP-binding pocket, the N-terminal 
domain that accommodates UDP-MurNAc and the C-terminal domain where the 
amino acid substrate binds (56). MurC generally catalyses the attachment of L-Ala 
on the carboxylate of UDP-MurNAc, with some exceptions e.g. M. tuberculosis and 
leprae MurC showed substrate affinity also for Gly (48) and L-Ser (54).  
MurD catalyses the formation of a peptide bond between the UDP-MurNAc-L-Ala 
free carboxyl group and the D-Glu amino group. Its specificity for its substrate D-Glu 
is particularly high, and this ability seems to make MurD an extremely promising 
target within the antibacterial drug discovery field (57). In E. coli, MurD doesn’t show 
any ligase activity in the presence of L-Glu, and it allows as substrates only the 
unusual DL-homocysteic acid, D-erythro-3- and 4-methylglutamic acids and 5- or 6-
membered cyclic analogues of D-Glu (57). A study on E.coli MurD highlighted how 
UDP-N-acetylmuramyl-L-Ala intracellular levels affect the enzyme activity. When its 
concentration reaches 10 μM it stimulates MurD ligase activity, while when it goes 
above 15 μM  it shows an inhibitory effect on MurD (58). In Gram positive organisms 
this effect is significantly lower (starting at concentrations of 1-2 mM). Given the 
different quantity of PG present in the different cell walls, this fact seems to suggest 
that MurD ligase activity could be the bottleneck regulating the thickness of the PG 
layer in Gram negative organisms (58). 
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Scheme 1.2 Biosynthesis of the glycopeptide in Mycobacterium tuberculosis 
MurE has a species-specific selectivity for its substrate: depending on the organism, 
it will accept mDAP or Lys for incorporation into the PG peptide stem. Mis-
incorporations lead to irreversible cell damage. E. coli overexpressing S. aureus 
MurE starts incorporating only L-Lys, instead of mDAP, in its PG leading to cell lysis 
within 1 h. The enzyme is active only in the presence of UDP-MurNAc-L-Ala-D-Glu. 
In E. coli MurE has been found to accept L,L DAP and other mDAP analogues but 
not L-Lys (59,60). The species specificity seems to be related to the residue in 
position 416 of the MurE sequence. In organisms that incorporate mDAP into their 
PG, an Arg residue, able to bind to the free end of mDAP, is found, while in those 
organisms that incorporate Lys into their PG, Ala or Asn is found (39,54,61). 
 
MurF seems to have fair substrate flexibility. It always adds a dipeptide to the 
growing peptide stem – generally D-Ala-D-Ala – but it has the ability to introduce a 
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variety of D-amino acids  e.g. by accepting D-Ala-D-Lac or D-Ala-D-Ser instead of the 
canonical D-Ala dimer. MurF from S. aureus showed an equal ability to add the 
dimer to the Lys-containing or mDAP-containing growing peptide stem (62). 
These are the key catalytic drivers of the peptidoglycan monomer assembly, but 
their actions are dependent on the availability of substrates produced by the activity 
of a number of corollary enzymes. For example DapF is an epimerase that converts 
L,L-DAP to mDAP – the required MurE substrate (63). The dimer D-Ala-D-Ala (the 
required substrate of MurF) is the result of the activity of Alr, a racemase that 
converts L-Ala to D-Ala, and Ddl (D-Ala:D-Ala ligase), which catalyses the formation 
of the dimer (64). Subsequently in PG assembly, lipid linked precursors are 
synthesised then translocated by a flippase protein across the membrane to the 
periplasmic space. This flippase has been identified as FtsW in E. coli, in which it 
has also been found to play an essential role in cell division (65). Similar lipid II 
flippases have been identified in other bacteria and within the Actinobacterium 
Corynebacterium glutamicum (66). In the periplasmic space, the lipid-linked 
precursors are substrates for transpeptidases and transglycosylases involved in PG 
polymerisation. These roles are played by bifunctional penicillin binding proteins 
(PBPs); they polymerise and cross-link the separate units, forming the final, 
alternating GlcNAc and MurNAc, structure of PG, which can finally be bound to the 
rest of the cell-wall (Fig 1.9) (61). The PBPs involved in PG polymerisation and 
cross-linking are of high molecular-weight (HMW-PBPs). 
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Figure 1.9 Schematic description of the biosynthesis, degradation and recycling of Gram negative 
bacteria peptidoglycan (modified from (61)) 
Cross-linking generally involves the third amino acid in one chain and the fourth in 
another one but in M. tuberculosis the cross-linking can also occur between two 
mDAP (third) residues (43). Furthermore, some of the N-acetyl groups on MurNAc 
can be oxidised to N-glycolyl groups causing the incorporation of N-glycolylmuramic 
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acid as the predominant component of the saccharide. In addition, a small 
percentage of the D-Glu residues are replaced by glycine and the side chain 
residues of D-Glu and mDAP can be amidated. These features, together with the 
unusual presence (for a Gram positive species) of mDAP, make M. tuberculosis 
peptidoglycan unique and can provide specific targets for the development of anti-
tuberculosis drugs (61,67). 
1.2.2.2 The peptidoglycan can also be synthesised through recycling 
Another important issue is the discovery that Gram negative bacteria such as E. coli 
have specific enzymes that are able to recycle components of the cell-wall that are 
broken down during normal cell-wall turnover (Fig. 1.9) (68). Mpl has been identified 
in a number of organisms, including E. coli (69), Psychrobacter arcticus (70) and 
possibly Salmonella paratyphi C (71). It is an enzyme involved in the recycling of 
peptidoglycan. Its existence has been speculated since the realisation that MurC did 
not have the ability to utilise the tripeptide H-Ala-D-Glu(mDAP-OH)-OH as a 
substrate to attach to the UDP-MurNAc; hence, within the recycling context, there 
had to be another enzyme with said activity (72). Mpl in E. coli was found first as a 
homologue of MurC lacking ligase activity in the presence of L-Ala (48,73). Later on, 
its activity in E. coli was evaluated and it was found to have high substrate affinity for 
the tripeptide H-Ala-D-Glu(mDAP-OH)-OH and it was therefore called UDP-N-
acetylmuramate:L-alanyl-γ-D-glutamyl-meso-diaminopimelate ligase. It was also 
shown to be able to accept the tetra and pentapeptide with similar efficiency, as well 
as demonstrating some ligase activity even with the dipeptide H-Ala-D-Glu-OH and 
L-Ala itself (69). Given that any Mur ligase reaction requires one molecule of ATP, 
re-introduction of, typically, a tripeptide fragment into the PG strand represents a net 
saving of two molecules of ATP. This seems to suggest the enzyme’s possible 
involvement in conserving energy during the transition to the dormant state in M. 
tuberculosis, and possibly a role in surviving harsh conditions (antibiotic presence 
and resistance). Through computational analysis, recent results in our laboratory 
have identified this enzyme in M. tuberculosis as Rv3712, which was initially 
identified as a MurC homologue.  
It has been estimated that in Gram negative organisms, recycling is believed to 
account for 30 to 60% of PG synthesis (11). It was thought that this phenomenon did 
not apply to Gram positive bacteria because of their thicker exoskeleton, their 
inside-to-outside synthesis of peptidoglycan and because of the detection of a 
significant quantity of PG fragments released in the medium by Gram positive 
organisms (74). Some Gram positive species, however, turn over up to 50% of their 
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peptidoglycan during vegetative growth (75). This would mean a massive loss of 
material, especially in Gram positive bacteria, as peptidoglycan constitutes 20% of 
their cell-wall mass. Recently, however, the identification in Bacillus subtilis of a 
gene cluster containing 5 orthologues of enzymes involved in recycling in E. coli 
(74,76) suggests that a recycling pathway exists also in Gram positive bacteria. 
Furthermore in the case of Mycobacteria it is believed that the thick lipid-containing 
outer wall prevents the fragments from diffusing away, allowing their reuptake for 
recycling purposes (41). This means that inhibition of the Mur ligases, which build 
the PG de novo, is unlikely to completely inhibit the synthesis of the cell-wall.  
A recent study by Borisova et al. showed how deletion of genes encoding for 
recycling enzymes (amgK, MurU, anmK, NagZ) in a fosfomycin-resistant strain 
restored the MIC of the antibiotic to therapeutic values (a fourfold increase) (77). 
In a comparative study on M. tuberculosis, the Mur synthetases, even though 
provided with the appropriate substrates, showed little product formation in the 
absence of metal ions (54). The presence of divalent cations seemed to greatly 
improve conversion. In particular, the concentration of Mg2+ was found to exert a 
strong influence on the activities of MurC, MurE and MurF. In the case of MurD, 
Mg2+ and Mn2+ proved similarly essential. Other cations such as Co2+ and Zn2+, K+ 
and NH4
+ exerted less significant effects (54). 
1.2.3 Cell-wall synthesis and recycling inhibition perspective: new or adjunct 
anti-TB therapy for existing drugs  
A connection between cell wall recycling and antibiotic resistance has already been 
suggested. Cell wall-targeting antibiotics, such as β-lactams, act by triggering (or 
causing) modifications in the cell wall structure, composition or integrity. It was found 
that detection of unusual quantities of modified or truncated muropeptides in the 
cytoplasm provided a good indication that something anomalous was happening 
(74). In the presence of β-lactams, in some Gram negative bacteria the 
muropeptides trigger the expression of the gene encoding for AmpC β-lactamase 
therefore initiating a resistance strategy (74). This is one example of how fragments 
of cell wall can trigger a resistant response from bacteria. In addition, it has been 
shown that deletion of certain genes encoding for recycling enzymes can increase 
susceptibility to antibiotics (78). This seems to demonstrate that the combination of 
cell wall-targeting antibiotics and inhibitors of cell wall recycling could be a highly 
promising strategy (74).  
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In addition, as some recycling activities can contribute to intrinsic antibiotic 
resistance (79), inhibition of said pathways could potentially repurpose old drugs, 
which were discarded from therapeutic use because of resistance. One important 
example is the case of fosfomycin, 22. This drug blocks the formation of UDP-
MurNAc by interfering with the activity of MurA. Pseudomonads can easily acquire 
resistance to its action. It was found by Borisova et al. (77) and Gisin et al. (79) that, 
in P. aeruginosa and P. putida respectively, a recycling pathway exists that 
bypasses the activity of MurA and MurB. This pathway is not found in Enterobacteria, 
E.coli included. In this way the bacterium is able to utilise the anhydro version of 
MurNAc (AnhMurNAc) product of the degradation of PG through a series of steps 
(involving AnmK, AgmK, MurU) to re-enter the synthetic cycle through UDP-MurNAc 
provision (79). The importance of this finding lies in the fact that when the salvage 
pathway was blocked, it was found that the susceptibility of P. aeruginosa 
specifically to fosfomycin increased 4- to 8-fold, bringing the MIC of this antibacterial 
agent back to therapeutic levels.  
These findings highlight the new perspective in antibacterial therapy provided by the 
inhibition of the recycling pathways. Interference with PG salvage routes could help 
in overcoming antibiotic resistance (to antibiotics that are no longer active because 
they directly target a biosynthetic step that can be bypassed through recycling). 
1.3 Antibacterial peptide drugs  
The use of peptides in therapy has increased since penicillin was discovered in the 
1920s.  Following that serendipitous finding, scientists have been searching for new 
antibiotic agents. Bacterial and fungal species have been tested extensively and, as 
a result, many antibiotics still used these days are, in fact, natural products. 
Naturally produced peptides can be classified as either non-ribosomally or 
ribosomally synthesised peptides. The latter, also abbreviated RiPPs (ribosomally-
synthesised and post-translationally modified peptides) are synthesised as 
precursor peptides and then sequentially modified post-translation, followed by 
proteolysis which removes non-core portions to release the actual mature peptide 
(80).  
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Many display potent bioactivity. Furthermore, more recently, non-ribosomally 
synthesised AMPs (antimicrobial peptides), such as vancomycin, 23, have 
increasingly become the focus for research. These are produced by peptide 
synthetases in all organisms as part of their innate immune system. This attention 
on peptides is because they are readily accessible; methodology for their effective 
synthesis has greatly improved from solution-phase to the use of solid supports, 
which allow the removal of soluble reagents from preceding steps, therefore yielding 
purer crude products. More recently the development of automated solid-phase 
synthesis has rendered this process even more convenient. In addition, peptides are 
easily modifiable and their building blocks are generally commercially available. This 
ease of production allows preparation of carefully designed peptides to suit the 
interaction with a desired target, if its structure is known and if its activity has been 
previously entirely or partially elucidated. In this way substrate analogues or tailored 
peptides capable of specific drug-target interactions can be inhibitors or enhancers 
able to interact with the active or collateral sites of the targets, resulting in 
modulation of their effects. 
1.3.1 β-lactam antibiotics target the cell-wall 
β-Lactams represent the oldest class of antibiotics discovered, penicillin G (Fig 1.10) 
being the first in 1929 (81). Penicillins, cephalosporins, cephamycins, carbapenems 
and monobactams all belong to the β-lactam antibiotic group; they are potent 
compounds and they are still the most prescribed antibacterial drugs around the 
world (82). Resistance however has arisen, mainly thanks to the horizontal transfer 
of genes encoding for β-lactamases – enzymes able to hydrolyse the β-lactam ring 
responsible for the antibacterial activity (82).  
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Figure 1.10 General structure of penicillins, substituents R vary largely; in penicillin G R = CH2C6H5 
The main known target of β-lactams are PBPs, which are D,D-transpeptidases 
responsible for a specific type of cross-linking between two D-Ala residues on 
adjacent PG peptide stems. The antibiotics bind selectively and irreversibly to the 
main active site of the PBPs and form adducts, which therefore inhibit the enzyme’s 
activity. This is due to the fact that β-lactams mimic the D,D-transpeptidase substrate 
(83). In the case of penicillin and cephalosporins, their structure resembles that of 
the natural substrate of PBPs, D-Ala-D-Ala (82,83). Carbapenems, have opposite 
configurations of the two chiral carbon atoms on the lactam ring and their 
resemblance is more similar to that of mDAP-D-Ala which is the substrate of the L,D-
transpeptidase (LdtMt2), responsible for the 3→3 cross-linking of the PG, which 
represent around 80% of the non-replicating TB bacillus PG links. In M. tuberculosis, 
β-lactams are not used widely because of the intrinsic resistance of the bacillus to 
them. The mycolic acid layer in this case does not seem to represent a significant 
obstacle to the penetration of the antibiotics (82). This natural resistance is mainly 
due to a strong β-lactamase activity in this species, mediated by BlaC – the only β-
lactamase found in the M.tuberculosis genome, which has very broad substrate 
specificity and is therefore able to act against the different β-lactams (82,84,85). 
Luckily the discovery and development of β-lactamase inhibitors has possibly 
provided the opportunity to overcome this problem (85,86). The combination of 
meropenem (a carbapenem) and clavulanic acid (β-lactamase inhibitor) has been 
shown to not only inhibit the lactamase but also LdtMt2 (87). This strategy combines 
different mechanisms of inhibition resulting in a higher, synergistic antibiotic effect. 
Meropenem alone is already a poor substrate for BlaC, contrary to other β-lactams, 
and clavulanate is the only FDA-approved β-lactamase inhibitor able to irreversibly 
inhibit BlaC activity (84). These two drugs together have shown high inhibitory 
activity on many XDR strains, on aerobically- and anaerobically-grown cultures of M. 
tuberculosis and exceedingly good results with the customary laboratory strains (84). 
These recent developments reinforce the continued importance of β-lactams in 
antibiotic treatments. 
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1.3.2 Current antibacterial peptides 
Among current antibacterials, many are of peptide origin. They might be unmodified 
natural products (as in most successful cases), such as those produced by bacteria 
themselves to compete against each other for survival, they can be of natural 
inspiration then modified to improve their activity or toxicity profile, or they can be 
totally synthetic. Gramicidin D, 24, is a mixture of hydrophobic linear peptides 
(where R1 could be Val or Ile and R2 Trp, Phe or Tyr) produced by Bacillus brevis, 
active mainly against Gram positive bacteria (88–90). They are ionophore molecules, 
able to make channels across the phospholipid membrane, increasing its 
permeability to inorganic monovalent cations (88). It is marketed in combination with 
dexamethasone and framycetin sulfate as a topical treatment of ear and eye 
inflammation (91).                                                                                         
 
Vancomycin, 23, is a glycosylated hexapeptide active against Gram positive 
bacteria and it is generally used against organisms that have demonstrated 
resistance to β-lactams. It inhibits cell wall synthesis, specifically the peptidoglycan 
assembly, by inhibiting transglycosylases (responsible for linking muramic acid and 
acetyl glucosamine) and transpeptidase (a cross-linking enzyme). It is active in the 
presence of UDP-MurNAc-pentapeptide and binds non-covalently to the D-Ala-D-Ala 
terminus of the peptide (92) blocking the cross-linking between monomers of the PG 
because of steric hindrance (93).  
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Vancomycin belongs to a family of glycopeptide antibiotics including teicoplanin, 25, 
(94). The latter is a complex of natural products produced by Actinoplanes 
teichomyceticus; they are cyclic glycopeptides that inhibit PG polymerisation. 
Teicoplanin is generally used against MRSA and some enterococci, especially in 
patients allergic to β-lactams (94,95). The structures of its constituent glycopeptides 
are similar to that of vancomycin but with an additional fatty acid chain (10-11 
carbon atoms), which is the variable component among the five different molecules 
belonging to this complex. 
 
Pexiganan, 26, is a linear cationic peptide of 22 amino acids and an analogue of 
magainin, a peptide isolated from the skin of the Xenopus laevis frog (96,97). It is 
currently in Stage 3 clinical trials for the treatment of diabetic foot ulcers. The 
product Locilex, a topical foot cream containing 0.8% pexiganan was rejected for 
FDA approval but the producing company is currently awaiting EMA (European 
Medicines Agency) Committee for Medicinal Products for Human Use (CHMP) 
approval through the submission of a Marketing Authorisation Application (MAA) for 
launch in the European Union (as of 2015, (98)). 
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1.3.3 Cyclic antibacterial peptides 
Bacitracin A, 27, is a cyclic polypeptide produced by Bacillus licheniformis. It is 
active against Gram positive bacteria (99) and works by inhibiting the 
dephosphorylation of undecaprenyl pyrophosphate, a reaction that leads to the 
regeneration of the lipid carrier involved in PG synthesis (99).  
 
 
Bacitracin sequesters the lipid-bound intermediate, via the formation of a ternary 
complex with a divalent cation, resulting in the reduction of PG precursor availability 
for cell wall synthesis (100). It is used mainly as a topical remedy in the form of 
antibiotic ointment for minor skin injuries. In the UK (91) it is marketed as a 
combination preparation with polymixin B, but the FDA approves its prescription-only 
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use also via intramuscular injection (101).A depsipeptide is a peptide in which at 
least one of the amide bonds generally involved in the peptide backbone is replaced 
by an ester.  
 
Lipodepsipeptides are molecules produced by a variety of bacteria and fungi, with a 
diverse range of activities. They feature an oligopeptide to which is attached a fatty 
acid chain of varying length (102). In cyclic lipodepsipeptides (CLPs), part of the 
peptide portion is condensed to form a lactone ring (102). The general mechanism 
of action of this class of agents seems to mediate cell death through the formation of 
pores and the subsequent depolarisation of the membrane (102–104). Among the 
CLPs daptomycin, 28, is probably the most well-known; it is licensed for intravenous 
administration in skin and soft tissue infections caused by Gram positive bacteria, 
including MRSA, and in endocarditis (91). It is a non-ribosomally synthesised 
peptide produced by Streptomyces roseosporus and is not active against Gram 
negative bacteria (104). 
 
 
Lantibiotics (105,106) are a group of antibacterial polycyclic peptides that 
characteristically contain at least one lanthionine (a diamino acid) residue. They are 
post-translationally modified from a protopeptide via dehydration of Ser or Thr to 
produce Dha (2,3-didehydroalanine) or Dhb ((Z)-2,3-didehydrobutyrine) respectively, 
which are cyclised via a Michael-type addition of a Cys across the double bond, 
forming a thioether bridge (106). They have potent antibacterial activity against 
Gram positive organisms and some of them also possess other types of biological 
activity (106). They are very promising molecules as they generally combine more 
than one antibacterial mechanism of action. This feature can become very important 
when trying to avoid resistance (105). 
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Another example of cyclic peptides with antibacterial activity is represented by the 
lasso peptides. These compounds are produced by bacteria and have a broad 
range of activities, including acting as antimicrobials. They are classified as RiPPs, 
ribosomally synthesised and post-translationally modified peptides; the polypeptide 
chain forms a head-to-side chain loop through which the C-terminal sequence is 
threaded. This constrained entropically-disfavoured topology is at the core of their 
extreme resistance to enzymatic activity (107). The first lasso peptide discovered, 
Microcin J25 (MccJ25), was isolated from E. coli and showed activity against 
Escherichia and Salmonella species (107,108). None of lasso peptides are at an 
advanced stage of research, but they all show promising activities.   
Cyclotides are ribosomally-synthesised head-to-tail cyclic peptides found in plants 
(mainly from Violaceae and Fabaceae, but also from Rubiaceae). These molecules 
generally comprise 28-37 amino acid residues and they feature several disulfide 
bridges, resulting in a characteristic cysteine knot structure (109). They have a 
broad range of activities, including antibacterial activity. As seen for the lasso 
peptides, their knotted topology confers upon them unusual resistance to enzymatic 
activity, physical and chemical stress (109,110). These peptides are not yet in 
clinical trials but there are great expectations for their ability to be scaffolds for the 
grafting of therapeutic peptides (110).  
1.3.4 Anti-tuberculosis peptides 
Teixobactin, 29, is a recently-discovered and very promising antibiotic of bacterial 
origin. It is an unusual depsipeptide produced by Eleftheria terrae and is active 
mainly against Gram positive bacteria, including M. tuberculosis (111). The MIC 
found for the susceptible M. tuberculosis strain H37Rv was 0.125 μg/mL. The 
mechanism of action has not yet been identified but intracellular accumulation of 
UDP-MurNAc-pentapeptide (in Staphylococcus aureus) seems to suggest a link to 
PG synthesis, more specifically the inhibition of membrane-bound steps. This fact 
and the observation that no resistant mutants arose in S. aureus and M. tuberculosis 
seem to suggest that the mechanism of action is non-specific (111).  
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Capreomycin, 30, is a polypeptide antibiotic first isolated from Streptomyces 
capreolus. It is currently clinically available and it is used as an injectable second-
line drug against TB in multidrug-resistant cases (112,113). It binds to the 70s 
ribosome subunit and inhibits protein synthesis. It actually consists of a mixture of 4 
active isoforms, all containing a cyclic pentapeptide core containing L-Ser, 2,3-
diaminopropionate, β-ureidodehydroalanine and L-capreomycidine. In two isoforms 
(IA and IB) a Ser side chain is modified with β-Lys, and in IB the second Ser is 
replaced by Ala (112).  
 
Among the already mentioned (Chapter 1.3.3) lasso peptides are the lariatins (A 31 
and B 32), which have shown specific activity against Mycobacteria (114). 
Furthermore lassomycin, 33, is a recently discovered cyclic peptide with anti-
tuberculosis activity, which might also be classified as a lasso peptide (115,116). 
Lasso peptides are a heterogeneous group of compounds of bacterial origin. They 
are all ribosomally synthesised and post-translationally modified by specific 
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enzymes. These modifications in mature RiPPs generally confer higher stability to 
the molecules. Within the lasso peptides such modifications include topological 
remodelling that leads to the formation of the actual “lasso” structure, also known as 
a lariat (114). This alteration brings the C-terminal tail through the ring (generally 
comprised of 7-9 residues) formed by an amide bond between the N-terminal amino 
group and the side chain carboxy group of an aspartate or glutamate residue, 
resulting in a structure that resembles a lasso. The direction in which the N-terminal 
cyclic sequence circles around the C-terminal tail defines whether the structure is 
left- or right-handed (107); so far only right-handed molecules have been discovered. 
This “entropically disfavoured fold” (114) confers exceptional stability, for a peptide, 
to the molecule. It is clear that such a structure is difficult to recreate. The steps 
involved require the assistance of specialised bacterial enzymes (114). In fact the 
tail cannot be threaded through after ring closure because its passage would be 
impeded by the steric bulk of certain ring and tail residues (114). At the same time 
the tail needs to be somehow anchored to the ring to maintain the energetically 
unfavourable conformation. These molecules generally feature disulfide bonds as 
braces holding the tail in the loop.  
The current classification system for lasso peptides is based on the type and 
number of said constraints. Compounds belonging to class I have two disulfide 
bonds between the tail and the ring, one of which involves an N-terminal cysteine 
residue. Class II lasso peptides, on the other hand, have no disulfide bond but bulky 
side chains, that act as “steric traps” (107,114). The only compound so far assigned 
to class III has one single disulfide bond. As extremely stable peptides that are 
mostly non-immunogenic, these molecules provide great potential as possible 
scaffolds for the delivery of drugs (117). Their unique folded conformations, however, 
present great challenges in being duplicated synthetically.  
These peptides generally have intrinsic antibacterial or antiviral activities through a 
variety of mechanisms of action (114,117). They seem to be produced mainly by 
Actinobacteria and Proteobacteria (114). Among them, interestingly, two lasso 
peptides, lariatin A, 31, and B, 32, have shown antimycobacterial activity (118–120). 
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They are produced by Rhodococcus jostii sp. K01-B0171, an Actinobacterium, and 
belong to class II, having no disulfide bridges. Lariatin A (18 residues) is a C-
terminally truncated analogue of lariatin B (20 residues) (118,120). The latter is 
active against M. smegmatis while lariatin A also shows significant bactericidal 
activity against M. tuberculosis.  
Lassomycin 33, is a molecule isolated from a Lentzea kentuckiensis sp., an 
Actinobacterium (115). 
 
The stability profile of lassomycin, discovered in 2014 (115), matches that of other 
lasso peptides, but X-ray analysis and structure elucidation studies suggested a 
non-threaded lasso structure, therefore putting it outside of the standard lasso 
peptide classifications. Subsequently Lear et al. (116) reported the synthesis of 
lassomycin with this suggested open topology and found out that it had no biological 
activity against M. tuberculosis. This finding may imply that the tail might actually be 
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threaded through the loop in a manner similar to that of other lasso peptides. This 
supposition seems to better match the extreme stability of this peptide. An open 
structure would be more likely to be attacked and degraded by enzymes. At the time 
this project was conducted, the available literature suggested the unthreaded 
structure, therefore the synthetic efforts here described were directed towards what 
was believed to be the peptide in its correct folding. 
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1.3.5 Peptide synthesis 
The production of peptides is based on the formation of the amide bond between 
two amino acids, an operation called “coupling”. 
 
 
 
Scheme 1.3 General scheme of peptide bond formation 
As carboxylic acids normally react with amines to give salts, in order to obtain the 
peptide bond, the carboxyl group must be activated, so that it is more susceptible to 
attack by the amino group of the second amino acid. This means that a leaving 
group has to be attached to the acyl carbon of the carboxyl group. Activation can be 
achieved either in a separate step, then adding the amino component, or the 
acylating intermediate can be formed in the presence of the amino component 
helped by the introduction of an activating agent. It is even possible to generate the 
acylating agent separately and eventually purify it before adding it to the reaction. In 
any case the amino group of the first amino acid has to be temporarily protected, 
while in the second amino acid the amino group must be free and any other 
exposed reactive group must be protected. Protection makes these groups 
unreactive, and permits the carboxyl group to react only with the amino group of the 
other amino acid (121). For every subsequent coupling step, the amino group of the 
growing peptide needs first to be deprotected in order to react with the activated 
carboxyl group of the next amino acid added. 
The choice of the protecting groups is extremely important. They should provide 
orthogonal protection: the permanent protecting groups should be resistant to the 
deprotecting conditions used to remove the temporary ones. Furthermore all of the 
protecting groups should be easily removable, without either causing fragmentation 
of the peptide or modification of any side chain functional groups, at the completion 
of synthesis. However it has to be taken into account that certain fully-protected 
building blocks may have poor solubility in the solvent used for coupling. 
α-Amino protecting groups 
The aim of protecting α-amino groups is to suppress their nucleophilic reactivity 
either by adding a substituent that draws the electron density away from the nitrogen 
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atom or that shields it through steric hindrance. Ideally it should be easy to both add 
and remove the protecting group without compromising either the assembled 
structure or its configuration. A good option is given by alkoxycarbonyl protecting 
groups, which are able to transform the amino function into a carbamate, therefore 
lowering the nucleophilic reactivity of the nitrogen atom. Furthermore these 
protecting groups can be easily removed by alkyl-oxygen fission, generating the 
corresponding carbamic acids which will spontaneously decarboxylate to regenerate 
the amine (121). 
The most commonly used alkoxycarbonyl α-amino protecting groups are Boc (t-
butyloxycarbonyl) and Fmoc (9-fluorenylmethoxycarbonyl).  
 
 
Boc, 34, introduced into peptide synthesis in 1957, by Anderson and McGregor 
(122), is widely used both in solution phase and solid phase synthesis (Merrifield 
type SPPS). It is stable to bases and most nucleophiles and is unaffected by 
catalytic hydrogenation. In addition, Boc can be introduced and deprotected in good 
yields and Boc-protected amino acids can be stored in the fridge even for long 
periods without incurring any deterioration. It can be removed by acidolysis using 
aqueous HCl or trifluoroacetic acid (TFA) at room temperature (Scheme 1.4). 
Deprotection via dissolution in TFA, either pure or diluted in dichloromethane, 
followed by flooding with ether or evaporation, is a fairly common procedure as it 
involves mild and reliable conditions. TFA protonates the carbonyl oxygen, resulting 
in the subsequent loss of a stable tert-butyl carbocation and the formation of the 
corresponding carbamic acid. The carbamic acid then spontaneously 
decarboxylates to give the deprotected amine. The tert-butyl carbocation can either 
be converted to isobutene or be quenched by an available nucleophile (121,123). 
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Scheme 1.4 Acid-mediated removal of the Boc group 
Fmoc, 35, is generally and widely used in SPPS, preferably in conjunction with t-
butyl side chain protecting groups because Fmoc is removed under mild basic 
conditions, allowing acid-labile groups (e.g. tBu and Boc) to be used for side chain 
protection. This means that its removal does not affect the stability of other groups, 
therefore offering true orthogonality. Generally Fmoc is not used in solution phase 
synthesis because the by-products of its deprotection are non-volatile (121). 
When preparing Nα-Fmoc-amino acids the use of the hydroxysuccinimide carbonate 
of Fmoc (Fmoc-OSu) for acylation is preferred because the use of Fmoc chloride 
can lead to the formation of dipeptide by-products (124). 
One drawback of some carbamates is that their cleavage generates a transient 
carbocation that could eventually modify the product by alkylation. Fmoc 
deprotection (Scheme 1.5), on the other hand, follows an E1cb β-elimination 
mechanism. The acidity of H9 on the fluorenyl system allows its removal by weak 
bases like piperidine, forming a resonance stabilised carbanion. This then eliminates 
to form the carbamic acid, which subsequently undergoes spontaneous 
decarboxylation to yield the free amine (rather than the ammonium cation) and the 
dibenzofulvene by-product (125). 
Fmoc is typically removed with a 20-25% v/v solution of piperidine in DMF, with the 
reaction generally complete in approximately 20 min (126). 
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Scheme 1.5 Deprotection of the Fmoc group using piperidine 
Side chain protecting groups  
Typically the protection of a carboxyl group is easily achieved via esterification. 
Methyl esters provide good protection – they are stable to HBr/CH3COOH or TFA 
treatment at room temperature, they are not affected by catalytic hydrogenolysis 
conditions, or by thiols or amines in organic solvents (121). On one hand, this 
means that the amino-protecting groups can be selectively removed; on the other 
hand, methyl esters tend to be difficult to remove in the final step, often requiring 
harsh conditions. t-Butyl esters are usually inert to nucleophilic and basic attack. 
Treatment with TFA cleaves any t-butanol-based protecting group (generally tBu 
ester for Glu, tBu ether for Ser and tBu carbamate for Lys), though under milder 
conditions, when carefully controlled, it is possible to cleave Boc groups and leave t-
Bu esters in place (121). Benzyl esters, on the other hand, cannot be removed with 
TFA. They are cleaved by saponification or hydrazinolysis, by treatment with very 
strong acids such as HBr/CH3COOH or hydrofluoric acid, or by catalytic 
hydrogenolysis and they are often unstable as their free bases (121). For these 
reasons in Fmoc SPPS the preferred side chain protection strategy involves tBu-
based groups, while generally when using Boc, benzyl esters are recommended. 
55 
 
Other protecting groups can be selected as long as orthogonality is maintained, 
therefore side chain protection in Fmoc strategy is chosen to be stable to mild 
bases, like piperidine and removable by acidolysis with TFA after peptide synthesis 
is complete.  
Coupling reagents 
To activate the carboxylic acid group of an amino acid in order to enable the 
formation of the peptide bond, the presence of an electron withdrawing group that 
will promote the nucleophilic attack by the amino group of the other amino acid is 
necessary. Common examples of coupling reagents are carbodiimides and the 
phosphonium and uronium derivatives (126). 
 
Carbodiimides include N,N’-dicyclohexylcarbodiimide 36 (DCC), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 37 (EDC) and N,N’-
diisopropylcarbodiimide 38 (DIC). The most widely known is DCC, which was 
introduced in peptide synthesis by Sheehan and Hess in 1955 (127). By addition of 
the carboxylic acid to the carbodiimide, an O-acylisourea (39) is formed, which can 
then be attacked by the nucleophilic amino group of the amino acid (Scheme 1.6). It 
is also possible that the O-acylisourea rearranges via O→N acyl shift to form the N-
acylisourea which, on the other hand, is unreactive. This eventuality can be 
prevented by adding a second equivalent of the carboxyl component that can attack 
the O-acylisourea and form a symmetrical anhydride, which can then react with the 
amine. The addition of appropriate additives, such as HOBt (1-
hydroxybenzotriazole), promotes the formation of an active ester (128), which also 
serves to reduce the occurrence of side reactions. Carbodiimides in general can 
demonstrate a propensity to cause racemisation of the activated amino acid as the 
high reactivity of the O-acylisourea can cause its intramolecular cyclisation, leading 
to the formation of a 5(4H)-oxazolone.  
56 
 
 
Scheme 1.6 Mechanism of DCC-mediated coupling in the presence of HOBt 
Auxiliary nucleophiles like HOBt or NHS (N-hydroxysuccinimide) can also help to 
minimise racemisation, as the active ester formed by reaction with the O-acylisourea 
(or symmetrical anhydride) is less reactive and less prone to oxazolone formation 
(121). 
Another issue is that carbodiimides are not completely selective and they can react 
with amines to form guanidines. In order to avoid the formation of this unwanted 
product, the carbodiimide should be added first to the carboxyl component in order 
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to form the O-acylisourea, followed by the addition of the amino component (128). 
Furthermore it is important that the amount of carbodiimide does not exceed the 
amount of the carboxylic acid 
 
 
 
The first aminium/uronium coupling reagent to be used, in 1978, was O-
(benzotriazol-1-yl)-1,1,3,3 tetramethyluronium hexafluorophosphate (HBTU, 40) 
(129); it reacts with the carboxyl component giving an active intermediate and one 
equivalent of an auxiliary nucleophile (HOBt, 41), which will subsequently react with 
the intermediate generating the active ester (Scheme 1.7). Many modifications have 
been made to the scaffold of HBTU, leading to different analogues with different 
levels of efficiency, like HATU, 42, O-(7-azabenzotriazol-1-yl)-1,1,3,3 
tetramethyluronium hexafluorophosphate (126). Nevertheless HBTU is still widely 
used. When first described HBTU, and subsequently HATU, was assigned a 
uronium structure but later X-ray crystallography revealed that it actually was an 
aminium (or guanidinium) salt (130). The original names though were kept as they 
were already well-known and widely used. 
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Scheme 1.7 Mechanism of HBTU-mediated coupling 
Solid-Phase Peptide Synthesis (SPPS) 
The concept of solid phase peptide synthesis was formulated in 1959 by R. Bruce 
Merrifield, the father of SPPS, when trying to find an easier way to synthesise 
peptides in higher yields than traditional solution-phase synthesis. The intent was to 
introduce an insoluble polymer as a solid support for a growing peptide chain 
covalently linked to it. In 1963 he achieved  the first solid phase synthesis of the 
tetrapeptide H-Leu-Ala-Gly-Val-OH (131). He later optimised the technique by 
choosing increasingly appropriate matrices, protecting groups and deprotection 
systems.  
The α-amino group of the initial amino acid is masked with a protecting group, while 
its carboxyl group is attached to the solid support, usually a polystyrene resin, 
through a linker. Any functional groups on the side chains must be masked with 
orthogonal protecting groups, which are able to resist the conditions of the reactions 
in the different following steps. Subsequently the temporary α-amino protecting 
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group is removed. The coupling of the next amino acid, protected at its α-amino 
functionality with an appropriate temporary protecting group, is achieved by 
activating its carboxyl group in order to allow the formation of the amide bond.  This 
usually happens through the generation of an active ester, typically obtained by 
reaction with a coupling reagent. After coupling, the peptide-resin is washed 
thoroughly to remove any excess reagents and/or any by-products, and the α-amino 
protecting group of the dipeptide is removed. The procedures for the coupling and 
deprotection are then repeated until the target peptide sequence is completed. In 
the final step, the desired peptide is cleaved from the support and the side chain 
protecting groups are removed (126). 
The development of the SPPS method improved the efficiency of peptide synthesis, 
allowing savings in time and labour. It became easier to separate the intermediate 
peptides from soluble reagents and solvents through simple filtration and washing, 
without the need for extraction, purification and characterisation of the 
intermediates. This also allows the use of excess of reagents to drive the reaction to 
completion and minimises physical losses.  Furthermore it is a technique feasible for 
automation, as witnessed by the development of automated peptide synthesisers, 
leading to a drastic decrease in the time and effort necessary to obtain a peptide.  
A potential disadvantage, however, is that incomplete reactions, side reactions and 
impure reactants can generate by-products that, in the case of SPPS, are resin-
bound and can accumulate on the resin to contaminate the final product. Moreover 
these impurities will have very similar characteristics to the desired compound, 
making the separation potentially difficult (121). The original Merrifield SPPS 
strategy used Boc α-amino protection in conjunction with benzyl (Bn) side chain 
protection. A Merrifield resin can be attached to the C-terminal residue of the target 
peptide by nucleophilic displacement (121). The deprotection and neutralisation 
leave a free amino group that can readily react with the second, appropriately 
protected, amino acid using DCC. Unfortunately this combination of protecting 
groups is not entirely orthogonal, as Boc is removed with a mild acid such as TFA, 
whereas Bn removal and cleavage from the resin requires a stronger acid, such as 
hydrogen fluoride. There remains the risk that the repeated use of TFA may result in 
gradual cleavage of the peptide and/or side-chain deprotection, even though these 
groups are less acid-labile. Furthermore the reactions are not necessarily 
quantitative, with the formation of incomplete peptides at each step potentially 
resulting in significant percentages of contamination. This problem can be partially 
solved with the use of an excess of acylating agent, or by repeating the coupling 
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step more times while monitoring the completeness of the reaction with an 
appropriate method like the Kaiser test (132), able to detect any residual free amino 
groups. In the event that the coupling reaction still remains incomplete, it is still 
possible to limit the consequences by “capping” any uncoupled α-amino groups. 
Acetic anhydride is added to react with the unreacted amino groups. This N-
acetylation prevents the elongation of these unreacted reactive amino groups, 
therefore avoiding the formation of deletion peptides (133). 
 
 
Scheme 1.8 Schematic representation of solid phase peptide synthesis  
Modern separation techniques have reached a high level of purification potential and 
the use of “hyphenated” techniques, for example LC-MS, allows the identification of 
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the peptides as they emerge. The desired peptide can thus be separated even from 
complex mixtures. 
Sheppard type SPPS, on the other hand, is based on the idea that the polymeric 
support should have a similar structure to the growing peptide chain and this led to 
the development of polyamide resins. This strategy usually combines this type of 
polymeric matrix with Fmoc α-protection and side chain protecting groups that are 
labile to mild acid. This approach offers complete orthogonality as the repeated 
removal of the temporary α-amino protecting groups is achieved under basic 
conditions, while the final side-chain deprotection and resin cleavage are achieved 
under much milder acidolysis conditions than that used for the Merrifield strategy 
(126). The milder nature of the reaction conditions used for Fmoc-based SPPS also 
lends itself to the construction of more complex peptides including glycopeptides 
and depsipeptides. 
Resins 
Polystyrene is the most widely used core resin in SPPS and it is generally prepared 
in the form of spherical beads. Linear polystyrene dissolves in hydrophobic solvents 
and precipitates in protic solvents, while cross-linked polystyrene is insoluble in 
almost all common solvents (11). An aprotic solvent will solvate cross-linked 
polystyrene resulting in swelling, which is important in order to facilitate the diffusion 
of the reagents into the core of the matrix, shortening reaction times as the resin-
bound intermediates behave more like they are in solution.  
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Resin linkers can be distinguished between integral, like the Merrifield resin 
(chloromethylstyrene-divinylbenzene, 43), in which the linker is part of the matrix 
itself, and non-integral resins, like the Wang resin 44, in which the linker is a 
separate entity attached to the polymer.  
The Wang resin 44, is widely used and incorporates a 4-hydroxybenzyl alcohol 
moiety attached to the polystyrene core through a phenyl ether bond. It is coupled to 
the desired amino acid with good stability through the formation of a benzylic ester 
bond that can be cleaved with moderate acid treatment. Another widely used resin is 
the Rink amide resin 45, which has a benzylhydrylamine attached through a 
benzylic ether bond to the polystyrene core. As with the Wang resin, it can be 
cleaved using moderate acidic conditions, usually with TFA (121) but, as the Rink 
amide resin is linked to the peptide through an amide bond, cleavage yields an α-
carboxamide. Trityl (triphenylmethyl) resins, specifically the 2-chlorotrityl chloride 
resin (CTC 46), are particularly acid-labile (due to the high stability of the trityl cation 
generated) and can be cleaved with acetic acid. This characteristic becomes useful 
when less acid-labile protecting groups need to left in place on the peptide. 
Furthermore, these resins are good for suppressing C-terminal racemisation, as 
their loading doesn’t require carboxyl activation. In addition, the steric hindrance of 
the triphenylmethyl group minimises diketopiperazine (DKP, piperazidinedione) 
formation (Scheme 1.9). 
 
 
Scheme 1.9 Diketopiperazine formation 
The formation of diketopiperazines, 48, is a common side reaction that can  
spontaneously occur at the dipeptide stage in peptide synthesis. It is an aminolysis 
reaction and is triggered generally by basic conditions, even though it has been 
reported that acidic conditions can also promote it, to a certain extent (134). After 
deprotection, the free amino group of the resin-bound dipeptide can cleave the resin 
ester link while forming a DKP. Numerous authors reported unwanted cyclisation 
and examined the problem. It seems that certain C-terminal residues are more 
prone to DKP cyclisation, Gly and Pro being the most cited ones, but also N-methyl 
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amino acids, Val, Ile and iminoacids. Furthermore it appears that DKP formation is 
particularly common when dealing with L,D-dipeptides (134,135). According to 
Bodanszky (135) the tendency towards cyclisation is enhanced in the latter case 
because the side chains are on opposite sides of the plane of the DKP ring. 
Bodansky (135) also reported a higher predisposition for cyclisation in Ala-
containing dipeptides when compared to the ones containing other lipophilic amino 
acids. The reaction is well-known in Fmoc-based solid-phase synthesis because of 
the need for basic conditions (piperidine) to bring about deprotection. The presence 
of a benzyl ester linkage to the resin also seems to be a common feature for the 
undesired DKP formation. 
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1.4 Aims and objectives 
In the light of the general quest for better antibiotic therapies able to eradicate 
increasingly threatening infectious diseases, there are a number of different specific 
strategies. With tuberculosis there is a growing need to tackle antibiotic resistance 
and to provide a shorter duration of therapy for susceptible TB that is more likely to 
be complied with by patients. The search for effective treatments should involve 
discovery or development of new lead compounds, repurposing of already known 
ones and also a search for compounds able to enhance the effect of the already 
available drugs. The latter strategy becomes particularly important in tackling 
resistance, when effective drugs are rendered useless by acquired resistance 
mechanisms. Knowledge of said mechanisms will lead to the identification of 
potential new targets which by themselves might not be essential but become 
fundamental for the cell survival when fighting against antibiotic attack. Elucidation 
of a target structure and evaluation of its activity allows the design of molecules able 
to selectively interact and possibly interfere with it, opening the opportunity for the 
production of inhibitors. New lead compounds can be obtained as classically done 
by exploring the activity of antibiotics of bacterial origin and other molecules 
naturally produced by different organisms as part of their immune response to 
bacterial attack.  
The project will examine a number of different strategies. 
The identification in M. tuberculosis of a potential antibacterial target, Rv3712, 
possibly encoding for Mpl, highlights the need to evaluate its activity utilising its 
possible substrates. This implied: 
- The synthesis of suitably-protected D-allylglycine 49 and L-vinylglycine  50  
olefin building blocks (Chapter 2.2.3)  
- The synthesis, via cross-metathesis of these olefin building blocks, of the 
unusual amino acid mDAP in an appropriately protected form, 51, to provide 
the orthogonality necessary for its employment in solid-phase peptide 
synthesis (Scheme 1.10) (Chapter 2.2.4) 
- The solid-phase synthesis of the mDAP-containing tripeptide H-Ala-D-
Glu(mDAP-OH)-OH, which is the putative Mpl natural substrate (Scheme 
1.10) (Chapter 2.3) 
- The heterologous expression and purification of recombinant Mpl (Rv3712) 
in E.coli using plasmid pCDFDuet-1 carrying the gene of interest (rv3712).  
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Scheme 1.10 Retrosynthesis of the putative H-Ala-D-Glu(mDAP-OH)-OH tripeptide substrate of Mpl 
Furthermore, structural analogues of the putative substrate would be a logical 
starting point for the production of possible inhibitors of the Mpl target. This would 
require: 
- Optimisation of automated solid-phase synthesis methodology (Chapter 
2.1.3) 
- The manual and/or automated synthesis of Lys-containing PG fragments 
(Chapter 2.1) 
- Testing of the inhibitory activity of the PG fragments on a whole-cell assay, 
using Mycobacterium smegmatis, M. aurum and M. bovis BCG, and E. coli 
(Chapter 2.1.5.2) 
 
Following on from the general aim, the discovery of anti-TB naturally-occurring lasso 
peptides inspired a different approach, with the purpose of evaluating if simplified 
analogues and the non-threaded precursors might retain any level of antibacterial 
activity. This would require: 
- The synthesis of the linear analogues of lariatins A and B (Chapter 2.4.1) 
- The synthesis of the linear analogue of lassomycin, and its C-terminal free 
acid derivative (Chapter 2.4.1) 
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- The synthesis of the cyclic natural products lassomycin and lariatins A and B 
(Chapters 2.4.1 and 2.4.2)   
- Evaluation of the antibacterial activity of the synthesised lasso peptides 
using a whole-cell assay, using Mycobacterium aurum, Mycobacterium 
smegmatis and Mycobacterium bovis BCG (Chapter 2.4.4) 
  
67 
 
2. RESULTS AND DISCUSSION 
2.1 C-Terminal truncated fragments of PG pentapeptide H-Ala-D-
Glu(Lys-D-Ala-D-Ala-OH)-OH 
We first sought to synthesise a series of truncated peptides based upon the 
pentapeptide 53 found in the peptidoglycan of Gram positive organisms. The 
peptides were truncated from the C-terminus, giving the di-, tri- and tetrapeptide (as 
well as the complete pentapeptide), all starting with the N-terminal L-alanine residue. 
As the C-terminal residues of the peptides were different, each synthesis had to be 
performed independently. 
 
2.1.1 Manual synthesis of lysine-containing peptides 
While a strategy for the synthesis of mDAP was being devised, the H-Ala-D-Glu-OH 
dipeptide and Lys-containing peptidoglycan peptide fragments were synthesised. 
These fragments could possibly act as inhibitors of the Mur ligases of organisms 
generally incorporating mDAP in their PG. In addition, they are the natural 
substrates of Gram positive bacterial Mur ligases, and are therefore also useful to 
evaluate the ligase activity in such organisms.  
The manual synthesis of the tripeptide 54 started from Fmoc-Lys(Boc)-Wang resin. 
Coupling between the D-Glu and Lys residues required the reaction between the 
side chain γ-carboxyl group of D-Glu and the α-amino group of Lys. After Nα-Fmoc 
deprotection, coupling of Fmoc-D-Glu-OtBu gave the desired linkage and the 
tripeptide was completed using standard SPPS, through deprotection followed by 
coupling of the Ala residue (Scheme 2.1).  
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The manual synthesis of tripeptide 54 required triple coupling with Fmoc-D-Glu-OtBu 
in order to obtain a negative Kaiser test result and yielded a product with a crude 
purity of 42%. 
 
Scheme 2.1 Solid-phase synthesis of tripeptide 54 
Reagents and conditions: a) 20% piperidine in DMF, 2 x 15 min; b) Fmoc-D-Glu-OtBu, HBTU, HOBt, 
DIEA, DMF, 2 x 30 min. 
The manual synthesis of tetrapeptide 55, starting from Fmoc-D-Ala-Wang, required 
three cycles with Fmoc-Lys(Boc)-OH to achieve successful coupling and yielded a 
crude product with a 34% purity. Synthesis was otherwise generally carried out as 
described for the tripeptide 54.  
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The manual synthesis of pentapeptide 53, starting from Fmoc-D-Ala-Wang resin, 
required three couplings with Fmoc-Lys(Boc)-OH and Fmoc-D-Glu-OtBu, and four 
couplings with Fmoc-Ala-OH to give a crude product with a 36% purity.  
Dipeptide 56, which is one of the naturally occurring substrates for Mpl and MurC 
both in Gram negative and Gram positive bacteria, was first synthesised manually 
starting from pre-loaded Fmoc-D-Glu(OtBu)-Wang resin. HPLC analysis showed a 
disappointingly low 18% purity of the crude product. The analytical HPLC 
chromatogram showed two substantial secondary peaks (Rt = 7.80 and 10.10 min) 
eluting after the desired peptide (Rt = 5.68 min). It was suspected that one could be 
due to the formation of a diketopiperazine (DKP, piperazinedione). Unfortunately it 
was not possible to efficiently separate the closely-eluting components by 
preparative HPLC in order to collect a sample of sufficient mass for full 
characterisation.  
 
As discussed above, the formation of diketopiperazines is a known side reaction, 
generally triggered by basic conditions, which can spontaneously take place after 
deprotection of the resin-bound dipeptide in peptide synthesis. In this case the 
dipeptide is pre-disposed to DKP formation as the two constituent amino acids are 
of opposite configuration (Scheme 2.2). 
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Scheme 2.2 The eventual cyclisation of deprotected H-Ala-D-Glu-OH would lead to the formation of a 
diketopiperazine, 3-(5-methyl-3,6-dioxopiperazine-2-yl)propanoic acid 57 
We therefore attempted to minimise the chances of DKP formation by using a 2-
chlorotrityl chloride resin (CTC), which has been shown to protect from undesired 
early cleavage through the steric hindrance of the bulky triphenylmethyl group close 
to the esterification site (136).  
 
Scheme 2.3 Fmoc-D-Glu(OtBu)-OH loading onto CTC resin 
Reagents and conditions: a) dry CH2Cl2, DIEA, N2, 120 min. 
Protected D-Glu first had to be loaded onto the resin as shown in Scheme 2.3. CTC 
resin is very sensitive to moisture and therefore the amount required was thoroughly 
dried in a desiccator prior to use and the loading procedure was carried out in 
anhydrous conditions under a nitrogen atmosphere. The dipeptide was completed 
by Fmoc deprotection and coupling of L-Ala in the normal manner, followed by 
cleavage.  Preparative HPLC led to the successful isolation of the pure dipeptide in 
47% yield, the identity of which was confirmed by MS analysis. The analytical HPLC 
chromatogram highlighted the presence of one single secondary peak, which 
remains unidentified. This approach represents an improvement over the Wang 
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resin-based attempt, as the yield recovered is more than double compared to that 
extrapolated from the HPLC (18%) of the Wang attempt. 
2.1.2 Automatic synthesis of lysine-containing peptides  
Synthesis of the peptides was repeated using a Biotage Syro I automatic 
synthesiser. The intention was to compare crude yields and purities obtained 
manually and automatically to find the best approach for the production of a series 
of analogues. For ease of comparison the synthesiser was programmed to mimic as 
closely as possible, given the machine limitations, the standard approach utilised for 
the manual synthesis (two couplings of 30 min per residue, including initial swelling 
of the resin in DMF for 1 h). On the other hand, it should be considered that the 
machine system performs deprotection using 40% piperidine for 3 min, followed by a 
longer reaction with 20% piperidine, while manually the two deprotection repetitions 
both consist of 15 min reactions with 20% piperidine. Furthermore automatic 
coupling was carried out without the addition of HOBt to the coupling mixture. It 
should also be taken into consideration that some of the manual synthesis required 
more than two couplings per residue to obtain a negative Kaiser test, while altering 
the programmed cycles based on the completeness of the coupling reactions would 
lose the principal advantage of no need for user intervention, provided by automatic 
synthesisers.  
Description Manual (%) Automatic (%) Combined yield (%) 
Pentapeptide 53 36 41 43 
Tetrapeptide 55 34 59 20 
Tripeptide 54 42 61 41 
Dipeptide 56 (Wang) 18 37 - 
Dipeptide 56 (CTC) 43 -  47 
Table 2.1 Comparison between manual and automated syntheses of 53, 54, 55 and 56. The values 
reported as “manual” and “automatic” represent the percentages of the desired peptide AUC compared 
to total AUC in the HPLC chromatogram. “Combined yield” represents the yield obtained after 
purification (System P3) of the combined crude samples obtained from manual and automatic 
syntheses.  
All the C-terminal truncated Lys-contaning PG fragments were therefore synthesised 
again using the automated system mentioned above. The comparison of the crude 
purities (percentage of total chromatogram AUC represented by the desired peak) 
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obtained from HPLC analyses of the manually and automatically synthesised 
samples is shown in Table 2.1. 
The crude product purities extrapolated from HPLC chromatograms were deemed 
sufficient for comparison purposes but in order to be able to utilise the peptides for 
evaluation of biological activity it was necessary to purify them, therefore the 
manually and automatically obtained samples were combined prior to purification. 
The yields of the combined syntheses are shown in Table 2.1. 
As the manual synthesis can be tightly controlled, monitoring couplings through the 
use of the ninhydrin test, and couplings repeated if incomplete, it would have been 
expected to observe a better purity profile in samples obtained manually. The results, 
however, indicated the contrary as the automatically synthesised peptides showed 
higher purities. 
For pentapeptide H-Ala-D-Glu(Lys-D-Ala-D-Ala-OH)-OH 53, manual and automatic 
syntheses did not differ significantly in terms of purity, though it should be taken into 
account that three additional coupling steps were performed for the manual 
synthesis. The automated synthesis was therefore more efficient than the manual 
one, allowing a saving in material and time. 
Repetition of the tetrapeptide H-Ala-D-Glu(Lys-D-Ala-OH)-OH synthesis with the 
automatic system gave a much purer crude product (59% purity) when compared to 
the manually synthesised one (34%). 
Automatic synthesis of tripeptide H-Ala-D-Glu(Lys-OH)-OH 54 set up with double 
coupling also significantly improved the purity of the crude product (61%) in 
comparison with the product from the manual synthesis. A second automated 
synthesis of 54 gave similar results (55% crude purity) and purification of this 
sample via preparative HPLC gave the desired peptide in 49% yield. 
The synthesis of the dipeptide H-Ala-D-Glu-OH 56 was attempted on the automatic 
synthesiser starting as before with Fmoc-D-Glu(OtBu)-Wang resin. HPLC analysis of 
the crude product indicated a crude purity of 37%. Two later-eluting peaks of 
unknown identity were visible on the HPLC chromatogram, as was the case for the 
manual synthesis  The crude sample was combined with the crude dipeptides from 
two Wang resin-based manual syntheses for preparative HPLC. Unfortunately, 
instrumental problems during the purification led to sample loss meaning that the 
overall combined yields of dipeptide cannot be reliably stated. It is still possible to 
compare the purities extrapolated from the HPLCs of the crude products. According 
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to these data the automated synthesis on the Wang resin gave a much better quality 
product than the manual one. The CTC approach, meant to reduce DKP formation, 
was the most successful resulting in a greater proportion of desired product (47%) 
compared to the manual and automated Wang resin samples extrapolated purities 
(18% and 37% respectively). 
It is apparent that the automated syntheses, in general, resulted in crude peptides of 
better quality than the same peptides synthesised manually. Considering that each 
manual synthesis required a number of additional couplings to obtain a negative 
Kaiser test at each cycle, this is perhaps surprising as it might be expected that 
reactions would proceed similarly during automated synthesis. One possible reason 
for this could be the consistency of the automated repeated task performance, 
particularly the efficiency of the mixing and washing steps, which may help to avoid 
the “operator error”. The use of the synthesiser also reduced the time and the 
material necessary for the obtainment of the products and required considerably 
less “operator time” than manual synthesis. 
The use of the automated system is therefore advisable even though it might be 
appropriate, when dealing with expensive or unusual amino acids, to investigate the 
optimum protocols first manually, in order to avoid excessive loss of precious 
material. 
2.1.3 Syro I optimisation 
Automated solid-phase peptide synthesisers are very useful tools for saving time 
and labour. The question is whether they are as reliable (giving the best chance of a 
high-quality product) and flexible (able to manage a variety of synthetic steps) as a 
manually operated synthesis. The laboratory is equipped with a Biotage Syro I 
synthesiser. This is a programmable single-channel synthesiser with a robotic arm 
capable of dispensing accurate volumes of liquid reagents and solutions (amino 
acids, coupling agents) into multiple reaction vessels. Other liquid handling 
processes (washing, filtration) and mixing are controlled automatically. Up to 24 
peptides can be synthesised simultaneously. The instrument has a default SPPS 
protocol that can be easily customised as preferred. There is a lack of published 
literature on the rationale for the selection of standard automated protocols used for 
coupling and deprotection, and typically no indication as to why instrument 
manufacturers pre-program certain protocols for SPPS. Therefore it was thought 
that a comparative study would be useful in order to investigate the optimal coupling 
protocol to be used and to verify how efficient the automated system is. The default 
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coupling protocol that is pre-programmed on the system utilises a four-fold excess 
(over resin substitution) of amino acid and HBTU and a two-fold excess (over amino 
acid residue amount) of DIEA in a single coupling step of 40 minutes. When working 
manually, the protocol adopted in our laboratory consists of a minimum of two 
couplings of 30 min each with 2.5 equivalents of amino acid, HBTU and HOBt and 5 
equivalents of DIEA. As a starting point, we first evaluated the use of this coupling 
protocol on the Syro I, but without using HOBt, followed by a series of protocols 
differing in the number and duration of couplings and the molar excess of activated 
amino acids used.  
Initially a biologically relevant test peptide, Leu-enkephalin 61, was used throughout 
the study.*  
 
In the initial investigation, an identical mass of Fmoc-Leu-Wang resin was used for 
each synthesis. The automated SPPS coupling protocol was varied from the pre-
programmed Syro protocol (entry #1, Table 2.2) to examine the effect on the yield 
obtained using a different number of couplings with the same individual duration 
(entries #2 and #5, #4 and #8, Table 2.2) and with different durations but adding up 
to the same overall coupling time, 60 min (entries #2, #3 and #4, Table 2.2). The 
duration of the repeated couplings (entries #2 and #8, #3 and #7, Table 2.2) and the 
number of amino acid equivalents used (entries #2 and #6) were also varied. One 
further investigation was carried out to evaluate a different work-up procedure to 
isolate the crude peptide after cleavage. Rather than the standard procedure in our 
laboratory of filtration after precipitation of the peptide in cold diethyl ether, we 
examined the use of a centrifuge to sediment the peptide after precipitation with 
(less volatile) tert-butyl ether (entry #9, Table 2.2). All syntheses were repeated in 
quadruplicate and the mean percentage yield calculated. The maximum expected 
yield of pure peptide was calculated by multiplying the percentage purity of the 
crude product (AUC of target Leu-enkephalin peak divided by total chromatogram 
                                               
*
 Some aspects of these preliminary studies were contributed to by MPharm project students, Ambica 
Bhambra and Min Tan, under my supervision. 
75 
 
peak area) by the mass of crude peptide. This method was adopted to remove the 
recovery from HPLC purification as a factor that might affect the yield. The retention 
time of 61 was known as an analytical standard was synthesised, purified and 
analysed.  
Entry Equivalents Couplings Time 
(min) 
Crude Purity 
(%) 
SD Notes 
1 4.0 1 40 60 3.5 
Syro default 
method 
2 2.5 2 30 69 2.6  
3 2.5 3 20 70 2.5  
4 2.5 1 60 41 1.7  
5 2.5 1 30 66 5.8  
6 4.0 2 30 32 10.8  
7 2.5 3 10 54 3.3  
8 2.5 2 60 35 3.7  
9 2.5 2 30 71 2.7 Centrifuge 
Table 2.2 Percentage yields obtained using different protocols for the automatic synthesis of Leu-
enkephalin on a Biotage Syro I instrument. Each protocol was carried out 4 times and the percentage 
yield shown is the mean. The equivalents mentioned in the column title refer to the amino acids and 
HBTU. 
The results obtained were statistically analysed using one-way ANOVA and the test 
showed that they are not to be considered statistically different. This outcome 
suggests that different number of couplings do not significantly affect the yield; one 
coupling of 30 min (#5) gave very similar results to two couplings of 30 min (#2). It 
also seems that increasing the duration of the coupling reaction may even produce a 
decrease in yield, as shown by the comparison between entries #4 and #5, involving 
individual couplings of 60 min, and their correspondent entries #2 and #8, involving 
double couplings of 30 min. This can possibly be due to the fact that longer reaction 
time allows an increase in the formation of side products, which will reduce the yield 
of the desired product. In addition it seems that using a higher number of amino acid 
equivalents does not necessarily result in an improved outcome; on the contrary, as 
noticeable by comparing #2 and #6, it appears to have reduced the percentage yield. 
A possible reason for this result could be that, given that increasing the equivalents 
produces a higher concentration of reactants is likely to increase the rate of by-
product formation, as well as the desired product formation. The use of 
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centrifugation during the peptide work up seems to not significantly affect the 
outcome (#2 and #9), which confirms this as a promising method that could be 
potentially less time-consuming and labour intensive, as well as being more 
consistent and suitable for higher throughput. A disadvantage is that access to 
appropriate equipment is required.  
A second attempt at the evaluation of the optimal automated synthesis involved the 
use of an HPLC calibration curve to more reliably calculate the mass of pure peptide 
obtained from each trial. The calibration curve was obtained by analysing known 
concentrations of a manually synthesised and purified Leu-enkephalin standard (see 
Chapter 4.7). The mass extrapolated this way will be more accurate because it won’t 
be influenced by any residual solvent present after freeze-drying or fluctuation in 
mass due to external factors. The crude product obtained through the Syro I could, 
once dissolved to make a fixed volume of solution, be analysed via HPLC and the 
concentration determined from the peptide AUC by interpolation on the calibration 
curve. At this point, knowing the solution volume, the mass of pure peptide in the 
crude sample can easily be calculated, avoiding the problem of recovery from 
preparative HPLC, but in a more accurate manner than the gravimetric method used 
before. 
Entry Equivalents Couplings 
Time 
(min) 
Crude 
Purity (%) 
SD Notes 
1 2.5 1 40 52 4.5  
2 2.5 1 30 56 1.0  
3 2.5 3 30 57 1.0  
4 2.5 2 30 46 1.5  
5 2.5 1 60 54 0.4  
6 2.5 3 20 61 1.9  
7 2.5 2 15 57 1.8  
8 2.5 2 45 60 0.6  
9 2.5 2 30 55 1.2 No swelling 
10 2.5 2 30 66 0.6 Centrifuge 
11 4.0 2 30 60 0.2  
12 5.0 2 30 57 2.1  
Table 2.3 Percentage yields obtained using different protocols for the automatic synthesis of Leu-
enkephalin (calibration curve method) on a Biotage Syro I instrument. Each protocol was carried out 3 
times and the percentage yield shown is the mean.  
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When performing routine solid-phase synthesis it is conventional to allow the resin 
to swell in the appropriate solvent before starting the first synthetic step. This 
ensures solvation of the polymer and aids penetration of reactants and reagents. 
Each synthesis was therefore preceded by one hour swelling of the resin in DMF, 
except for one, in order examine the effect, if any, that this step may have on the 
yield. The experiment involving the use of a centrifuge during work up was also 
reproduced and evaluated using the current method. Each protocol was repeated in 
triplicate and the mean percentage yields obtained are shown in Table 2.3. 
Statistical analysis of the results using one-way ANOVA showed that the variation 
between the yields obtained through different protocols are not to be considered 
significantly different (the centrifuge experiment was not included in the statistical 
analysis because its outcome is to be considered a result of the different treatment 
after cleavage). The experiment with the standard conditions used for manual 
synthesis (entry #4, Table 2.3) gave an unexpectedly low mean yield (46%), which 
was the result of a quite high standard deviation of the three repeats; the 
corresponding experiment without pre-swelling (entry #9, Table 2.3) gave a mean 
yield of 55%. In the light of other results it would seem beneficial to repeat that 
individual trial (entry #4, Table 2.3) but technical issues at the time made it 
impossible. For the purpose of comparing yields, when the variable is the duration of 
each coupling (entries #7 and #8, Table 2.3), a more reliable comparison might be 
made with the result obtained without swelling (entry #9, Table 2.3). It might be 
expected that a longer coupling time would improve the yield, but the results 
obtained with 15, 30 and 45 min couplings are not statistically different. This finding 
actually agrees with the findings of Fields (137) that most coupling reactions reach a 
plateau, in terms of percentage completion, in less than 30 minutes and cannot be 
pushed any further forward by extending the reaction time. In addition, long reaction 
times may favour kinetically slower side reactions leading to an increased 
percentage of undesired side products. The duration of the reaction therefore seems 
not to play a significant role in the yield obtained when performed for longer than 30 
minutes. The lack of improvement with increase coupling duration agrees with the 
results of the first study. Varying the number of couplings also did not result in a 
significant difference in percentage yield, according with the results of entries #2, #3 
and #9, as also found through the previous Leu-enkephalin protocol evaluation 
(Table 2.2). Partly in contrast to the previous study, the employment of higher amino 
acid equivalents per coupling (#9, #11 and #12) did not appear cause any significant 
variation in the percentage yield. The results in this study do not seem to indicate 
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that increasing the number of equivalents is as detrimental as suggested in the first 
study. 
Collectively, these outcomes likely suggest that the chosen peptide sequence is 
insufficiently challenging to synthesise, therefore it was deemed necessary to re-
evaluate the series of protocols using a more challenging sequence.  
Still, it is clear that eliminating the swelling step does not appear to significantly 
influence the product yield for this sequence (in which the first synthetic step is 
deprotection). This means that the overall SPPS process can potentially be speeded 
up by eliminating or reducing the duration of this step as sufficient swelling may 
occur during deprotection. Furthermore the use of the centrifuge to facilitate isolation 
of the peptide after cleavage and precipitation has been demonstrated to be at least 
comparable to, if not slightly better than, the normal filtration-based manual work-up 
typically employed in our laboratory, from a quantitative point of view. As mentioned 
above, the use of a centrifuge, depending on its capacity, can allow the post-
cleavage work-up of multiple samples at the same time. This is ideally suited for use 
in conjunction with an automatic synthesiser if several peptides are synthesised 
simultaneously.   
In the light of the outcomes with Leu-enkephalin, the acyl carrier protein fragment 
ACP 65-74 (62) Val-Gln-Ala-Ala-Ile-Asp-Tyr-Ile-Asn-Gly) was selected as an 
appropriately challenging sequence (138). This peptide has been extensively used 
as a model to evaluate different aspects of peptide synthesis, due to the difficulties 
commonly encountered in the coupling reactions and in its purification (138). The 
progressive elongation results in folding of the peptide and the steric hindrance of 
side chains reduces peptide-polystyrene solvation which usually renders reactive 
sites increasingly inaccessible resulting in lower yields (139). 
 
In order to prepare a calibration curve, a pure analytical standard of ACP 65-74 
needed to be synthesised. Firstly manual synthesis was performed starting from 
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Fmoc-Gly-Wang resin. Most amino acids required three (or even four) couplings of 
30 min (using a 2.5-fold molar excess of amino acid, HBTU and HOBt in the 
presence of a 5-fold excess of DIEA) for the Kaiser test to be negative. Coupling of 
the last amino acid, Fmoc-Val-OH, was not complete after five attempts. An 
extended 4 h coupling using double amounts of reagents, still failed to bring the 
reaction to completion, therefore a further 4 h coupling, using DIC activation in the 
presence of catalytic DMAP, was conducted. As the Kaiser test result was still not 
completely satisfactory, the remaining free amino groups were capped using acetic 
anhydride. These difficulties agree with previous findings, in which the ACP 
sequence folds into a β-sheet conformation after coupling of the penultimate Gln 
residue. This folding makes it very difficult for the activated Fmoc-Val-OH to 
approach the free N-terminal amino group in such a way as to result in acylation 
(138). Unfortunately preparative HPLC separation of the crude mixture failed to yield 
any completely pure product, even after a further HPLC purification of the fractions 
containing the peptide of interest. An automated synthesis on Wang resin utilising 
double-couplings of 30 min duration for every residue was subsequently 
programmed. Careful purifications of the crude product obtained led to the isolation 
of a small quantity of pure ACP 65-74. Serial two-fold dilutions of a standard solution 
of the peptide and analysis of the resulting diluted solutions via HPLC allowed the 
construction of the calibration curve. The peptide was synthesised following the 
different coupling protocols previously evaluated with Leu-enkephalin, with the 
inclusion of an experiment involving the addition of HOBt to the coupling mixture. 
This coupling reagent is used, in combination with HBTU, in the standard manual 
protocol used in our laboratory and, as it is not included in the pre-loaded default 
automated protocol of the synthesiser, it seemed appropriate to evaluate whether its 
use affects the outcome. The centrifuge-based work-up was not further examined as 
its use would not be dependent on the sequence chosen, therefore the results so far 
obtained were deemed sufficient for its evaluation. Each experiment was performed 
in triplicate; the samples were analysed and data collected as described previously 
with Leu-enkephalin. The resulting percentage yields are shown in Table 2.4. 
Statistical evaluation using one-way ANOVA shows that the mean yields are not 
significantly different from each other except for protocol #4. This lack of significance 
is likely due to the small number of repeats (three) for each experiment. However it 
appears that, in general, coupling times longer than 30 min do not necessarily offer 
any improvement (entries #1, #2 and #5, Table 2.4), and that increasing the number 
of couplings from one to two brings a modest yield improvement (entries #2 and #4) 
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but further increasing to three couplings has very little, if any, effect (entries #3 and 
#4, entries #6 and #8). Increasing the molar excess of reactants per coupling does 
not seem to significantly improve the yield. In contrast to the Leu-enkephalin results, 
swelling the resin prior to SPPS seemed to have a beneficial effect on this sequence, 
but the addition of HOBt to the reaction mixture did not seem to offer any significant 
advantage. 
Entry Equivalents Couplings Time 
(min) 
Crude 
purity (%) 
SD Notes 
1 2.5 1 40 21 1.5  
2 2.5 1 30 25 0.5  
3 2.5 3 30 33 1.7  
4 2.5 2 30 39 1.2  
5 2.5 1 60 27 0.3  
6 2.5 3 20 29 2.0  
7 2.5 2 10 27 0.6  
8 2.5 2 20 25 2.2  
9 2.5 2 30 27 1.5 No swelling 
10 2.5 2 30 26 1.4 HOBt 
11 4.0 2 30 28 2.6  
12 5.0 2 30 32 0.2  
Table 2.4 Percentage yields obtained using different protocols for the automatic synthesis of ACP 65-
74 on a Biotage Syro I instrument. Each protocol was carried out 3 times and the percentage yield 
shown as the mean. One-way ANOVA with Bonferroni correction showed that protocol #4 is 
significantly different from protocol #1 (P<0.001), #2 (P<0.01), #5 (P<0.05), #7 (P<0.05), #8 (P<0.01), 
#9 (P<0.05), #10 (P<0.05). 
Given these results, the protocol analogous to that used for manual SPPS (2 
couplings of 30 min employing 2.5 amino acid equivalents per coupling, entry #4) 
was adopted for subsequent syntheses, because it seems a good compromise 
between coupling repetitions, duration and material usage especially when 
compared to the other protocols whose running time adds up to 1 h (entries #5 and 
#6).  
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2.1.4 Automatic synthesis of analogues of Gram positive bacterial PG 
fragments† 
After the optimisation of the automatic synthesis, the chosen protocol was used to 
synthesise a number of structural analogues of the previously synthesised Gram 
positive bacterial PG fragments. A series of tripeptide sequence analogues was 
synthesised replacing the L-Ala residue with similar small, lipophilic amino acid 
residues: L-Val, L-Leu and L-Ile (63, 64 and 65 respectively), or replacing the basic 
Lys residue with an Arg residue (66). Similarly, the pentapeptide sequence analogue 
H-Ala-D-Glu(Lys-Gly-Gly-OH)-OH (67), in which both D-Ala residues were 
substituted by Gly residues, was prepared.  
These peptides were each synthesised on 25 μmol scale. Each of the crude 
peptides was of sufficient quality (judged by their HPLC profiles, >90% purity) to be 
used for preliminary biological evaluation without further purification.  
  
                                               
†
 Some aspects of this study were contributed to by a Doctoral Training Programme rotation project 
student,  Yuen Tin Lui, under my supervision. 
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2.1.5 Biological evaluation  
2.1.5.1 Target-based evaluation 
Ideally the peptide fragments and analogues were intended to be tested on the 
heterologously expressed and purified M. tuberculosis Mpl, in order to evaluate 
whether the molecules interact with the target protein and if they exert any type of 
activity. They were also supposed to be tested on Gram positive bacteria Mur 
ligases. Unfortunately, due to time restrictions, this testing has yet to be performed. 
2.1.5.2 Whole-cell evaluation 
The antibacterial activities of the peptide fragments were evaluated using the whole-
cell SPOTi assay (as described in Chapter 4.6.5.13), while the isolation of the pure 
Mpl enzyme was being optimised. The mycobacteria chosen for testing are M. 
aurum, M. smegmatis and M. bovis BCG. The Gram negative organism used was 
E.coli  DH5α. The bacteria were grown as described in Chapter 4.6.5.6. These 
experiments were intended to demonstrate any degree of growth inhibition by these 
compounds which could be misincorporated into the peptidoglycan by Mur ligases. 
Tripeptides 54, 63, 64, 65 and 66 have the potential to specifically interact with MurE 
and Mpl, while tetrapeptide 55 would be expected to interact with Mpl only, and 
pentapeptides 53 and 67 with MurF, as they most closely resemble the natural 
substrates of those enzymes. 
The 96-well plate SPOTi method, developed at Birkbeck College (140), is ideal for 
rapid evaluation of potential antibacterial drugs against the whole cells. Dilutions of 
the compounds are transferred to a 96-well plate, the plate is filled up with agar, and 
shaken to achieve a homogeneous dispersion. After drying the plate, bacteria are 
inoculated on top of the solidified agar and the plate is incubated for the appropriate 
time. The outcome of the assay is determined by observation of growth, tipically in 
the form of a spot, and the MIC is assigned based on the lowest concentration of the 
compound where no growth is visible. Two-fold serial dilutions in water of every 
peptide were prepared starting from a concentration of 50 mg/mL. Isoniazidwas 
used as a positive control, with serial dilutions from 5 mg/mL. 
The drug dilutions were transferred onto a 96-well plate, followed by addition of agar 
directly on the plate. Water was used as the negative control. The bacterial liquid 
culture was then inoculated and the plate incubated at a temperature and for a 
duration suitable to the organism against which activity was tested (as described in 
Chapter 4.6.5.13). In the case of E.coli the structural analogues of the Lys-
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containing PG fragments (63-67) were not evaluated because of a lack of  material 
available. 
Unfortunately none of the peptides tested showed any inhibition on the whole-cell 
assay, while the positive control isoniazid showed its characteristic MICs. 
This outcome could either be due to the inability of the peptides to reach their target 
sites or to exert an action on them. In the first case, possibly, the layer of mycolic 
acids, or the outer membrane in the case of E.coli, might be the barrier stopping 
them from entering the cytosolic space. A previous study on E.coli found that the 
Lys-containing tripeptide was not being accepted as a substrate by Mpl (141). As 
there are no studies on the permeability of these layers to these compounds it is not 
possible to draw definitive conclusions from these results regarding their apparent 
lack of activity in this assay. This is why a target-based assay would be more 
appropriate.   
Furthermore it is not currently known whether these other mycobacteria species 
possess a gene encoding for Mpl. An ortholog, MSMEG_6276, of the putative 
M.tuberculosis Rv3712, showing  81% sequence homology has been identified in M. 
smegmatis in our group, using bionformatic methods, but has yet to be fully 
investigated.  
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2.2 mDAP: Access to the putative substrates 
2.2.1 The challenges 
The main issue that needed to be addressed in order to approach the synthesis of 
the substrates was how to obtain mDAP in a protected form suitable for solid-phase 
synthesis. mDAP is a stereoisomer of 2,6-diaminoheptanedioic acid (Fig. 2.1) in 
which the two chiral centres (C2 and C6) are of opposite configuration.  
 
Figure 2.1 2,6-diaminoheptanedioic acid 
In a symmetrical molecule with n = 2 chiral centres, like mDAP, the number of 
possible stereoisomers is not 2n because two of the four possible configurations are 
superimposable (and therefore identical), as shown in Fig. 2.2. Such a molecule can 
therefore exist as only three different isomers – (R,R), (S,S) and meso. The meso 
isomer has opposite absolute configuration (R and S) at each chiral centre. For this 
reason DAP can exist as a mixture of three different molecules that are 
indistinguishable via mass spectrometry.  
 
Figure 2.2 Possible configurations of a symmetrical molecule with two chiral centres. The (R,S) and 
(S,R) isomers can be superimposed through a 180° rotation.  
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The meso form could be distinguished from both the (R,R) and (S,S) isomers via 
NMR spectroscopy and liquid chromatography; the (R,R) and (S,S) enantiomers 
would have identical NMR spectra and retention times. Separation of the meso form 
from the other two DAP stereoisomers using a standard reversed-phase HPLC 
column would not be possible as the molecule is small and the differences in polarity 
are minimal; a chiral stationary phase would be beneficial.   
Isolating the correct isomer would be followed by the issue of finding a protection 
strategy suitable for solid-phase synthesis. Mycobacterial PGN contains a meso-
DAP residue, incorporated into the pentapeptide chain through its (S)-configuration 
centre, while the (R)-configuration centre forms the free side chain. When 
incorporated into the peptide backbone, the symmetry is thus lost and the amino 
acid residue strictly no longer fulfils the conditions of a meso compound. 
Consequently the amino group of the (S) centre is the one that needs to be Fmoc-
protected and its carboxylic acid group needs to remain unprotected to participate in 
the solid-phase coupling reaction. For the same reason the (R) centre amino and 
carboxyl groups have to be protected differently, such that the protecting groups 
remain in place until cleavage of the completed peptide from the resin.  
The fact that selectively-protected mDAP is not available on the market presents a 
challenge. mDAP can only be purchased in its unprotected form and it is very 
expensive (£724 for 250 mg from one source). Even if purchased, this would still 
present the problem of how to differentiate between the identical carboxyl and amino 
groups. A cheaper (long-term) option available would be the purchase of DAP, 
followed by isolation of the meso isomer on a preparative HPLC chiral column, but 
still leaving the issue of protection. The most viable option left to access selectively-
protected mDAP is its synthesis.  
2.2.1.1 Stereoselective approaches to mDAP and PG fragments 
Given the limitations of separating and selectively protecting isomers, the synthetic 
route of choice should be stereoselective, aiming to obtain the protected meso form 
alone.  
Solution-phase synthesis of mDAP has been reported through a number of lengthy 
or inconvenient procedures.  
Gao et al. (142) tried four different methods: the olefin metathesis skeleton 
assembly proved unsuccessful due to the propensity of the vinylglycine to isomerise. 
On the other hand they obtained the desired DAP derivatives following three 
different routes: an ene reaction employing chiral 2-cyclohexyl auxiliaries gave a 
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dissatisfying isomer ratio, while the stereospecific reduction of 2-keto-6-
aminopimelic derivatives with Binap-ruthenium catalyst and the ene reaction 
catalysed by a chiral copper oxazoline were more successful yield-wise but 
nonetheless produced mixtures of the desired DAP diastereoisomers (meso- and 
S,S-DAP), meaning that separation was still needed (Scheme 2.4). The products 
obtained with these strategies still contained unprotected carboxyl moieties, leaving 
the additional problem of how to protect them separately. One further disadvantage 
of these methods is that they involve a large number of steps.  
 
Scheme 2.4 Synthesis of mDAP by Gao et al. (142) 
Reagents and conditions: a) H2, MeOH, (S)-Binap-Ru (II), 4 atm, 100 °C, 4 h, 90%; b) Ph3P, THF, 
diethyl azodicarboxylate, 5 h, 79%; c) THF, BuLi, -78 °C, 10 min, sulfonyl chloride, -60 °C, 4 h, 90%; d) 
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CF3COOH, THF, 4 h, 79%; e) benzyl chloroformate,  CH2Cl2, pyridine, 4 h, 98%; f) MeO2CCHO, (R)-
2,2′-isopropylidenebis-(4-phenyl-2-oxazoline), Ar, 2 h, 42%; g) NaBH4, NiCl2, 15 min, 42%; h) Bu4NF, 
THF, 15 min, 99%; i) NaOH, 4 h, 94%; j) H2/Pd-C, glacial acetic acid, 14 h;  CF3COOH,  CH2Cl2, 64%. 
In 2007 Inamura et al. (143,144) reported the synthesis of derivatives of iE-DAP (H-
D-Glu(mDAP-OH)-OH) dipeptide 85 from a DAP isomeric mixture, with 
homoprotected carboxylic groups via solid phase synthesis (Scheme 2.5).  
DAP dibenzyl ester was loaded through an amino group onto a 2-chlorotrityl resin, 
and the remaining free amino group was then acylated with the γ-carboxyl group of 
Fmoc-D-Glu-OBn. After Fmoc deprotection, the amino group was derivatised with 
one of a number of acyl substituents using octanoic acid, tridecanoic acid, 
tetradecanoic acid, pentadecanoic acid, palmitic acid, 4-cyclohexylbenzoic acid, 4-
propylbenzoic acid, 4-fluorobenzoic acid, 3-(4-aminocyclohexyl)propionic acid or 
tetrahydrofuran-2-carboxylic acid (Scheme 2.5). 
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Scheme 2.5 Synthesis of D-Glu(DAP) dipeptide (143) 
Reagents and conditions: a) Fmoc-D-Glu-OBn, DIC, HOBt, DMF; b) 20% piperidine/DMF; c) R1COCl , 
Et3N; d) 10% TFA/CH2Cl2; e) Boc2O, Et3N; f) H2, Pd(OH)2; g) TFA. Yields vary, depending on R1, 
between 24 and 33%,  except for the dipeptide bearing the fluorophenol substituent where a 40% yield 
was reported. 
 
Separation of the different iE-DAP isomers was achieved using a chiral column. The 
analogues synthesised were used to evaluate the specificity of the interaction with 
NOD1 (nucleotide-binding oligomerisation domain-containing protein 1), a protein 
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able to recognise bacterial peptidoglycan products, specifically H-D-Glu(mDAP-OH)-
OH (143,144) and mediate immune responses.  
 
Scheme 2.6 Kocienski-modified Julia olefination (145)  
Reagents and conditions: a) NaHMDS, THF, -70 °C, 71%; b) 1 N HCl in MeOH; c) triphosgene, Et3N, 
CH2Cl2, 22% (over two steps); d) Pd/C, H2, MeOH; e) CbzCl, NaHCO3, 1,4-dioxane/H2O 1:1, 82% 
(over two steps); f) RuCl3·nH2O, NaIO4, acetone/H2O 1:1, 66%; g) AcCl, MeOH, 89%; h) Boc2O, DMAP, 
Et3N, THF, 86%; i) LiOH, THF/H2O 3:1; j) 1) Cs2CO3, MeOH; 2) BnBr, DMF, 83% (over two steps); k) 
PDC, DMF, 86%. 
The same research group successfully synthesised protected mDAP starting from 
an aldehyde, 86, and a sulfone, 87, via a Kocienski-modified Julia olefination 
(Scheme 2.6) (145). Acidolysis of the resulting protected alkene 88, then treatment 
with triphosgene to give the cyclic carbamate 89 was followed by alkene reduction 
and Cbz protection to yield an N-Cbz-protected amino alcohol at the R configuration 
centre 90. Oxidation and protecting group manipulation followed by hydrolysis at the 
oxazolidinone on the second chiral centre yielded (after Boc re-protection) an N-
Boc-protected amino alcohol at the S configuration chiral centre (94). Finally benzyl 
ester protection and oxidation of the primary alcohol group gave the N-protected 
mDAP derivative 96. The final mDAP derivative obtained in this manner displayed 
90 
 
two differently-protected amino groups, one protected carboxyl group and one free 
carboxyl group.  The protecting groups utilised in this approach are not suitable for 
Fmoc-based solid-phase synthesis and this synthetic route requires a significant 
number of steps. It was nonetheless successful in obtaining an orthogonally-
protected mDAP, which was subsequently incorporated in dipeptide and tripeptide 
fragments (and those conjugated to anhydro MurNAc) that were used for the 
purpose of evaluating the stimulation of NOD1 (143,144).  
 
Scheme 2.7 Cross-metathesis of Garner aldehyde-derived vinylglycine derivative and protected 
allylglycine. Isolation of the desired product is followed by further elaboration to give a partially 
protected mDAP (146)  
Reagents and conditions: a) toluene, Grubbs 2
nd
 gen. catalyst, reflux 4 h, 76%; chromatographic 
separation; b) H2/cat. PtO2, EtOAc, 14 h, 97%; c) p-TsOH/H2O, MeOH, H2O, 36 h, 81%; d) TEMPO, 
NaClO2, MeCN, H2O, bleach, 40 °C, 18 h, 94%. 
In 2013 Saito et al. (146) also reported a method for the synthesis of orthogonally-
protected mDAP. It was obtained by cross-metathesis between a Garner aldehyde-
derived vinylglycine derivative 97 and a Cbz/Bn protected D-allylglycine 98 in the 
presence of a second-generation Grubbs catalyst (Scheme 2.7).  
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The cross-metathesis produced three alkenes that could be separated through 
chromatography. The heterodimer was the required product. Selective reduction of 
the double bond and hydrolysis of the amino acetal produced yielded amino alcohol 
103. Subsequently the alcoholic group was converted to the carboxylic acid using 
TEMPO (Scheme 2.7). The protected mDAP 104 was then coupled with D-Glu, in 
order to obtain iE-DAP. This protection strategy could possibly be modified to yield 
an Fmoc-protected mDAP starting from N-Fmoc-protected D-allylglycine benzyl 
ester. 
2.2.2 Cross-metathesis approach 
 
 
 
Scheme 2.8 mDAP synthesis via cross metathesis (36)  
Reagents and conditions: a) Grubbs II gen. catalyst, CH2Cl2, 59%; b) Pd/C, H2, EtOH, CH2Cl2, H2O, 
>90%. 
A simpler stereoselective synthesis of appropriately-protected mDAP was 
successfully achieved by Roychowdhury and co-workers (36,147). The method 
involved an olefin cross metathesis in the presence of Grubbs second-generation 
catalyst, and reduction of the β-γ double bond through hydrogenation over a Pd-C 
catalyst (Scheme 2.8). The reported method was performed starting from D-
allylglycine and L-vinylglycine with different combinations of protecting groups. In the 
reported synthesis (36), the combination of Fmoc-vinylglycine and benzyl protecting 
groups gave the best yield when combined with Boc- and tBu-protection of the 
allylglycine fragment. Subsequently mDAP-containing fragments of the 
peptidoglycan peptide strand were synthesised on a solid support using this 
approach.  
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2.2.3 Building block synthesis  
Roychowdhury et al. (36) started the synthesis of mDAP from two building blocks: D-
allylglycine, which was purchased as the Nα-Boc protected tBu ester, and L-
vinylglycine, which was obtained according to the procedure described by Pellicciari 
et al. (148) and Salituro et al. (149). 
In order to access sufficient quantities of these building blocks to attempt a large-
scale synthesis of protected mDAP, we decided to investigate their de novo 
synthesis.  
2.2.3.1 Boc-D-allylglycine-OtBu efforts 
2.2.3.1.1 De novo synthesis of Boc-D-allylglycine-OtBu  
At first we sought to synthesise appropriately protected D-allylglycine de novo, 
obtaining a racemic mixture of Nα-acetylated amino acid. This would then be 
resolved using acylase I from Aspergillus melleus, an enzyme able to remove Nα-
acetyl groups selectively from amino acids with L relative configuration (150).  
In the first step, diethylacetamidomalonate 106 reacted with allyl bromide 107. 
Different attempts, aimed at improving the recovery, yielded the alkylated 
intermediate 108 in 31-47% yield.  
 
Scheme 2.9 Alkylation of diethylacetamidomalonate 
Reagents and conditions: a) Na (solid), abs. EtOH,  24 h, 110 °C, 47%. 
After the reaction, ice-water was used to promote precipitation of the waxy product, 
which was separated from the inorganic salts and excess allyl bromide (liquid) via 
filtration.  The highest yield was achieved by extraction into CHCl3 and concentration 
under reduced pressure prior to precipitation. 
The following step required the removal of one ethoxycarbonyl group and hydrolysis 
of the other ethyl ester to give the racemic Nα-acetylated allylglycine. An initial 
attempt at complete decarboxylation and hydrolysis (to yield the free amino acid) 
using HCl was unsuccessful. NMR analysis showed that this attempt resulted in the 
electrophilic addition of HCl across the double bond. The reaction resulted in four 
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possible diastereoisomers, 109, 110, 111, 112, as two pairs of enantiomers in the 
ratio 79% to 21%, with 1H-NMR signals for γCH at 4.91 and 5.11 ppm. This outcome 
was anticipated despite a report (151) that suggested the transformation could be 
carried out without competing electrophilic addition. 
 
As a result, partial hydrolysis was pursued by refluxing alkylated malonate derivative 
108 with NaOH as performed by Lin and Chalker (152). Nα-Acetyl-D,L-allylglycine 
113 was obtained with 73% yield and the identity of the molecule confirmed by 1H 
and 13C NMR.  
 
Scheme 2.10 Partial hydrolysis and decarboxylation of diethyl 2-acetamido-2-allylmalonate 
Reagents and conditions: a) NaOH, EtOH, 105 °C, 16 h, neutralisation with 2 M HCl, 73%.  
The resolution of Nα-acetyl-D-allylglycine and Nα-acetyl-L-allylglycine was attempted 
through the use of the enzyme acylase I from Aspergillus melleus.  
As mentioned above, this enzyme selectively removes Nα-acetyl groups from L 
amino acids leaving a mixture of free L-amino acid and Nα-acetyl-D-amino acid (150). 
These two molecules should then be separable on the basis of their polarities. The 
use of a preparative HPLC column would have been ideal and would have allowed 
the separation and isolation of both pure compounds, but was not suitable given the 
reaction scale (the crude product masses recovered were 10-20 g). Alternatively, 
extraction using ethyl acetate was performed. Sequential extractions showed, as 
expected, that a diminishing mass of Nα-acetyl-D-allylglycine 114 was extracted from 
the mixture with each further extraction. 
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Scheme 2.11 Resolution of the N
α
-acetylallylglycine racemic mixture 
Reagents and conditions: a) acylase I, LiOH, 72 h, 87% (114). 
The optimised procedure involved two extractions with equal volumes, compared to 
that of the aqueous solution, of ethyl acetate (recovering 61% of the final mass) then 
two extractions with an excess of ethyl acetate (1.67 volume equivalents, recovering 
24% of the final mass) followed by concentration of the volume of the aqueous 
phase and one further extraction with a double volume equivalent of ethyl acetate (a 
further 15% of the final mass). The organic fractions were combined and 
concentrated to give a mass corresponding to 86% of the theoretical yield. NMR 
analysis of the organic phase showed a single, acetylated product, therefore 
believed to be Nα-acetyl-D-allylglycine.  
The L-allylglycine product 115 needed to be separated from the inorganic salts 
present in the aqueous phase. Removal of the water and extraction with hot ethanol 
also resulted in some dissolution of the salts and hence the yield of L-allylglycine 
could not be reliably measured. This could be an issue that needs to be resolved if 
the L-isomer has to be recovered. NMR analysis seemed to indicate the absence of 
any secondary product in the aqueous phase.   
 
Scheme 2.12 Hydrolysis of N
α
-acetyl-D-allylglycine 
Reagents and conditions: a) 2.5 M NaOH, 60 °C, 24 h; neutralisation with 5 M HCl. 
In order to determine the enantiomeric ratio of the products derived from the 
aqueous and organic phases, Marfey’s advanced method was used (153). Firstly a 
small sample of the organic phase residue was hydrolysed to obtain the free amino 
acid (Scheme 2.12). 
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The hydrolysis product 116 was derivatised with 1-fluoro-2,4-nitrophenyl-5-L-
alaninamide (FDAA, 117). This reagent has one chiral center (L relative 
configuration in this case) and it forms adducts by reacting with the amino group of 
amino acids. If FDAA is used to derivatise a racemic mixture of amino acids, two 
diastereoisomers, L,L and L,D, will be formed. As diastereoisomers, the derivatised 
D-amino acids interact differently with chromatographic stationary phases compared 
to the derivatised L-amino acids. This difference allows the separation of the two 
adducts by reverse-phase HPLC, and the L-derivative (in this case) elutes earlier. 
With a small molecule like allylglycine, a chiral column was beneficial to improve the 
resolution of the FDAA derivatives.  
 
Scheme 2.13 FDAA derivatisation of D-allylglycine 
Reagents and conditions: a) NaHCO3 1 M, 1% FDAA/acetone, 45 °C, 1 h; b) HCl 1 M 
The HPLC chromatogram of the derivatised organic phase shows three peaks, 
corresponding to the free FDAA and the two derivatised allylglycine stereoisomers. 
Their elution order was determined by overlapping the results obtained from a pure 
FDAA control and the one from the FDAA derivatisation of the aqueous phase 
residue, assuming it contains primarily the L-isomer. Hence it was determined that 
the first component to elute was the residual FDAA, the second one was the L-
amino acid derivative and the third was the D-amino acid derivative (Fig. 2.2).  
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Figure 2.3 Overlapping Marfey’s HPLC chromatograms, (black line for pure FDAA, blue for aqueous 
phase FDAA-derivatised sample, green for organic phase FDAA-derivatised sample) 
The crude products of different attempts were hydrolysed and derivatised with FDAA 
and HPLC analysis showed similar outcomes. The results for the products obtained 
from the most thorough extraction are presented here and discussed.  
The chromatograms from FDAA derivatisation of both the aqueous and organic 
phases were compared (Fig. 2.3). Integration of the peak areas indicated that the 
hydrolysed organic phase contains 78% of the expected D-isomer and 22% of the L-
isomer, while the hydrolysed aqueous phase showed the presence of 3% D-
allylglycine versus 97% L-amino acid. This seems to indicate that the extraction was 
not fully complete, but that only 3% of Nα-acetylated allylglycine was left behind in 
the aqueous phase. In the light of the results from the organic phase it is likely that 
the enzymatic resolution failed to hydrolyse all of the L-enantiomer. This would mean 
that there would be a mixture of Nα-acetyl-L-allylglycine, Nα-acetyl-D-allylglycine and 
L-allylglycine in the reaction mixture. Therefore, after the extraction, in the organic 
phase there would be a mixture of L and D acetylated amino acids and hydrolysis 
(prior to FDAA derivatisation) would lead to both L and D free amino acids. This 
explanation is consistent with the NMR spectrum of the product from the organic 
phase as Nα-acetyl-L-allylglycine and Nα-acetyl-D-allylglycine would be 
indistinguishable.  
Analysis of a sample of hydrolysed organic phase using a polarimeter measured an 
[α]D = +20.0°. Calculation of the expected specific rotation, based on a published 
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value of +35.0° for pure D-allylglycine (154) and on the 78:22 ratio (D:L) found from 
the FDAA derivatisation, gives [α]D = +19.6°. These findings seem to support the 
enantiomeric ratio found with the FDAA method. 
In order to improve the enantiomeric purity of the Nα-acetyl-D-allylglycine, the 
residue from the organic phase obtained in a separate experiment was processed a 
second time with the acylase. In this way any acetylated L-amino acid that might be 
left over would be hydrolysed and therefore could be separated through a new 
extraction. The EtOAc extract from this reprocessed reaction was then chemically 
hydrolysed with NaOH, refluxing for 24 h at 110 °C to ensure complete reaction. 
After neutralisation, the isolated crude product was extracted into hot EtOH as 
described above. Some NaCl (produced during neutralisation) was again present in 
the mixture after extractions with hot EtOH, but derivatisation with FDAA indicated a 
composition of 17% L-allylglycine and 83% D-allylglycine.  
This enantiomeric purity was not considered sufficient to use the product for the 
cross-metathesis. The presence of both L- and D-allylglycine in the mixture would 
lead to the formation of both L,L- and meso-DAP. This outcome would jeopardise the 
enzyme activity assay accuracy in determining the affinity for the substrate, as the 
substrate composition would be only approximate.  
Unfortunately the separation proved itself a challenging step and our experience of 
the results of the enzymatic reaction proved different to those of the study’s authors 
with this amino acid (150). As a consequence it was decided to set this strategy 
aside with the intent of investigating the optimal conditions for the acylase reaction 
in the future, particularly given the commercial availability of D-allylglycine. 
2.2.3.1.2 Purchased and protected D-allylglycine 
As the enzymatic resolution outcome was not satisfactory and because of the lack of 
time for further optimisation it was decided to purchase commercial Boc-D-
allylglycine, protect its carboxylic moiety as the tBu ester, then to proceed to the 
cross-metathesis.  
2-Allyl-N-Boc-D-glycine (Boc-D-allylglycine), purchased from Alfa-Aesar, is 
commercially available as the dicyclohexylamine (DCHA) salt. Neutralisation of the 
salt is desirable to avoid any by-products formed by reaction with DCHA. As a 
secondary amine, DCHA can react with an activated carboxylic acid to give an 
amide. As many tBu ester protection methods involve activation of the acid, e.g. with 
DCC, it is important to prevent the possibility of reaction with DCHA. With this 
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purpose the neutralisation is ideally carried out prior to the tBu protection reaction, 
rather than during. The neutralisation of the salt was achieved through partitioning 
between ethyl acetate and aqueous potassium hydrogen sulfate, giving pure Boc-D-
allylglycine free acid in high yields (> 95%).  
Three different methods were evaluated for the the tert-butyl protection: first it was 
attempted (with the DCHA salt) using Boc2O in combination with DMAP (155), then 
(with the free acid) with DCC, or DIC, and tBuOH with DMAP (Scheme 2.14 a, b and 
c) (156). 
 
Scheme 2.14 tBu protection of Boc-D-allylglycine 
Reagents and conditions: a) Boc2O, DMAP, tBuOH, rt, 24 h  or b) DCC, DMAP, tBuOH, dry CH2Cl2, rt, 
18 h, 43% or c) DIC, DMAP, anhydrous tBuOH, dry CH2Cl2, Ar, 18 h, 60%. 
During the first attempt to synthesise Boc/OtBu protected D-allylglycine using Boc2O 
and DMAP in tBuOH (Scheme 2.14 a) (155)the reaction failed to reach completion 
after 30 min, which was the reaction time suggested by the original report (157) of 
this method. As in this case the Boc-D-allylglycine had been used directly as the 
DCHA salt, one further equivalent Boc2O was added and the reaction continued up 
to 24 h. The excess of Boc2O should have reacted with the DCHA then proceeded 
to react with the allylglycine. Unfortunately no improvement was observed; TLC 
analysis throughout the reaction time showed remaining starting material.  
 
 
Figure 2. 4 DCHA, dicyclohexylamine 
As a consequence, another method using DCC, DMAP and tBuOH (Scheme 2.14 b) 
to protect the carboxyl group as the tBu ester was followed, in the hope of improving 
the outcome.  
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In this case the Boc-D-allylglycine·DCHA was first neutralised as described above to 
allow isolation of the free acid. As the article from Rees et al. (158) did not provide 
full experimental details for this reaction, DCC was first added to the amino acid and 
the mixture left to stir in CH2Cl2 for 30 min, prior to the addition of the DMAP and 
tBuOH, in the attempt to maximise the yield. Again the reaction failed to reach 
completion but purification afforded the tert-butyl ester 49 in disappointing but 
acceptable 43% yield. NMR spectroscopy confirmed the successful synthesis of 
compound 49, showing the typical tBu and Boc singlets at 1.44 and 1.46 ppm 
respectively.  
The third attempt (Scheme 2.14 c) utilised DIC instead of DCC, as the urea by-
product derived from DIC is more soluble in CH2Cl2 than the one from DCC, which 
needs to be removed by thorough and repeated filtration prior to the purification, 
making DIC easier to handle in comparison. The whole procedure was conducted 
under dry conditions, including the use of anhydrous tBuOH, in order to limit the 
hydrolysis of active intermediates. Even in this case, residual starting material was 
evident on the TLC plate after 18 h, however the conversion was considered 
sufficient to proceed to the purification. Significant improvements were obtained by 
observing strictly dry conditions, using anhydrous tBuOH and keeping the reaction 
under argon. The substitution of DCC with DIC did not hinder the efficiency of the 
reaction. Given the fact that this reaction was the one that gave the highest yield 
(60%), it was chosen as the most suitable method for the tBu protection of readily 
available Boc protected D-allylglycine. 
  
Scheme 2.15 tBu protection of Cbz-Leu-OH 
Reagents and conditions: tert-butyltrichloroacetimidate, BF3·Et2O, dry CH2Cl2, N2, rt, 16 h. 
Another attempt to find a more suitable method for tBu protection was performed 
using Cbz-Leu-OH – a different and less expensive amino acid – that also has the 
advantage of being Cbz-protected, making it UV active and easily visualised on TLC. 
The supplied DCHA salt was first neutralised and the free Cbz-Leu-OH was 
dissolved in dry CH2Cl2. t-Butyl trichloroacetimidate (122) and the Lewis acid boron 
trifluoride diethyl etherate (123) were added to the mixture and the reaction allowed 
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to proceed overnight (Scheme 2.15). Unfortunately TLC analysis showed residual 
starting material in this case; addition of more t-butyl trichloroacetimidate and BF3 
and prolonging the reaction time failed to drive the reaction any further towards 
completion. This approach was not pursued further with the Boc-D-allylglycine. 
 
Scheme 2.16 Mechanism of tBu protection with tert-butyl trichloroacetimidate and BF3·Et2O 
2.2.3.2 Fmoc-vinylglycine-OBn synthesis 
The second building block required for the cross-metathesis reaction is an 
appropriately-protected L-vinylglycine, the synthesis of which was attempted through 
decarboxylative elimination of an appropriately-protected glutamate derivative (159), 
and alternatively via elimination of the primary alcohol, via a selenide intermediate, 
from an appropriately-protected homoserine derivative (148). 
The reaction published by Hanessian and Sahoo (159) describes a decarboxylative 
elimination with lead (IV) acetate, catalysed by copper (II) acetate, of Nα-Cbz-
protected glutamic acid α-methyl ester. This combination of protecting groups is not 
suitable for this project’s intention to synthesise appropriately protected mDAP. 
 
Scheme 2.17 Synthesis of protected vinylglycine from protected glutamate 
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Reagents and conditions: a) copper (II) acetate, benzene, Ar, 1 h, rt; b) lead (IV) acetate, benzene, Ar, 
1 h, rt; c) benzene, reflux 90 °C, 42 h, 2% (over three steps). 
A suitable derivative for the intended cross-metathesis requires an L-vinylglycine 
derivative with Fmoc as the amino-protecting group and a benzyl ester as the α-
carboxyl protecting group. This combination of protecting groups will eventually be 
required for the S-configuration centre of the protected mDAP precursor (Scheme 
2.8). The initial attempt involved the use of commercially available Fmoc-Glu-OBn 
but since Fmoc-Glu(OtBu)-OH is considerably (ca. 25 times) less expensive it was 
decided to utilise the latter as a precursor for the required substrate. Reaction of the 
caesium salt of the α-carboxylate with benzyl bromide gave the corresponding 
benzyl ester, followed by selective acidolysis of the side chain tert-butyl ester 
(Scheme 2.18).  
  
Scheme 2.18 Synthesis of Fmoc-Glu-OBn 
Reagents and conditions: a) Cs2CO3, MeOH, 0 °C to rt, 20 min; b) BnBr, dry DMF, rt, Ar, o/n, 72% 
(over two steps); c) 50% CH2Cl2/TFA, N2, 2h, 87%.  
One further modification to the conditions used by Hanessian and Sahoo (159) was 
the length of the reflux. After the prescribed 15 h, the TLC still showed a significant 
amount of starting material. The reaction was continued for several days, up to one 
week, to check whether longer reaction times might improve the yield. Increased 
reaction time seemed initially to improve conversion to the desired product but only 
up until around 42-65 h, at which time an optimum point in terms of conversion and 
by-product production seemed to be reached. 
Purification by flash chromatography afforded the desired building block in a 
disappointing yield of 12% and NMR indicated the persistence of a minor 
contaminant, not detected by TLC. 
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Scheme 2.19 Isomerisation of vinylglycine 
There is evidence (160) to suggest that prolonged contact with silica may promote 
isomerisation of the vinylglycine 50 to the corresponding dehydrobutyrine derivative 
127 (Scheme 2.19), which further complicates its isolation and purification. 
The other products of the reaction do not correspond to any of the reactants. 
Hanessian reported only three products from their reaction, but it is important to 
bear in mind that they used a differently-protected substrate. A subsequent 
purification allowed the isolation of the pure desired protected vinylglycine, but the 
yield corresponded to only 1% of the theoretical yield. The mass of the product was 
not useful for further synthesis but served as a pure standard for the further methods 
developed.  
Further attempts were made to try to improve the yield using the Hanessian method 
(159). Based upon the time course of the reaction from the first trial, in the following 
attempts to obtain vinylglycine, the reaction mixture was allowed to reflux for 48 h. 
Unfortunately after purification the yield obtained was essentially unchanged at a 
disappointingly low 2%. Therefore it was deemed necessary to find another strategy. 
Pellicciari et al. (148) accomplished the synthesis of vinylglycine starting from 
appropriately-protected homoserine. This methodology was investigated as well. 
This reaction was first attempted starting from purchased L-homoserine 128. The 
amino acid was Nα-Fmoc and benzyl protected as shown in Scheme 2.20. 
 
Scheme 2.20 Protection of L-homoserine 
Reagents and conditions: a) Fmoc-OSu, NaHCO3, water, acetone, 18 h; b) benzyl bromide, DMF dry, 0° 
C for 3 h, rt for 18 h; 64% over two steps. 
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Alternatively the protected homoserine derivative could be obtained from aspartic 
acid. The published reaction (148) involved carboxybenzyl amino protection and 
isopropyl carboxylic protection, which did not comply with the protection strategy 
selected for this project. Conveniently Fmoc-Asp(OtBu)-OH is commercially 
available and cheap. Therefore (as for Glu above) reaction with benzyl bromide was 
used to protect the α-carboxyl group, followed by acidolysis of the tBu protecting 
group on the γ-carboxyl group to yield Fmoc-Asp-OBn 132 (Scheme 2.21). 
 
Scheme 2.21 Synthesis of homoserine from protected aspartic acid 
Reagents and conditions: a) Cs2CO3, MeOH, 0 °C to rt, 20 min; b) BnBr, dry DMF, rt, Ar, o/n, 82% 
(over two steps); c) CH2Cl2, TFA, Ar, 2 h, 89%; d) N-methylmorpholine, isobutyl chloroformate, dry THF, 
-10 °C, Ar; 30 min, e) NaBH4, 2 h, 55% (over two steps). 
Vinylglycine was obtained via a Grieco-modified Mitsunobu protocol (148) for the 
primary alcohol elimination using o-nitrophenylselenocyanate and tributyl phosphine, 
resulting in the desired terminal alkene 50 (Scheme 2.22). 
 
Scheme 2.22 Synthesis of Fmoc-vinylglycine-OBn from appropriately-protected homoserine, via 
elimination of the primary alcohol 
Reagents and conditions: a) tributyl phosphine, 2-nitrophenylselenocyanate, THF, rt, 3 h; b) 30% H2O2, 
rt, 18 h, 45% (over two steps). 
In this reaction (Scheme 2.23), the alcoholic oxygen is converted into a good leaving 
group leading the formation of selenide 134, which is subsequently oxidised to a 
selenoxide 135 and eliminated to release the terminal alkene (161). 
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Scheme 2.23 Mechanism of the Grieco elimination (reaction between oNO2SeCN and PBu3 in 
presence of a primary alcohol) 
The initial attempt at conversion of protected homoserine derivative 133 into 
vinylglycine via the Grieco elimination (Scheme 2.22), was unsuccessful; the TLC 
plate showed two spots, one corresponding to the protected L-homoserine and 
another that was identified as the 2-nitrophenyl selenocyanate.   
In the second attempt THF, which is more difficult to dry exhaustively, was 
substituted with dry CH2Cl2 and the tributylphosphine was freshly distilled, as the 
original paper prescribed. Although the tributylphosphine appeared unusually turbid, 
the reaction was carried out, but TLC analysis showed that the starting material 
appeared not to have reacted.  
A further attempt, using newly purchased tributylphosphine and again using dry 
CH2Cl2, was made. In this case the TLC plate showed the formation of three 
products, including Fmoc-vinylglycine-OBn. The first analytical TLC mobile phase 
(hexane/EtOAc 1:2) unexpectedly had a different elution order compared to the flash 
chromatography mobile phase (petroleum ether/Et2O 4:1) so the first isolated 
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product was not the desired one. The post-purification TLC plate revealed this error, 
and further fractions were collected. Unfortunately, during the lengthy purification, a 
new spot appeared with a very similar Rf to the desired product, making its 
purification impossible, as the desired product and the by-product co-eluted in the 
system used. It is very likely that the by-product was the rearranged dehydrobutyrine 
isomer (127) of the desired product.  
The reaction was repeated once more (in THF) and the crude product quickly 
purified, minimising contact time with silica, and Fmoc-vinylglycine-OBn was 
successfully obtained (Scheme 2.22) in acceptable yield (45%). 
2.2.4 Cross-metathesis between Boc-D-allylglycine-OtBu and Fmoc-
vinylglycine-OBn 
Firstly the cross-metathesis was attempted following a method based on that of 
Roychowdury and Boons (36) at room temperature (Scheme 2.24).  
The first attempt at the cross-metathesis, using a 1.8-fold molar excess of 
vinylglycine 50 over allylglycine derivative 49 (0.28 mmol) for 24 h at room 
temperature, followed the literature procedure (36).   
 
Scheme 2.24 Cross-metathesis between appropriately protected D-allylglycine and L-vinylglycine (36) 
Reagents and conditions: Grubbs 2
nd
 gen. catalyst, dry CH2Cl2, rt, Ar, 24 h, 64%. 
TLC analysis showed a significant amount of residual starting materials, an 
additional non-UV-visible spot most likely to correspond to the D-allylglycine 
homodimer and one new UV-visible one, which was assumed to be the desired 
product. Three fractions were isolated via flash chromatography and analysed by 
NMR. The least polar component was confirmed to be the unreacted Boc/tBu 
protected D-allylglycine, as its NMR spectrum matched that of the starting material. 
The second fraction contained a mixture of two more polar components, 
corresponding to the D-allylglycine homodimer and Fmoc-vinylglycine-OBn; it was 
not possible to fully separate these two components through flash chromatography 
but 1H-NMR spectra highlighted the presence of all the characteristic signals 
corresponding to Fmoc-vinylglycine-OBn: Fmoc aromatic protons at 7.23 to 7.29, 
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benzyl methylene at 5.20, alkene protons at 5.25 to 5.40 and 5.89 to 6.00. The NMR 
of this fraction also confirmed the presence of Boc and tBu groups (singlets at 1.44 
and 1.46). This is consistent with the allyglycine homodimer (a fact that was later 
confirmed by comparison with the Rf of a synthesised analytical standard of the 
homodimer. 
The 1H-NMR spectrum of the final fraction, containing the most polar (lowest Rf) 
component, showed again the typical singlets for Boc and tBu protecting groups, 
together with a singlet at 5.20, consistent with a Bn methylene, and signals 
characteristic of an Fmoc group. The expected signal corresponding to the α-CH 
adjacent to the benzyl ester and those for the alkene protons were not seen.  
On this evidence the desired compound 105 seemed not to be present in any of the 
fractions isolated therefore the possibility of utilising microwave technology was 
considered. 
A first attempt under microwave heating was performed on a small scale (0.01 mmol) 
and monitored via TLC. The objective was to quickly identify the best conditions for 
the reaction as this was a departure from the methodology reported in the literature.  
First a cross-metathesis to obtain a Boc-D-allylglycine-OtBu homodimer 136 was 
performed with the intention of isolating an analytical standard to be able to identify 
this as an expected side product (Scheme 2.25).  
 
 
 
Scheme 2.25 Synthesis of Boc-D-allyglycine-OtBu homodimer 
Reagents and conditions: dry CH2Cl2, 5% Grubbs 2
nd
 gen. catalyst, times and temperatures as detailed 
in Table 2.5. 
 
For the homomeric cross-metathesis, the reaction was allowed to proceed under 
microwave heating at increasing temperatures (40 to 130 °C) and monitored via TLC. 
At 10-minute intervals the sample was analysed and then the reaction continued at 
a higher temperature for another 10 min, for a total of 40 min (Table 2.5). 
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Reaction time (min) Temperature (°C) 
0 
40 
10 
65 
20 
120 
30 
130 
Table 2.5 Range of temperatures applied during the homodimeric and heterodimeric cross-metathesis 
reactions (Scheme 2.24 and 2.25) 
TLC analysis indicated a decreasing concentration of the starting material and 
increasing conversion to the homodimer over time. The homodimer was easily 
distinguished (TLC) from the monomer and catalyst as a non-UV-active spot of 
lower Rf. The isolated sample was kept as a TLC standard. 
2.2.4.1 Investigation of microwave-assisted reaction conditions 
The first small scale attempt at the cross-metathesis of the protected vinylglycine 50 
and D-allylglycine 49 derivatives was also performed with the temperature settings 
described in Table 2.5; each time the vial was removed from the microwave, a small 
sample was taken for TLC, the vial repositioned and a higher temperature used for 
the next 10 min.  
The TLC profile of the samples taken showed the presence of 5-8 components in 
the reaction mixture, including the homodimer and the two starting materials. UV 
activity was fundamental to exclude spots corresponding to compounds without 
Fmoc protection. Two new UV-visible spots were identified, one of which was likely 
to be the desired product. Higher temperatures seemed to increase the 
concentration of non UV-visible products.  
The literature seems to suggest, in order to avoid isomerisation of olefins, to 
mantain low temperatures and use short reaction times (162–164). As a 
consequence, a larger scale microwave-assisted cross-metathesis was attempted 
with stirring at 55 °C for 1 h (Scheme 2.26). TLC analysis of the crude product 
showed 3 major UV-visible products.  
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Scheme 2.26 Cross-metathesis between Boc-D-allylglycine-OtBu and Fmoc-vinylglycine-OBn 
Reagents and conditions: dry CH2Cl2, Grubbs 2
nd
 gen. catalyst, microwave 55 °C, 1 h, 8%. 
Preparative TLC permitted the isolation of sufficient masses of the individual 
compounds to send for MS analysis. This analysis confirmed the presence of the 
desired product among the samples sent (though the sample was not completely 
pure). Further preparative TLC of the sample allowed isolation of a sufficient 
quantity of the desired product 105 for HPLC analysis, enabling identification of the 
peak corresponding to 105 in the crude HPLC chromatogram.  
The HPLC profile of the crude cross-metathesis product promisingly showed well-
resolved peaks (Fig. 2.5). The peak eluting at 22.95 min corresponds to the desired 
cross-metathesis product 105. 
 
Figure 2.5 HPLC profile of the cross-metathesis crude product (detection at 214 nm, see Chapter 4.2).  
 
A comparison with the profiles of the two starting amino acids showed the complete 
disappearance of Boc-D-allylglycine-OtBu but the persistence of Fmoc-vinylglycine-
OBn (Rt = 20.93 min), as expected, given the use of a 1.8-fold molar excess of the 
latter. One minor peak (Rt = 13.85 min) appeared to correspond to Grubbs 2
nd gen. 
catalyst and two novel peaks (Rt = 22.95 and 23.71 min) were present with similar 
retention times. In order to identify the peak belonging to the desired product, the 
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crude chromatogram was overlapped with the one obtained from the compound 
isolated via preparative TLC. This fraction contains two peaks, one of which, 
according to the MS results obtained, belongs to the desired cross-metathesis 
product. The overlap identified the desired product peak as the one eluting at 22.95 
min in Fig. 2.3. The fourth peak (Rt = 23.71 min) was not identified. It was initially 
suspected to be the Boc-D-allylglycine homodimer but its absorption at 254 nm 
seems to suggest that this by-product contains an Fmoc and/or benzyl group.  
The HPLC chromatogram showed good baseline resolution between the desired 
product and said by-product (Rt = 23.71 min), therefore small aliquots of the crude 
product mixture were dissolved in ca. 50% aqueous MeCN and used to develop a 
gradient system suitable for preparative HPLC. The pure product was successfully 
isolated in a disappointing 8% yield and its identity confirmed by MS and NMR 
analyses. HPLC was used for purification of all subsequent reaction mixtures. 
The cross-metathesis reaction was then repeated several times in order to obtain a 
greater quantity of product. Unexpectedly, HPLC analysis of early larger-scale trials 
(see comments below in Chapter 2.2.4.3) indicated either the absence or 
considerably reduced concentration of the desired product. It was possible that 
proportionally increasing the amount of catalyst could trigger further side reactions 
including breakage of the very bond formed in the cross-metathesis, as it is known 
that cross-metathesis is a reversible reaction  (165). Consequently, repetition of the 
reaction was kept on a small scale and the crude products were combined for 
purification. Occasionally, despite the same conditions and quantities being used, 
the desired product was not present, according to analytical HPLC results. Adding 
more catalyst and repeating the microwave heating occasionally lead to the 
production of some desired product. The apparent variability of outcomes in this 
reaction under essentially identical conditions and its lack of scalability proved 
frustrating. It is currently unlikely to be viable for the large-scale production of 
protected mDAP without much more optimisation, probably at each scale used. The 
number of variables in the reaction – relative quantities of reactants, concentration, 
type and quantity of catalyst, time and temperature – make this challenging. 
Later on, a smaller-scale cross-metathesis at room temperature for 24 h was 
attempted in order to quickly compare its results against the ones from the 
microwave-assisted reactions. TLC analysis of the crude product showed no 
significant difference from the profile of the microwave-assisted crude product. The 
D-allylglycine seemed to have been completely consumed, while the vinylglycine (in 
excess) was still visible. Four additional by-products were observable, one of which 
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was not UV-active. Given the similarity of the results, it was decided that microwave  
heating was the most suitable option for the subsequent cross-metathesis reactions 
as it seemed to drastically reduce the reaction time. 
2.2.4.2 Comparison of Hoveyda-Grubbs and Grubbs 2nd gen. catalyst activity 
Two parallel microwave-assisted experiments were run with the same molar 
equivalents of starting materials and amount of catalyst but different types of 
catalyst. This was done to evaluate whether Hoveyda-Grubbs 2nd gen. would lead to 
better results than Grubbs 2nd  gen. catalyst, the latter being used in the literature 
(36,147). The crude products were analysed by HPLC and the peak area for the 
desired product was similar for both - 19.7% for Grubbs vs. 23.3% for Hoveyda 
(measured as percentage of total chromatogram peak area). As no significant 
difference was detected, it was decided to favour the use of Grubbs 2nd gen. catalyst, 
as suggested by the literature (36,147). 
2.2.4.3 Larger-scale cross-metathesis investigations 
Early preliminary attempts at scale-up had proved unsuccessful (see above). 
Attempting to scale-up the cross-metathesis from the initial 0.088 mmol (24 mg of 
the allylglycine component), the reaction was repeated with 100 mg (0.370 mmol) of 
allylglycine under the same conditions (including 5 mol % catalyst quantity). 
Analytical HPLC of the crude product showed only an extremely small, almost 
negligible peak consistent with the desired product. The crude product was thus 
evaporated and a further 5 mol % catalyst was added before repeating the cross-
metathesis step. After this treatment the expected peak was detectable via HPLC 
and therefore purification was carried out leading to the isolation of the desired 
product in 6% yield. It seemed that increasing the quantity of catalyst might have 
negatively influenced the outcome, possibly pushing the reaction back to the starting 
material rather than the products or catalysing alternative side reactions. Given 
these issues, it was deemed sensible to only slightly increase the quantity of starting 
material and to avoid scaling up the catalyst quantity.  
The following attempts therefore employed the use of 0.175 mmol of Boc-D-
allylglycine-OtBu and a quantity of catalyst corresponding to the one used for the 
initial attempt (3.6 μg). The crude products of several identical reactions were 
combined prior to purification. The yields recovered from each of these reactions 
frustratingly varied between 4 and 6% and were considered acceptable given the 
impracticality of conducting a proper study for the optimisation of scale-up. 
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2.2.4.4 Hydrogenation step 
The final step in the synthesis of the suitably-protected mDAP derivative was the 
reduction of the alkene resulting from the cross-metathesis, with simultaneous 
removal of the benzyl ester (Scheme 2.27). Roychowdhury et al. (36) suggested the 
use of 3% Pt/C catalyst, while Kastrinsky et al. (166) used 10% Pd/C to reduce the 
alkene in a differently-protected mDAP, still bearing the Fmoc amino protecting 
group. Some reported a risk of possible Fmoc removal with 10% Pd/C during benzyl 
deprotection (167–169,155) contrasting with Kastrinsky’s outcome and statements 
of its supposed stability to hydrogenation conditions (155,170,171). A small-scale 
test was performed on Fmoc-Glu(OtBu)-OH to evaluate the effect of the two 
catalysts on Fmoc stability. A solution of the amino acid in a mixture of MeOH, H2O 
and CH2Cl2 (the intended eventual reaction solvent) was stirred at room temperature 
under a hydrogen atmosphere for 2 h in presence either of 3% Pt/C or 10% Pd/C. 
The reaction mixtures were analysed by TLC and, in the case of 10% Pd/C, showed 
the consumption of the starting material, whereas the the use of 3% Pt/C resulted in 
no change. These findings led to the decision to utilise 3% Pt/C. 
Reduction via hydrogenation in most cases works at room temperature just above 
atmospheric pressure, which can be achieved using a hydrogen-filled balloon. 
Different pressure and temperature conditions might be needed in cases of poor 
reactivity as in the presence of a highly substituted double bond  (172). 
Following evaluation of the conditions for the hydrogenation, all the pure products 
obtained from the different cross metathesis reactions were combined. The 
reduction of the double bond and removal of the benzyl protecting group was 
achieved under a hydrogen atmosphere at room temperature, monitoring over 30 h.  
 
 
Scheme 2.27 Hydrogenation of the cross-metathesis product 
Reagents and conditions: 3% Pt/C, MeOH, H2O, CH2Cl2, H2, 30 h, 72%. 
 
TLC and HPLC analysis indicated the almost complete consumption of the starting 
material after 30 h and the appearance of one major compound and two minor 
compounds, each more polar than the starting material. The product was sufficiently 
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pure to be used crude for the next step. Any possible side products of the 
hydrogenation would probably retain the benzyl ester protection, which would 
prevent loading onto the resin, which requires a free carboxyl group. Alkenes are 
reduced more promptly than benzyl protecting groups are removed (173), therefore 
the formation of a free carboxyl-containing by-product retaining the alkene function 
is highly unlikely.  
2.3 Synthesis of the putative Mpl tripeptide substrate H-Ala-D-
Glu(mDAP-OH)-OH 
Following the hydrogenation step and MS and NMR confirmation of the presence of 
the desired product, the mDAP-containing crude product was loaded onto a 2-
chlorotrityl chloride derivatised resin (Scheme 2.28) and used for the synthesis of H-
Ala-D-Glu(mDAP-OH)-OH (52).  
 
Scheme 2.28 Loading of appropriately-protected mDAP onto 2-ClTrt resin 
Reagents and conditions: a) dry CH2Cl2, DIEA, Ar, 2 h; b) CH2Cl2, MeOH, DIEA, 1 h. 
Unusually, an excess of 2-chlorotrityl chloride resin (based on manufacturer’s 
substitution) was used to maximise the amount of the mDAP building-block that 
could be successfully loaded. Unreacted 2-chlorotrityl chloride groups were capped 
after loading using methanol. This loading procedure had been previously validated 
using Fmoc-Glu(OtBu)-OH followed by deprotection and coupling with Fmoc-Ala-OH. 
The loading of mDAP proceeded as shown in Scheme 2.28.  
Manual Fmoc deprotection with 20% piperidine was performed, followed by coupling 
with Fmoc-D-Glu-OtBu then Fmoc-Ala-OH, using HBTU/HOBt/DIEA-mediated 
activation as described in Chapter 4.3. Deprotections and couplings were repeated 
and success monitored using the Kaiser test. Positive Kaiser tests were generally 
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quite weak, most likely as a consequence of the low loading of the resin, so the 
initial mDAP Fmoc deprotection was performed three times as a precaution. Final 
cleavage of the tripeptide proceeded as described in Chapter 4.3. 
 
HPLC analysis showed closely-eluting components with low retention times. 
Purification via semi-preparative HPLC led to a product containing two components. 
Mass spectrometry and NMR confirmed the presence of the desired product but no 
further purification could be performed due to the small mass of the sample. The 
main issue was the very early elution of the components, due to their high polarities, 
giving little opportunity to interact with the stationary phase. Both components eluted 
together right at the start of the preparative run. MS analysis seems to indicated the 
presence of M+57, which is characterisitic of the incomplete deprotection of the tBu 
ester. It could possibly also be an alkylated by-product (the tBu cations produced 
during cleavage can theoretically react irreversibly with nucleophilic groups like the 
amino groups). As the NMR spectrum showed little evidence of impurities, HPLC 
analysis was repeated; interestingly, the chromatogram showed that the 
concentration of one of the major components had decreased, perhaps suggesting 
that it had been hydrolysed.  
2.3.1 Biological evaluation 
2.3.1.1 Target-based evaluation (Mpl overexpression and purification) 
The mDAP-containing PG fragments were meant to be used for the characterisation 
of M. tuberculosis Rv3712, the putative Mpl. Due to the time required for the 
synthesis of the suitably-protected mDAP building block and the fact that the sample 
of tripeptide 52 was insufficiently pure, a full evaluation has yet to be performed. 
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Nonetheless the recombinant enzyme has been heterologously overexpressed in 
E.coli and purified (full experimental details are described in Chapter 4.6). 
2.3.1.1.1 Transformation 
The plasmid pCDFDuet-1, carrying the gene of interest rv3712, the tigA insert and 
streptomycin resistance (a gift from Professor Gabriel Waksmann, see Chapter 
4.6.3), was transformed by heat-shock into competent BL21(DE3)pLysS E. coli cells, 
selected for over-expression of Mpl through previous optimisation studies, as 
described in Chapter 4.6.5.5. The successful transformation was confirmed by the 
positive growth of colonies in the presence of streptomycin and chloramphenicol, as 
the competent cells also contained a plasmid conferring chloramphenicol resistance 
upon them.  
2.3.1.1.2 Over-expression of Rv3712 (M. tuberculosis Mpl) 
The colonies obtained after transformation were used to start small seed cultures 
(as described in Chapter 4.6.5.6) that were inoculated into an appropriate volume of 
medium containing streptomycin and chloramphenicol and incubated at 37 °C until 
the culture reached the appropriate OD. Following the data from a previous 
optimisation of the over-expression procedure, the culture was induced with IPTG to 
reach a final concentration of 0.5 mM. One culture was not induced but was kept as 
a negative control (uninduced). Overnight incubation at 18 °C followed. The cells 
were harvested as described in Chapter 4.6.5.6. A small sample was not centrifuged 
after sonication to keep as a control (whole cell protein).  
 
 
 
 
 
 
 
Figure 2.6 Gel electrophoresis showing the successfull overexpression of recombinant Mtb Rv3712 in 
E.coli. The band corresponding to the target protein, which has an estimated molecular weight of 45.3 
kDa (174), is highlighted by the red arrow. Lanes: (1) uninduced sample; (2) whole-cell sample; (3) cell 
pellet; (4) marker; (5) cell lysate  
1 2 3 4 5 
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The pellet and the soluble fraction were run on an SDS-PAGE gel, as described in 
Chapter 4.6.5.9, against the uninduced and whole cell sample (Fig. 2.6).  
It can be observed that all of the fractions contain the band corresponding to 
Rv3712. The band is more distinguishable and intense in the cell lysate sample than 
in that for the uninduced cells, as expected. It is also noticeable that the cell pellet 
sample also contains a band consistent with the molecular weight of Rv3712, which 
may mean that the protein was partially segregated in inclusion bodies, due to 
possible misfolding. 
 
 
 
 
 
 
 
  
 
 
Figure 2.7 Western blot showing the successful overexpression of recombinant Mtb Rv3712 in E. coli. 
The 6x-His epitope tag monoclonal antibodies, used in this method, bind to the 6His-tag on Rv3712 
resulting in an orange coloured band (highlighted by the red arrow). Lanes: (1) cell pellet; (2) marker; 
(3) cell lysate; (4) whole-cell sample.  
Another gel was loaded with the cell pellet, cell lysate and whole-cell sample and 
used for western blotting (Chapter 4.6.5.12). The western blot, which involves the 
use of antibodies specific to, in this case, a polyhistidine-tag (6His-tag), shows a 
clear brown-orange band corresponding to the desired protein. The 6His-tagged 
protein can be seen as present in the whole cell sample, in the cell pellet and in the 
cell lysate (Fig. 2.7). 
2.3.1.1.3 Purification of Rv3712 
Following the over-expression of Rv3712 in the BL21(DE3)pLysS competent cells, 
50kDa- 
40kDa- 
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isolation and purification of the protein was attempted.  
Plasmid pCDFDuet-1Rv3712Tig was designed to contain a sequence for the 
expression of an N-terminal 6His-tag on the target protein; therefore the 
recombinant protein can be isolated by affinity purification using Ni-NTA resin. 
Columns were run using 10 to 250 mM imidazole solutions to elute the protein. Ni-
NTA has coordinated (chelated) Ni2+ cations that bind to the basic nitrogen atoms in 
the side chain imidazole rings of histidine residues. Imidazole competes for binding 
with nickel and displaces the histidine. 
 
 
 
 
 
 
 
 
 
Figure 2.8 Gel electrophoresis of the fractions obtained from the lysate purification on Ni-NTA column. 
The red arrowhighlights the band corresponding to Rv3712. Lanes: (1) marker; (2) 10 mM imidazole 
eluate; (3) 50 mM eluate; (4) 100 mM eluate; (5) 150 mM eluate; (6) 200 mM eluate; (7) 250 mM eluate 
The fractions obtained were loaded and run on an SDS-PAGE gel (Fig. 2.8). The 
developed gel shows the Rv3712 protein eluting clearly with the 200 mM imidazole 
solution. It is also evident that other proteins are eluting together with the target 
protein, therefore the Ni-NTA purification system needs to be optimised further and 
the product further purified by gel filtration, using size exclusion to separate the pure 
protein. 
The promising results for the over-expression and purification of Rv3712 will 
eventually present the opportunity, when a sample with the required purity (>95% in 
the case of recombinant proteins) has been obtained, for crystallisation trials. Such 
 
1 2 3 4 5 6 7 
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trials generally require 10 mg/mL solutions but, in case of proteins larger than 30 
kDa, 2-5 mg/mL should prove sufficient. A previous study (174) estimated the weight 
of Rv3712, including the 6His-tag, to be 45.3 kDa. For now, visual preliminary 
observations estimate the purity to be around 60% and, as 70-80% is considered 
sufficient for biochemical assays, the product needs to be subjected to further size-
exclusion chromatography.  
Considering the need for further purification, the quantities of enzyme obtained after 
Ni-NTA resin purification (typically 20-50 μg/mL) are currently inadequate to reach 
the amount required for crystallisation trials. 
The observation of the M. tuberculosis Mpl band in the cell pellet suggests the 
presence of the enzyme in inclusion bodies. This is not a rare occurrence when 
trying to express foreign proteins in a host cell through the use of plasmid 
expression vectors; furthermore it seems that non-native proteins expressed in E. 
coli, especially if genetically modified, are particularly prone to the formation of 
inclusion bodies (175).   
In the hope of finding out the reason why the expression of pure Mpl didn’t reach 
desirable levels, cultures of different E.coli cells were grown and monitored: one 
culture of BL21(DE3) competent cells containing plasmid pLysS only, one culture of 
E. coli DH5α cells (used for cloning) containing pCDFDuet-1, and two cultures of 
BL21(DE3)pLysS cells containing the plasmid pCDFDuet-1 carryng tigA and rv3712 
constructs were compared (Fig. 2.9).  
 
Figure 2.9 Comparison of E. coli growth curves for different cultures 
The seed cultures were prepared according to the procedure in Chapter 4.6.5.6. The 
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seed cultures were inoculated as described in Chapter 4.6.5.8, but the first two 
types of cells (BL21(DE3)pLysS and DH5α+pCDFDuet) were grown at 37 °C 
continuously, while the cultures carrying the constructs were moved and incubated 
at 18 °C once they reached OD = 0.5. One of the latter two cultures was induced 
with IPTG while the other was kept as an uninduced control as described in Chapter 
4.6.5.8. The growth curve comparison shows how the cultures incubated at 37 °C 
grew faster and reached a steady state within 12 hours, while the others significantly 
slowed their growth after being moved to 18 °C incubation; during exponential 
growth the curve shape switched from sigmoidal to linear (for what is possible to 
observe within 12 hours). This could be considered as a direct effect of the 
temperature. On the other hand, when all four cultures were incubated at 37 °C, a 
difference in the growth velocity could still be noticed with the cultures carrying the 
construct growing more slowly. It is also possible to observe that the two identical 
cultures of BL21(DE3)pLysS+pCDFDuet-1+TigA+rv3712, even when treated equally 
(before OD = 0.5) grew at different velocities. This is suggestive of the variability that 
can often be encountered when growing cells but further experiments will follow. 
The behaviour of the cells could be better evaluated by growing three 
BL21(DE3)pLysS cultures, two with and one without the M. tuberculosis Mpl 
construct, under the same conditions (37 °C until OD = 0.5, then 18 °C) but then 
only inducing one of the cultures carrying the construct with IPTG. This would 
provide a clearer negative control.  
2.3.1.2 Whole-cell evaluation 
Testing mDAP-containing fragments on mycobacteria or Gram negative bacteria in 
a whole-cell assay would be unlikely to provide any useful information, as they 
would be the desired substrates of the Mur ligases, therefore participating in the 
normal processes of the cell and not providing any insight as to whether they 
entered the cell. They could be tested on Gram positive bacteria eventually to see 
whether they are able to exert any inhibitory activity. As mentioned before, ultimately 
the real value in having access to the mDAP-containing PG fragments is to 
characterise the activity of the isolated recombinant Mpl, with the ultimate goal of 
evaluating the effect of inhibitors on this activity. 
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2.4 Synthesis of lasso peptides with anti-tuberculosis activity‡  
Lasso peptides are potent cyclic natural products of bacterial origin. They have a 
knotted structure consisting of a C-terminal tail threaded through a loop, which 
confers upon them extreme stability to enzymatic degradation. They typically 
possess a variety of different activities, but the lariatins and lassomycin have shown 
bactericidal activity against M. tuberculosis. 
2.4.1 Synthesis of lasso peptides and linear precursor analogues using Dmab 
side chain protection strategy 
While the primary goal was to complete the total syntheses of the natural products, 
we also sought to synthesise their non-cyclised (linear) analogues to examine if they 
retain any antimycobacterial activity. It was also unknown at this time if the 
synthesised natural product sequences would spontaneously fold to give the native 
threaded conformation. If that proved not to be the case, we would also be able to 
evaluate if the non-threaded structures retained antimycobacterial activity. Taking 
lariatin A, 31, as an example, the assembly of the linear sequence would be 
followed by head-to-side-chain cyclisation reaction, between Gly1 and Glu8. The 
first strategy adopted involved the use of Dmab (138, 4-(N-[1-(4,4-dimethyl-2,6-
dioxocyclohexylidene)-3-methylbutyl]amino)benzyl) as the side chain protection for 
the Glu residue involved in this coupling reaction. This protecting group can be 
removed on resin under mild conditions using 2% hydrazine hydride in DMF and it is 
stable to piperidine and removal of Fmoc, Boc and trityl (167).  
 
Linear lariatin A would be synthesised using standard SPPS before selective 
removal of the Dmab group, and on-resin cyclisation using DIC and HOAt (Scheme 
                                               
‡
Some aspects of this work were contributed to by MPharm and MSc project students Sienna Feguson 
and Ammar Ahmed, under my supervision 
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2.29). On-resin cyclisation presents the advantage, compared to cyclisation in 
solution, of favouring intramolecular reaction over intermolecular reaction and of 
taking place while the other residues remain protected. 
 
Scheme 2.29 Head-to-side-chain cyclisation of lariatin A linear precursor 
Reagents and conditions: a) 20% piperidine in DMF, 2 x 15 min; b) 2% hydrazine monohydride in DMF,  
5 x 3 min; c) DIC, HOAt, DMF, 24 h. 
2.4.1.1 Synthesis of lariatin A and B  
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The first attempt at the (automated SPPS) synthesis of lariatin A 31 was conducted 
starting from H-Pro-2-ClTrt resin. The synthesis of the similar lariatin B 32 was 
conducted in parallel. The bulky 2-ClTrt resin is preferred over the use of a Wang 
resin as the latter can result in unwanted DKP formation at the dipeptide stage (see 
Chapter 1.3.5). Glu8 was incorporated as the side chain Dmab-protected derivative. 
After completion of the linear sequence and removal of the final Fmoc group, the 
Dmab group was selectively removed according to the standard protocol (2% 
hydrazine monohydrate), followed by treatment with 5 mM sodium hydroxide in 
aqueous methanol to fully remove any residual aminobenzyl ester (176). A Kaiser 
test at this stage was expected to confirm the presence of the free amino group at 
the N-terminus, but the test was unexpectedly negative. The same problem was 
seen with the lariatin B sequence. A further piperidine treatment to ensure complete 
Fmoc removed failed to change the result of the Kaiser test. Consequently 
cyclisation was not attempted at this stage and the peptide was cleaved from the 
support and analysed by ESI-MS in order to investigate what had happened. 
ESI-MS analysis of the crude lariatin A cleavage product showed signals at m/z 
1035.6 and 1247.6, which are consistent with the presence of the [M+2H]2+ ion of 
the desired/expected molecule (the deprotected linear precursor of lariatin A, acyclic 
31) and the [M+H]+ ion of a truncated pyroglutamyl-peptide (139) respectively. The 
ESI-MS results for the linear lariatin B sample showed signals at m/z 1112.5, 
consistent with [M+2H]2+ ion of the desired/expected peptide (the linear precursor of 
lariatin B, acyclic 32), and at 1401.7 suggesting similarly the presence of the [M+H]+ 
ion of a truncated pyroglutamyl-peptide (140).  
 
The formation of such pyroglutamyl derivatives is due to the reaction of the Nα-
amino group of Glu (or Gln) with its side chain carboxyl (or carboxamide) to give a 
lactam ring (Scheme 2.30). If this occurs during chain elongation, there is 
subsequently no N-terminal free amino group, required for further coupling, 
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generating a truncated peptide. This phenomenon would explain the negative (or at 
least very weak) Kaiser test results. In the case of Glu, this side reaction seems to 
be promoted in the presence of a base. Piperidine deprotection therefore provides 
an environment that might encourage such a reaction to take place. This reaction 
can also occur when the side chain of Glu has an activated γ-carboxyl group, which 
could be problematic during cyclisation attempts (177). Furthermore, Dmab 
deprotection conditions have previously been reported to trigger the production of 
unacceptable levels of side products (178). 
 
Scheme 2.30 Pyroglutamate formation 
The crude products of the attempted lariatin A and B syntheses were not purified, 
given the high proportion of the pyroglutamyl by-product present and their poor 
resolution from the linear precursors, therefore no definite quantitative data are 
available on the degree of pyroglutamate formation. Nonetheless it might be inferred 
that pyroglutamate formation was sufficiently significant (>50%) to produce an 
essentially negative Kaiser test. The intramolecular cyclisation leading to 
pyroglutamate formation and subsequent failed elongation has been previously 
reported to have taken place using the Dmab protecting group (177). 
MS analysis also indicated the absence of any glutamic acid aminobenzyl ester, 
indicating that complete Dmab removal had been achieved. While this may seem to 
justify the use of the 5 mM NaOH treatment (176), it is possible that complete 
removal was achieved using the 2% hydrazine monohydrate treatment alone. There 
remain, however, some concerns over the stability of the 2-ClTrt linker to these 
conditions (labile at pH >10), which may lead to premature peptide cleavage (169). 
There was also concern that the use of the 5 mM NaOH might increase the 
likelihood of pyroglutamate formation. 
The automated synthesis of lariatins A and B was therefore repeated. Dmab 
removal was achieved as previously using hydrazine monohydrate, but without the 
additional NaOH treatment to try to minimise any premature cleavage or 
pyroglutamate formation. This time the Kaiser test (after N-terminal Fmoc removal) 
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was positive and the cyclisation was therefore attempted using DIC and 1-hydroxy-
7-azabenzotriazole (HOAt) coupling methodology. The cyclisation step had to be 
repeated three times, for both lariatin A and B, before a negative Kaiser test was 
obtained, implying complete reaction of the N-terminal amino groups. After cleavage, 
the crude samples were purified using preparative HPLC and samples were sent for 
ESI-MS. 
HPLC analysis of the crude products for the intended cyclic lariatins A and B 
indicated the presence, in both cases of one major peak. ESI-MS of the fraction 
from the lariatin A product  isolated via RP-HPLC, showed signals at m/z 1291.8 and 
1247.8 consistent with the [M-H+2Na]+ and  [M+H]+ ions of the truncated 
pyroglutamyl-peptide. Likewise the pure fraction obtained from purification of the 
intended lariatin B showed signals at m/z 1401.8, 1423.9 and 1447.8 consistent with 
the [M+H]+, [M+Na]+ and [M+2Na]+ ions of the truncated pyroglutamyl-peptide. This 
outcome, despite the avoidance of the NaOH treatment, provides further evidence 
about the unsuitability of Dmab for this synthesis. It seems that the Nα-Fmoc 
deprotection of the Glu(ODmab) residue, possibly as well as subsequent 
deprotection(s) and/or activation of the Gly γ-carboxyl group are responsible for the 
pyroglutamate formation and truncation, preventing successful cyclisation. In the 
chromatograms of the crude products of both attempted lariatin A and B syntheses, 
a minor peak (poorly resolved) elutes immediately before the truncated 
pyroglutamyl-peptide. We speculate that these slightly more polar compounds are 
more likely to be uncyclised linear peptides rather than the successfully cyclised 
lariatins. Unfortunately it wasn’t possible to isolate these compounds in order to 
verify this hypothesis.  
2.4.1.2 Synthesis of linear lariatin A and B analogues  
Linear lariatin A and B analogues were synthesised with the aim of evaluating 
whether their antimycobacterial activity persisted even when uncyclised. They were 
automatically synthesised starting from preloaded H-Pro-2-ClTrt resin. The naturally-
occurring Glu8 residue was substituted with Gln (introduced as the side chain trityl-
protected derivative) as the side chain terminal amide is structurally more similar to 
the amide (lactam) group found in the cyclic peptides, mimicking the amide bond 
formed with Gly1 (141, 142).  
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After cleavage, HPLC analysis of the crude linear analogue of lariatin A showed two 
major products in an approximately 1:1 ratio. HPLC purification led to isolation of the 
two compounds and ESI-MS analysis confirmed the presence of the desired product 
and its pyroglutamate derivative. The desired product was isolated in a 5% overall 
yield after RP-HPLC purification. The crude product of the automated synthesis of 
the lariatin B linear analogue showed one single main component in the HPLC 
chromatogram. Purification via preparative HPLC resulted in its isolation (4% overall 
yield), and it was confirmed as the desired product by ESI-MS. The apparent 
absence of pyroglutamate formation in the Gln(Trt)-containing linear lariatin B 
analogue (and the much-reduced formation in the lariatin A analogue) could suggest 
that the Glu(ODmab) residue rendered its formation more favourable. This finding 
has been corroborated previously in the literature: the use of Glu(OtBu) in Fmoc-
based peptide synthesis overcame previously noted pyroglutamate formation (177). 
The same authors also reported that the use of amino acids of varying steric size as 
residues adjacent to an N-terminal Glu(ODmab) residue had little effect on the rate 
of the undesired reaction (177).  
2.4.1.3 Synthesis of lassomycin linear C-terminal free acid analogue 
Linear analogue 143 was synthesised with the intention of comparing its 
antitubercular activity with that of the native lassomycin (33, pg. 45) and deduce 
whether cyclisation and methyl esterification at the C-terminus are necessary for 
activity. 143 was synthesised automatically on preloaded Fmoc-Ile-Wang resin. In a 
similar approach to that used for the lariatins, the side chain residue involved in the 
head-to-side chain cyclisation, in lassomycin’s case Asp8, was substituted with Asn 
in the linear analogue, as the amide better resembles the peptide bond found 
between Asp8 and Gly1 in the cyclic molecule. The synthesis was largely 
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straightforward and the crude product HPLC chromatogram indicated very good 
purity, with only minor quantities of contaminants. A small portion was purified via 
preparative HPLC for a final yield of 25%. LC-MS analysis of the pure sample 
showed signals consistent with the desired product. 
 
 
2.4.1.4 C-Terminal methyl esterification of lassomycin linear free acid  
The purity of the Asn-containing linear analogue was deemed sufficient to use the 
crude product as the starting material for the Fischer methyl esterification of the C-
terminus, thus avoiding two HPLC purifications. This synthesis of 144 was 
attempted to produce a linear analogue structurally closer to lassomycin, as a C-
terminal methyl ester is found in the natural product. The peptide was dissolved in 
dry methanol and treated with a solution of HCl in dioxane for 24 h. HPLC analysis 
of the resulting crude product showed the formation of a single major product with a 
few minor side products and therefore the sample was purified via preparative HPLC 
and the fractions containing the major peak (5% yield) analysed via ESI-MS. The 
results showed signals at m/z 475.0 and 479.0 consistent with the [M+4H]4+ ion of 
the target structure and with the [M+4H]4+ ion of a possibly doubly methylated by-
product. The site of the second methylation is unknown. A possible explanation 
begins with rearrangement of a carboxamide-containing side chain residue, such as 
Asn, via a two-step deamidation reaction, and has been previously reported 
(Scheme 2.31) (179,180). 
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Scheme 2.31 The succinimide can open to an aspartate or an isoaspartate 
Nucleophilic attack by the amide nitrogen of the peptide bond with the adjacent 
residue causes the formation of a succinimide, which can then open in two possible 
ways: either where the cyclisation occurred, yielding the corresponding aspartate 
(146) or on the other side, causing the formation of isoaspartate (147). In both cases 
a free carboxyl group is generated and would be available for methylation (Scheme 
2.31). 
The esterification was repeated once more using the purified linear peptide acid, to 
evaluate if the additional purification step might improve the overall yield. Samples 
of the reaction mixture were taken every hour and examined via HPLC to monitor 
the progression of desired (and unwanted) product formation over time. The AUCs 
were used to calculate the proportional concentrations of each reactant or product in 
the mixture at each time point. The reaction was stopped after analysis of the 
reaction mixture at the 4 h time point, at which time the reaction was essentially 
complete. The mixture was poured into water and diethyl ether and the peptide-
containing aqueous phase washed several times with more ether (181). The product 
was purified to afford the target esterified peptide in 45% yield. The esterification 
exhibited first-order kinetics with respect to the free carboxylic acid. Fischer 
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esterification is generally a second-order reaction but in this case the large excess 
of methanol causes it to follow pseudo-first-order kinetics (182).  
 
Figure 2.10 Linear plot of ln AUC vs. time (h) confirming the pseudo-first-order kinetics of the Fischer 
esterification reaction performed 
As shown in Fig. 2.10 the calculated slope of the line of best fit gives a rate constant 
of 0.64 h-1. Given this value, the half-life of the reaction was calculated at 
approximately 1.1 h, fitting with the fact that the concentration of reactant seemed to 
steadily almost halve at every hourly sampling. As R2 = 0.98 indicates a strong 
linear relationship between ln AUC and the reaction time, the data appear to fit 
closely to a pseudo-first-order reaction model. 
 
Figure 2.11 Plot of AUC vs. time (h) showing the reaction progression in terms of starting material and 
final product 
Monitoring of the reaction progression allowed a suitable time point to be chosen at 
which to stop it when the conversion of starting material to product was essentially 
complete and when the levels of by-product formation remained acceptable. 
Comparison of the HPLC profiles of the collected samples showed how, within the 
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first hour, starting material and desired product had approximately reached the 
same concentration (as the line intersection suggests in Fig. 2.11). After 2 h the 
reaction was approximately 75% complete. Within the subsequent 2 h, consumption 
of the starting material was observed but the concentration of minor by-products 
started to become more noticeable, and by 4 h the amount of starting material was 
negligible, with by-product formation starting to increase further.  As highlighted in 
Fig. 2.9, during the last hour the concentrations of starting and desired final product 
almost reached a plateau. From these results, it was unsurprising that in this second 
attempt at esterification, lasting only 4 h instead of 24 h (as done previously and as 
reported in the literature (181)), the yield of pure product isolated was much higher, 
as the optimum point in terms of conversion to product and acceptable by-product 
formation had been reached. It is therefore clear that for this sequence a long 
reaction time is not recommended.  
2.4.1.5 Synthesis of the cyclic lassomycin free acid precursor  
 
The cyclic lassomycin precursor was synthesised starting from preloaded Fmoc-Ile-
Wang resin. The sequence was assembled via SPPS, incorporating Asp8 with side 
chain ODmab protection. The removal of Dmab (2% hydrazine monohydrate) was 
followed by on-resin cyclisation using DIC and HOAt. Two cyclisation steps of 24 h 
failed to give a negative Kaiser test, so the reaction was repeated a third time and a 
negative result was obtained after 24 h. In a subsequent attempt at the synthesis of 
148, the peptide-resin was treated with 5 mM NaOH for 3 h after the 2% hydrazine 
monohydrate treatment in order to ensure full removal of the Dmab deprotection 
prior to the cyclisation. In this attempt, the cyclisation still remained incomplete after 
two 24 h treatments with DIC/HOAt, but a negative Kaiser test was obtained after 6 
h of a third cyclisation step. The HPLC profiles of the crude products from both 
syntheses showed no significant differences, and as a consequence they were 
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combined for purification purposes. The desired cyclic peptide was isolated in 1.5% 
yield. This outcome suggests that the NaOH treatment is apparently unnecessary 
and perhaps the cyclisation steps could be shorter in duration, while keeping the 
number of repetitions. A further attempt at the synthesis utilised a different 
cyclisation strategy; as two cycles of 24 h in DIC/HOAt failed to give a negative 
Kaiser test two cycles of a 6 h reaction using benzotriazole-1-yl-oxy-tris-
pyrrolidinophosphonium hexafluorophosphate (PyBOP) and HOAt in the presence of 
DIEA were employed. The results of the Kaiser test seemed qualitatively improved, 
but the crude product had a similar HPLC profile to that of the other attempts. The 
crude product obtained using the latter cyclisation method was purified and resulted 
in an improved yield of 3.9%.  
The HRMS (ESI) results for the isolated compound confirmed the presence of a 
signal at m/z 622.7047 consistent with the [M+3H]3+ ion of the desired cyclic product 
(1865.1 Da). It should be noted, however, that the theoretical internal aspartimide 
by-product 149 has exactly the same molecular weight. Formation of aspartimide 
(Scheme 2.32) can be acid or base catalysed (183) and piperidine is generally the 
cause of its formation in Fmoc SPPS (184). This by-product has been reported to 
spontaneously form during elongations of Asn- or Asp-containing sequences (185); 
the nitrogen from the amide bond with the adjacent residue can attack the side chain 
carboxyl moiety of Asp. In a side-chain protected amino acid, such as Asp(ODmab), 
this carboxyl group is masked as an ester and can act as a leaving group in this 
reaction. Nucleophiles such as piperidine (or water, if present) can attack either one 
of the carbonyl carbon atoms and open the aspartimide ring (Scheme 2.33) (186). 
Unfortunately the isolated product has not yet been synthesised in sufficient quantity 
to allow unequivocal confirmation of the success of cyclisation via NMR. It is 
therefore not yet possible to realise to exclude the formation of the aspartamyl-
peptide.  
 
Scheme 2.32 Mechanism of aspartimide formation 
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Interestingly, in these syntheses some fractions were found to contain, according to 
ESI-MS signals, an unknown product of molecular weight corresponding to 2024.0 
Da and products consistent with the α-piperidide of the β-peptide (150) or the β-
piperidide of the α-peptide (151) (1951.0 Da). These molecules can be derived from 
the aspartimide ring opening mediated by the piperidine nucleophile (Scheme 2.33), 
or could be due to premature loss of the Dmab group, which might subsequently 
lead to activation of the Asp carboxylic side chain, which might then react with 
piperidine. 
 
Scheme 2.33 Piperidine nucleophilic attack on the aspartamyl-peptide 
2.4.2 Synthesis of lasso peptides and linear analogues using allyl ester side 
chain protection strategy 
Following these findings the further attempts to attain the cyclic lasso peptides 
featured the use of a different semi-permanent protecting group on the side chain of 
the residue involved in the cyclisation. The use of the allyl ester (OAll) protecting 
group strategy has been found to produce high yields of cyclic peptides and fewer 
side products, when compared to the use of Dmab on the same sequence (177,178). 
It was therefore chosen as the Glu8 (lariatins) and Asp8 (lassomycin) side chain 
protecting group even though the moisture-free palladium-catalysed removal of OAll 
might prove itself more challenging and less convenient than the hydrazinolysis 
required for Dmab.  
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2.4.2.1 O-Allyl strategy synthesis of cyclic lariatins A and B  
The first trial to synthesise lariatin A using allyl side chain protection on Glu8 was 
attempted manually following the usual manual protocol described in the general 
methods. The final residue coupling was not followed by Fmoc deprotection (as is 
typical in the Dmab strategy): the OAll deprotection step is performed first. Allyl ester 
removal requires anhydrous conditions, which were achieved by sealing the vessel 
with a rubber septum, followed by removal of air by vacuum and insertion of an Ar 
balloon. Through use of a syringe dimethylamineborane in dry CH2Cl2 was added to 
the resin, followed by quick addition of tetrakis(triphenylphosphine)palladium(0) 
catalyst (Pd(PPh3)4) (187). Deprotection proceeded for 1 h, followed by removal of 
the solvents using positive pressure of inert gas. After allyl ester removal, the 
terminal Fmoc group was removed with 20% piperidine and its success confirmed 
via the Kaiser test. A wash with 5% DIEA in DMF was added to remove any residual 
piperidine that might react with the free carboxylic acid moiety after its activation. 
Cyclisation for 24 h with DIC and HOAt was successfully confirmed by a negative 
Kaiser test, followed by cleavage of the peptide from the resin.  
In parallel, a second trial was also attempted using automated SPPS, following the 
optimised protocol previously identified (two couplings of 30 min each using a 2.5-
fold molar excess of activated amino acid). The remaining steps (deprotections, 
cyclisation and cleavage) following the assembly of the linear sequence were 
conducted identically as described for the manual synthesis.  
Both cleaved crude lariatin A products (217 mg from the manual synthesis and 235 
mg from the automated synthesis) were analysed via HPLC and their profiles were 
extremely similar. Each crude sample was divided into two portions (to avoid 
exceeding the capacity of the preparative column) and purified by preparative HPLC. 
The fractions collected, after being analysed via HPLC, were combined according to 
their identity and purity and sent for LC-MS analysis. The signals at m/z 1026.6 and 
684.7 are consistent with the [M+2H]2+ and [M+3H]3+ ions of the desired product, 
which was isolated in a final yield of 1.5%. Some impure fractions, whose HPLC 
profiles confirmed the presence of lariatin A as the major component, were 
combined for a total mass of 22 mg. After evaluation of possible systems that could 
have allowed the separation of the contaminants, purification of this impure sample 
was attempted on a semi-preparative HPLC column. The fractions collected, 
however, were unfortunately still not completely pure.  
As the products from the manual and automated syntheses were of very similar 
quality, the synthesis of lariatin B, incorporating Glu(OAll), was conducted 
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automatically (for its obvious advantages of time and convenience). The synthesis 
was also programmed to utilise the standard 2 × 30 min double coupling protocol 
with 2.5 equivalents of activated amino acid per coupling and all the steps were 
performed similarly to the synthesis of lariatin A. The crude product HPLC 
highlighted the presence of two major peaks. Approximately half of the crude 
sample was subjected to purification; the pure fractions corresponding to the later 
eluting peak, which added up to a disappointing 3% yield, were analysed by LC-MS 
and showed signals at m/z 1103.5 and 736.1 consistent with the [M+2H]2+ and 
[M+3H]3+ ions of the desired cyclic lariatin B product.  
2.4.2.2 O-Allyl strategy synthesis of cyclic lassomycin free acid precursor  
The synthesis of the cyclic lassomycin precursor 148 using Asp(OAll) was attempted 
automatically. The synthesiser was programmed to follow the same optimised 
protocol as developed above. As with the lariatin synthesis, the final Fmoc 
deprotection of the linear peptide was not performed and the resin-bound peptide 
was transferred to a sealed vessel, under Ar atmosphere, to provide for the required 
anhydrous conditions of allyl ester deprotection. The removal of the Asp8 side chain 
protection was followed by Fmoc deprotection prior to the cyclisation step. In the 
case of lassomycin, as experienced previously, one 24 h treatment with DIC and 
HOAt  did not result in a negative Kaiser test, therefore the cyclisation was repeated 
a second time which unfortunately failed to lead to any improvement. One possible 
reason could have been that the allyl deprotection failed or was incomplete, 
subsequently resulting in the lack of sufficient activated carboxyl component to allow 
the cyclisation to take place fully. Therefore the peptide-resin was washed 
thoroughly and the anhydrous conditions under Ar atmosphere re-established. The 
OAll removal step was repeated, followed by a third attempt at cyclisation for 24 h. 
Once again the Kaiser test remained positive and no further trials were attempted. 
The peptide was cleaved and the crude sample analysed: the HPLC chromatogram 
shows three major peaks; purification lead to the isolation of a compound whose MS 
analysis showed signals at m/z 988.9, 622.8 and 467.4 consistent with the [M+2H]2+, 
[M+3H]3+ and [M+4H]4+ ions of either the desired product or its aspartimide-
derivative (see discussion above). The retention time of the compound isolated was 
longer (Rt = 9.92 min) than that of the product obtained via the ODmab side chain 
protection strategy (Rt = 9.10 min). It is likely that one of these two different products 
is the desired cyclic product and the other is the aspartimide by-product, as both 
have the same molecular weight, consistent with the mass spectral data. It might be 
expected that the product with the longer retention time (from the OAll strategy 
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synthesis) is more likely to be the cyclic product as it lacks a free N-terminus and 
should be lower in polarity.   
2.4.3 General discussion of attempted lasso peptide syntheses 
The synthesis of the linear analogues of the three lasso peptides has been 
successfully achieved, as well as the Fischer C-terminal esterification of the 
lassomycin linear analogue. Unthreaded cyclic lariatins A and B have been 
synthesised for the first time. The SPPS strategy demonstrated itself prone to a 
number of undesirable side reactions which resulted in poor yield recovery. The 
main difficulties were encountered while using γ- and β-carboxyl Dmab side chain 
protection, which has previously been reported to be associated with the 
problematic formation of pyroglutamate and aspartimide by-products. Asp(ODmab)-
containing sequences are particularly prone to the formation of the latter derivatives, 
while Glu(ODmab) (and Gln) containing sequences can lead to the occurrence of N-
terminal pyroglutamyl peptides. The pyroglutamyl-peptide was identified in and 
isolated from the crude products of the attempted lariatin syntheses, while the 
aspartamyl product has likely been identified among the products of the attempted 
cyclic lassomycin free acid precursor syntheses, but preliminary MS data cannot 
unequivocally identify it as the molecular weights of the aspartimide-containing 
peptide and the desired cyclic peptide are the same (1866.3 Da). In addition, 
piperidine adducts were isolated from the cyclic lassomycin precursor crude mixture; 
these are formed by aspartimide ring opening by nucleophilic attack on either of the 
carbonyl carbon atoms, or by premature loss of Dmab. 
The use of γ-carboxyl side chain allyl protection proved to be a better strategy than 
the employment of Dmab for the synthesis of the lariatins allowing their isolation, 
even though in very low yields (1.5 and 1.8% respectively). The HPLC profiles 
enabled the identification of pyroglutamyl-peptides even using this strategy, though 
present in lower concentrations than seen in the Glu(ODmab) strategy synthesis. 
Allyl removal is more challenging due to the necessity to maintain dry conditions and 
there was some suspicion that this may have compromised the outcome of the 
cyclic lassomycin synthesis, but MS signals are consistent with ions corresponding 
to the desired product or the aspartimide derivative. In the case of lassomycin the 
crude product obtained with the OAll strategy, analysed via HPLC, showed the 
presence of a peak distinct to that from the crude product obtained via the ODmab 
strategy. Isolation of this peak was achieved and the sample analysed by NMR, with 
the intention of comparing the spectra of the two products to find differences that 
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would allow identification of the isolated compounds. Unfortunately the NMR 
obtained from the latest purification was of poor quality possibly because of the very 
limited amount available, therefore it was not possible to come to any definitive 
conclusions. Automated SPPS proved itself a satisfactory method to access the 
linear precursors. Overall, however, the chosen synthetic strategies still require 
some optimisation for the synthesis of these cyclic peptide natural products.  
2.4.4 Biological evaluation 
The lariatins have previously been tested on M. tuberculosis and M. smegmatis  
(118,120); lariatin A showed bactericidal activity against both organisms, while 
lariatin B only against the latter. Lassomycin has been selectively tested only on M. 
tuberculosis against which it shows a minimum inhibitory concentration (MIC) of 0.8-
3 mg/mL (depending on the strain used) (115). 
2.4.4.1 Target-based evaluation 
The mechanism of action of the laritins has not yet been investigated. Under these 
circumstances it is clear how it would not have been possible to perform a target-
based assay. The reported mechanism of lassomycin action is based on the 
inhibition of the ATP-dependent protease ClpC1P1P2 (115), but the attainment of 
the target enzyme was beyond the scope of this work.  
2.4.4.2 Whole-cell evaluation  
Among the lasso peptides, the pure cyclic lariatin B sample was tested on the SPOTi 
assay on M. smegmatis, M. aurum and M. bovis BCG. The bacteria were cultured 
as described in Chapter 4.6.5.6. The 2.4 mg of lariatin B available were dissolved in 
water to a concentration of 50 mg/mL and the dilution plate was prepared as 
described in Chapter 4.6.5.13. The dilutions were transferred to a 96-well plate and 
mixed with agar. Once the agar had solidified the bacterial cultures were inoculated 
and the plates incubated according at 37 °C for 3 days for M. smegmatis, 35 °C for 
5 days for M. aurum and 37 °C for 14 days for M.bovis BCG. 
The plates showed no inhibition of bacterial proliferation, while the INH positive 
control performed as expected. This is very likely to be due to the fact that an 
unthreaded structure will lack the stability to hydrolytic enzymes that is probably one 
of the main reasons for lasso peptides potency and effectiveness. The threaded 
conformation may also be crucial for interaction with a specific target, which 
mediates the antibacterial activity. 
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The remaining cyclic and linear peptides are still in the process of being evaluated 
for their activities against mycobacterial strains.  
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3. CONCLUSIONS 
3.1 Synthesis of Lys-containing PG fragments and analogues 
The Lys-containing fragments of the peptidoglycan have successfully been 
assembled both manually and automatically. Comparison of the two synthetic 
methods showed that, despite the lack of monitoring of coupling completion that is 
possible during manual synthesis, the automated system gave products with a 
significantly higher level of purity. Automated solid-phase peptide synthesis has 
therefore revealed itself to be the ideal methodology in obtaining these short peptide 
sequences, representing a saving in time, money and workload.  
The optimisation of the Syro I system was conducted through testing of a series of 
protocols. These involved the synthesis of the same peptide (Leu-enkephalin) 
sequence with different combinations of equivalents of amino acid per coupling, 
numbers of couplings and durations of couplings. While tentative trends could be 
seen, the results obtained showed no clearly significant differences in the pure 
yields, fuelling the doubt that the sample peptide utilised might have been too easy 
to synthesise, such that the method could not discriminate between the protocols. 
Consequently ACP 65-74, a well-known challenging sequence, was used to repeat 
the evaluation of the protocols. The outcomes showed no clearly apparent 
differences in yield among the various protocols, except for the one involving two 30 
min couplings with a 2.5-fold molar excess of activated amino acid, which was 
subsequently utilised as the standard for the automated synthesis of several 
analogues of the Lys-containing PG fragments and the lasso peptides. Nonetheless 
it is possible to observe how increasing the number of couplings and the duration of 
the reaction, up to 30 min, seems to improve the yield to a certain extent.  Swelling 
of the resin prior to deprotection and HOBt addition did not appear to exert a great 
influence on the synthetic outcome for this sequence. It is possible that the lack of 
statistical significance in the observed differences in yield may have been a 
consequence of the small number of repeats of each trial. 
The peptides obtained were evaluated against M. aurum, M. smegmatis and M. 
bovis BCG, using the SPOTi whole-cell assay, in the hope of detecting their 
potential as antimycobacterial/anti-TB agents. Unfortunately the compounds did not 
show any interesting activity. The intention was also to evaluate them as substrates 
or inhibitors for Mpl, using an enzyme-based assay, but the heterologous expression 
and purification of M. tuberculosis Mpl had not yet been perfected to enable these 
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studies to be conducted. The Lys-containing fragments and their sequence 
analogues also failed to show any inhibitory effect against the Gram negative 
organism E. coli. 
The Lys-containing PG fragments are now available for characterisation of the 
activity of different Mur ligases in Gram positive bacteria and to be tested for any 
inhibitory effect on M. tuberculosis Rv3712. The sequence analogues will also be 
evaluated against Gram positive and negative bacterial Mur ligases to determine if 
they have any inhibitory activity.  
3.2 Synthesis of mDAP-containing PG fragments and analogues 
The production of protected mDAP was successfully achieved via cross-metathesis 
between olefins  D-allylglycine and L-vinylglycine, as suggested by Roychowdury et 
al. (36,147). In order to utilise the product in SPPS for the production of peptide 
fragments of PG, an appropriate orthogonal protection strategy needed to be 
followed. The necessary building blocks chosen were Nα-Fmoc-protected 
vinylglycine benzyl ester and Nα-Boc D-allylglycine tert-butyl ester. Their synthesis 
was attempted following a variety of methods which led to the successful attainment 
of the vinylglycine component. Unfortunately, the use of an enzymatic resolution 
methodology for the large-scale synthesis of D-allylglycine proved unsuitable as the 
acylase enzyme was not very efficient for hydrolysis of the Nα-acetyl-L-allylglycine, 
resulting in poor enantiomeric purity. Commercially available Nα-Boc D-allylglycine 
was purchased instead and subsequently protected as the tBu ester.  
Similar published cross-metathesis reactions prescribed 24 h at room temperature. 
A preliminary evaluation of times and temperatures seemed to suggest the suitability 
of a microwave-assisted methodology. This method was pursued and the product 
successfully obtained at 55 °C within 1 h on a small scale, conveniently followed by 
preparative HPLC purification. Comparison of the efficiency of two different catalysts 
– Hoveyda-Grubbs and Grubbs 2nd generation – showed no significant difference, 
therefore the reaction was repeated using the Grubbs 2nd generation catalyst as 
suggested by reported methods (36,147). Attempts to conduct the reaction on larger 
scale were inconsistent and often unsuccessful, so the small scale cross-metathesis 
reactions were repeated a number of times, combining and purifying the products 
until sufficient mDAP precursor was collected. The successful hydrogenation of the 
double bond led to the isolation of the suitably-protected mDAP, retaining the Fmoc 
protecting group.  
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The product was loaded onto a 2-ClTrt resin and the tripeptide H-Ala-D-Glu(mDAP-
OH)-OH manually assembled. The purification was only partially successful; MS 
confirmed the presence of the tripeptide in the sample, but the desired product was 
contaminated by another co-eluting compound of similar Rf. The two compounds 
eluted very quickly by RP-HPLC even using 100% water as the mobile phase. 
Unfortunately it was not possible to further purify the product because of the small 
amount collected and because of time limitations.  
While protected mDAP can be now synthesised, the methodology requires much 
optimisation. With more mDAP in hand, more tripeptide could be synthesised and 
purification perhaps attempted using a longer column or different stationary phase. 
Another possibility could be to couple the N-terminal Ala as the Boc-protected 
derivative, prior to mild cleavage from the 2-ClTrt resin. In this manner, after removal 
from the solid support, the peptide, and possibly the unwanted product too, will bear 
a protecting group that will render them less polar. This should make them elute 
later when the gradient is changing, therefore allowing for a better separation. 
The tripeptide will then be available for activity evaluation as a substrate for Mpl or 
MurE. Furthermore, ready access to mDAP will be useful for the preparation of other 
PG fragments and analogues. The fragments could then be used to evaluate the 
activity of different Mur ligases in a number of pathogens and analogues could be 
developed as possible inhibitors that may have value in TB therapy.  
The recombinant heterologous expression of Rv3712, M. tuberculosis putative Mpl, 
was successfully achieved in E. coli BL21(DE3)pLysS competent cells, using 
pCDFDuet-1 as a vector. However, its isolation still requires optimisation, especially 
for the purification step.  It will be necessary to consider performing a second 
purification before utilising the product enzyme in any biological evaluation. That 
should be sufficient to start testing the enzyme activity. This could be assessed 
through a colorimetric assay (Scheme 3.1) able to detect the release of inorganic 
phosphate derived from the hydrolysis of ATP following enzyme activity in the 
presence of substrates. There is a 1:1 proportion between the enzyme’s use of ATP 
and the molecules of peptide substrate used. This assay was originally developed to 
characterise the activity of recombinant Mur ligases from M. tuberculosis (Mur C, D, 
E and F) (39,54,61); it uses PiColorLock Gold kit (Innova Biosciences) and requires 
the enzyme, ATP, UDP-MurNAc and the investigated peptide.  
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Scheme 3.1 Activity assay: the dye binds to the inorganic phosphate and turns from orange to green.  
This assay can be readily used to evaluate enzyme activity using the single amino 
acid L-Ala, the already synthesised dipeptide (L-Ala-D-Glu, 53) and the crude mDAP-
containing tripeptide (Chapter 2.3), even in its impure form, and eventually tetra- and 
pentapeptides. It will also serve to investigate the substrate analogues/inhibitors and 
the associated inhibitory kinetic parameters. This information would contribute to the 
biochemical characterisation of this enzyme in M. tuberculosis. 
With the purpose of elucidating the structure of the enzyme it is intended to set up 
crystallisation trials. This would require larger amounts of pure enzyme, as 
discussed in Chapter 2.3.1.1.3. Improvements in the enzyme yield could be 
investigated by changing the vector, the surrogate or the cloning strategy.  
For this purpose it may be useful to change the surrogate cells used for the protein 
expression. BL21(DE3)pLysS competent cells were picked after an optimisation 
study performed by Nukala et al. (174), who compared results with those obtained 
with NEB Express and Rosetta DE3. Munshi et al. (54), though, during the study of 
the M. tuberculosis Mur ligases Mur C and Mur F, switched from BL21(DE3)pLysS 
to Pseudomonas putida strain KT2442 and it was found that the latter allowed the 
isolation of higher amounts of purer enzyme. Therefore the transformation of the 
construct into this specific strain is currently being considered a viable option to 
improve the recovery of pure M. tuberculosis Mpl.  
140 
 
 
Figure 3.1 Schematic representation of plasmid pVLT31 
The P. putida cells used by Munshi et al. (54) were carrying pVLT31 (Fig. 3.1) as a 
vector. The Mtb-Mpl construct will need to be cloned into pVLT31 and the clones will 
be selected in E. coli DH5α. The P. putida cells will need to be rendered electro-
competent before being able to be transformed. 
Another option would be to approach an alternative cloning strategy following the 
work of Usha et al. (188). The M. tuberculosis genome is highly biased towards C- 
and G-ending codons. It seems that when using a surrogate this can become an 
issue; the M. tuberculosis gene is being translated by ribosomes belonging to a 
different organism (E. coli) which has a different bias. This causes the ribosome to 
stall when it encounters alternatively biased codons. This critically reduces the 
amount of protein produced. In their work, Usha modified only the first 30 
nucleotides to match the preferences of the surrogate, without changing the product 
composition. Their efforts resulted in a dramatic increase in the production of the 
desired mycobacterial protein.  
Substrates to be tested will include L-Ala, the Lys- and mDAP-containing 
pentapeptide (L-Ala-D-Glu(Xaa-D-Ala-D-Ala-OH)) and N-terminal truncated di-, tri- 
and tetrapeptides and their UDP-MurNAc derivatives. Peptides including isosteres of 
mDAP or of other residues in the chain will also be evaluated. 
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3.3 Synthesis of anti-TB lasso peptides and linear analogues  
The synthesis of the threaded lasso peptides, such as the lariatins, is an intriguing 
challenge but an objective of this study was to evaluate whether unthreaded or 
linear peptides with the same sequences might retain a degree of antibacterial 
activity. Lassomycin was initially reported to have a non-threaded structure, but a 
later study by Lear et al. (116) suggests that its structure is actually threaded.  
The linear analogues of both lariatins A and B were successfully synthesised. The 
syntheses of the lariatins were challenging and complicated by pyroglutamate 
formation, probably promoted by the basic conditions used during Fmoc 
deprotection, with subsequent failed elongation of the peptide considerably reducing 
the yields. Dmab side-chain protection removal seems to further facilitate the 
formation of pyroglutamate as previously reported. Linear peptides bearing Gln 
instead of Glu seemed also to be affected by this side reaction. Pyroglutamate 
formation severely hindered the production of the cyclic lariatins. HPLC analysis of 
the crude lariatin cyclisation products showed only one major peak in each case, 
and these were identified through ESI-MS to be the pyroglutamate derivatives. ESI-
MS analysis of the crude samples failed to indicate the presence of the desired 
cyclised peptides.  
In the case of lassomycin, the linear analogue with a free C-terminal carboxyl group 
and bearing Asn in position 8, was obtained successfully. Methyl esterification of the 
C-terminus was also successful. HPLC-based analysis of the reaction kinetics 
helped define a better reaction time (reducing it from 24 h to 4 h) and improved the 
yield. Lassomycin cyclisation using a Dmab protection strategy produced a product 
which, according to MS analysis, has a molecular weight corresponding either to the 
cyclised peptide or the aspartimide derivative. Additional material will be required for 
the necessary NMR studies to fully elucidate the structure of the product.  
Given the problems encountered with the Dmab protection strategy, the syntheses 
of the cyclic molecules were repeated using an allyl ester side chain protecting 
group. Using this strategy, pyroglutamate formation proved less problematic, but the 
conditions required for allyl deprotection are less convenient than those for Dmab 
removal. The allyl strategy allowed the successful attainment of the cyclised lariatins 
A and B, even though in disappointingly low yields. The synthesis of the lassomycin 
free acid using this strategy yielded a compound with a molecular weight consistent 
with that of either the desired cyclic peptide or its aspartimide derivative.  
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Overall the synthetic routes examined seemed far from optimal. Of the cyclic 
peptides successfully synthesised only the lariatin B product was tested against 
different mycobacterial strains and it failed to show any inhibitory activity. This may 
be a consequence of the fact that it is very unlikely to be threaded like the natural 
product as this conformation does not seem to form spontaneously. As expected, 
the unthreaded conformation does not possess the activity of the threaded one. This 
may be related to its conformation or increased susceptibility to hydrolytic enzymes 
as the unusually high stability of the lasso peptides, which may be related to their 
potency, would be missing.   
Lariatin A, the linear lariatin analogues and C-terminal free acid and methylated 
linear lassomycin analogues are in the process of being evaluated against 
mycobacteria. The products isolated from the synthesis of the cyclic lassomycin free 
acid with the two different strategies have different retention times and both have a 
molecular weight consistent with the desired cyclic free acid. It is likely that one is 
the desired cyclic free acid and the other is the aspartimide. NMR analysis of the 
pure samples has unfortunately not, at this stage, helped to definitively identify 
which compound is which, due to the very small amounts available. Additional 
material will be necessary in order to confirm the structure of these products. 
Possible options to improve the outcomes include reduction of the occurrence of 
aspartimide formation by using milder bases than piperidine (such as piperazine), as 
reported by Wade et al. (189). This might lead to a lower efficiency of deprotection 
but could possibly be overcome by an increased number of deprotection steps. 
Addition of 0.1 M HOBt to the piperidine solution has also been suggested to 
minimise the formation of aspartimide (183). 
3.4 General conclusion and future work 
The establishment of a successful method for the synthesis of protected mDAP 
provides the opportunity for the production of a number of PG fragments that could 
be used for the evaluation of Mur ligases from both Gram positive and Gram 
negative bacteria to aid understanding of the PG synthesis machinery. In the first 
instance, larger quantities of protected mDAP will need to be synthesised to allow 
incorporation into fragments that will be used for the characterisation of M. 
tuberculosis Rv3712, through the assay mentioned in Chapter 3.2. Furthermore, the 
availability of protected mDAP will allow its incorporation into different peptides 
designed to inhibit recycling enzymes. Peptides of future interest will also include 
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UDP-MurNAc-linked PG fragments, fragments truncated in different positions and 
fragments modifiec on the N- or C-terminus.  
The heterologous expression of M. tuberculosis Rv3712 could be improved by 
changing the vector and competent cells, as suggested in Chapter 3.2, and if 
isolated in sufficient quantities could be used for crystallisation trials, alone or in 
combination with its substrates.  
The large-scale synthesis of Nα-Boc D-allylglycine tert-butyl ester from allyl bromide 
and diethylacetamidomalonate, followed by enzymatic resolution, still needs to be 
optimised. Access to a preparative HPLC chiral column may provide an opportunity 
for more efficient isolation of the desired product.  
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4. EXPERIMENTAL 
4.1 Materials and general methods 
All amino acids and resins were purchased from Novabiochem (Merck), Nottingham, 
UK. CDCl3, D2O and CD3OD for NMR spectroscopy were purchased from 
Cambridge Isotope Laboratories Inc. Peptide synthesis grade DMF was obtained 
from Rathburn Chemicals, Walkerburn, UK. All other chemicals, solvents and 
reagents were obtained from Sigma-Aldrich, Fisher Scientific or Tokyo Chemical 
Industry Co., Ltd. When required, solvents were purchased in the anhydrous form, 
freshly distilled or dried accordingly to established practices. Merck pre-coated 
(aluminium-backed) silica gel 60 F254 TLC plates were used for monitoring the 
reactions. TLC plates were either visualised under UV radiation at 254 nm, or 
stained with ninhydrin (in 95% ethanol and 4.5% acetic acid) or with PMA 
(phosphomolybdic acid in ethanol, 5% w/v solution), followed by heating.  
4.2 Spectroscopic methods 
NMR characterisation was performed using a Bruker Avance Spectrometer, 
operating at 400 MHz or 500 MHz frequency. The data collected were processed 
using Bruker NMR Suite 3.5 and TOPSPIN 3.2 Plot Editor software. The chemical 
shifts (δ) are expressed in ppm downfield from TMS and calibrated to the residual 
peak of the deuterated solvent. The peaks have been described as: singlet (s), 
broad singlet (br s), doublet (d), double doublet (dd), broad doublet (br d), triplet (t), 
quartet (q) or multiplet (m), coupling constants are stated in Hz. Spectral 
assignments were assisted using the appropriate 2D experiments, including 1H-1H 
COSY, HMQC and HMBC. Mass spectrometry data were obtained from a Finnigan 
Navigator Single Quadrupole Mass Spectrometer (low resolution) or Waters Q-TOF 
Global Ultima® (high resolution) instrument using electrospray ionisation (ESI). LC-
MS data were acquired on a Shimadzu LC-MS 2020 system combined with a LC-
20AD Prominence pump (running 10% MeCN for 1 min, then 10-95% MeCN over 7 
min and then 95% MeCN for 5 min), a SPD-20A Prominence UV/VIS detector, a 
CTO-20A Prominence column oven (40 °C), a DGU-20A5 Prominence degasser 
and a SIL-20ADht Prominence autosampler. Analytical RP-HPLC separation was 
generally achieved using a 4.6 × 250 mm Waters Atlantis® dC18 5 μm column or 
(when specified) a Macherey-Nagel EC 4.0 × 200 mm NUCLEODEX βOH chiral 
column. Both preparative and analytical HPLC used a mixture of solvent A (0.02% 
v/v TFA in water) and solvent B (0.016% v/v TFA in 90% aqueous MeCN) as the 
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mobile phase. A gradient system was generally used for analytical HPLC, running   
0% to 100% B over 20 minutes, then 100% B for 5 minutes, then 100% to 0% B 
over 5 minutes (flow rate 1.2 mL/min) (System A1), or 0% to 50% B over 25 minutes, 
then 50% to 100% B over 2 minutes, then 100% B for 5 minutes, then finally 100% 
to 0% B over 3 minutes (flow rate 1.2 mL/min) (System A2). Analytical separations 
were carried out using System A1 unless otherwise stated. The gradient was 
controlled with a Waters Alliance e2695 Separations Module and elution was 
monitored at 214 or 254 nm (except for Marfey’s method analyses, which were 
monitored at 340 nm) using a Waters 2489 dual wavelength detector. Retention 
times (using System A1 unless otherwise stated) are reported in minutes. 
Semi-preparative and preparative RP-HPLC separation were achieved using, 
respectively, a 10 × 250 mm and a 19 × 250 mm Waters Atlantis® dC18 10 μm 
column. The preparative gradient was controlled with a Waters 600 Controller and 
Delta 600 pump and elution was monitored at 214 nm using a Waters 2487 detector. 
Different gradient systems were used for separation depending on the mixture. A 
flow rate of 10.4 mL/min was used unless otherwise specified. System P1: 0% to   
20% B over 20 minutes, then 20 to 70% B over 50 minutes, then 70% to 100% B 
over 20 minutes. System P2: 50% to 100% B over 40 minutes, then 100% B for 20 
minutes. System P3: 0% B for 10 minutes, then 0 to 30% B over 40 minutes, then 
30% to 50% B over 30 minutes and finally 50% B for 20 min. System P4: 10% B 
over 10 minutes, then 10 to 60% B over 50 minutes, then 60% to 100% B over 20 
minutes. System P5: 0% to 20% B over 20 minutes, then 20 to 60% B over 60 
minutes, then 60% to 100% B over 20 minutes. System P6: 10% B for 10 minutes, 
then 10 to 60% B over 30 minutes, then 60% B for 10 minutes and finally 60 to    
100% B over 10 min. System P7: 0% to 20% B over 20 minutes, then 20 to 80% B 
over 80 minutes, then 80% to 100% B over 20 minutes. 
4.3 Solid-phase peptide synthesis 
Unless otherwise specified, Nα-Fmoc-protected amino acids pre-loaded onto Wang 
resins were used. The resin was washed and swelled in DMF (ca. 2 mL) for 1 hour. 
Nα-Fmoc deprotection was performed with 20% v/v piperidine in DMF (ca. 4 mL) for 
2 × 15 minutes followed by a thorough wash with DMF.  
Couplings with Fmoc-protected amino acids were performed using a 2.5-fold excess 
(over manufacturer’s resin substitution) of amino acid, HBTU and HOBt in the 
presence of a 5-fold excess of iPr2NEt (DIEA), dissolved in minimal DMF. Each 
coupling was allowed to proceed for 30 min unless otherwise specified, before 
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briefly washing the resin and repeating once. The Kaiser test (190) was used to 
monitor the completion of the coupling. Briefly, a sample (ca. 2-3 mg) of resin was 
removed from the coupling mixture, washed with DMF and 50% v/v CH2Cl2 in 
methanol then dried briefly under suction. 80% m/v phenol in ethanol (1 drop), 0.04 
mg/mL KCN in pyridine (2 drops) and 0.28 M ninhydrin in ethanol (1 drop) were 
added to the dried resin, followed by heating at 110 °C for ca. 3 min. In the case of 
positive test, the coupling step was repeated until a negative test result was 
obtained. After a final deprotection step, the resin was washed thoroughly with 
CH2Cl2 then 50% v/v CH2Cl2 in methanol and finally dried for 2 min under vacuum. 
The resin was then transferred to a desiccator where it was left to dry under vacuum 
for at least 3 h (and preferably overnight). Cleavage of the peptides from the resin 
was performed by acidolysis with TFA. For each 100 mg of resin used, 2 mL of a 
mixture of 95% TFA, 2.5% water and 2.5% triisopropylsilane (v/v/v) was added to 
the sample and the suspension gently stirred for 2 h. The sample was then filtered 
under vacuum through a sintered glass funnel and the resin beads washed with 
fresh TFA. The filtrate was evaporated to near dryness and then cold diethyl ether 
was added to the residue to precipitate the product. The crude peptide was filtered 
by gravity and washed with fresh ether before extraction into 95% (v/v) aqueous 
acetic acid. Finally the product was freeze-dried. 
The side chain protecting groups used for amino acids were (unless otherwise 
specified): Pbf for Arg; Boc for Lys, Trp and His; Trt for Asn and Gln; tBu for Ser and 
Tyr; and OtBu for Asp and Glu.  
4.4 Automated solid-phase peptide synthesis  
Automated solid phase synthesis was performed using a Syro I single channel 
automatic peptide synthesiser (BioTage, Sweden).  
Prior to the synthesis, the resin was swelled in DMF for 1 h. The synthesiser was 
programmed to perform deprotection using two different concentrations of piperidine 
in DMF: a first deprotection cycle of 3 min with 40% v/v piperidine in DMF and a 
second one of 12 min with 20% v/v piperidine in DMF solution followed by 6 washes 
of 1 min with DMF (vortexing for 10s, followed by a 1 min break). Unless otherwise 
specified, couplings were programmed to use 2.5 molar equivalents (over resin 
substitution) of amino acid (in DMF) and HBTU and a two-fold excess of DIEA. 
Stock solutions of 0.5 M HBTU in DMF, 0.5 M protected amino acid in DMF and 2 M 
DIEA in NMP were freshly prepared and loaded into the synthesiser. The machine 
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was programmed to perform 2 × 30 minutes couplings for each amino acid, with 
intermittent vortexing for 15 s, followed by 2 min breaks. Between couplings three 
washes of 1 min with DMF were performed (vortexing for 10 s, 1 min break). After 
the final deprotection step the resin was washed with CH2Cl2 and finally dried for 2 
min under vacuum. The solid phase vessels containing the resin were then 
transferred to a desiccator where they were dried for at least 3 h. 
Cleavage and isolation proceeded as described above for manual synthesis. For  
protocols involving the use of a centrifuge, cleavage was followed, after TFA 
removal, by addition of 10 mL cold tert-butyl methyl ether. If required, the sample 
was refrigerated overnight to maximise precipitation of the peptide and was then 
centrifuged twice at 3500 rpm (4 °C), decanting and replacing the tert-butyl methyl 
ether supernatant at the end of the first run. After the second run, the supernatant 
ether was discarded and the residue was dissolved in 95% aqueous acetic acid and 
freeze-dried. 
4.5 Advanced Marfey’s method: FDAA derivatisation 
1-Fluoro-2-4-dinitrophenyl-5-L-alanine amide (FDAA) derivatisation was achieved by 
dissolving the amino acid in distilled water and adding to it 0.8 equivalents of 1 M 
aqueous NaHCO3. To the solution, 1.85 molar equivalents of a 1% m/v solution of 
FDAA in acetone was added and the mixture was left to stir 1 h at 45 °C. 1 M HCl 
was added to quench the reaction and the mixture was transferred to an HPLC vial, 
making up the volume to 1 mL with Solvent B. The mixture was analysed by RP-
HPLC on a chiral column using System A2. 
4.6 Biological methods 
4.6.1 Chemicals, reagents and solutions  
Reagents for molecular biology were obtained from New England BioLabs (UK) Ltd 
(Hitchin, UK). Protein ladders and DNA purification kits were obtained from Thermo 
Fisher Scientific (Loughborough, UK). All stock solutions were prepared in double 
distilled water (ddH2O) unless otherwise stated. Percentage solutions are described 
as volume/volume (v/v) or as weight/volume (w/v). 
4.6.2 Bacterial strains 
BL21(DE3)pLysS Singles Competent Cells were obtained from Merck Millipore 
(Watford, UK). These competent cells are highly efficient for protein expression. 
Protein expression is controlled by the T7 promoter and has a ribosome binding site 
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(RBS). It is lysogenic for λDE3. It contains the T7 bacteriophage gene encoding T7 
RNA polymerase under control of the UV5 promoter. pLysS carries T7 lysozyme, 
which lowers the background expression level of the target gene under control of the 
T7 promoter but does not interfere with the level of expression achieved by IPTG 
induction. The BL21(DE3)pLysS competent cells provide higher control of protein 
expression and are chloramphenicol-resistant. 
4.6.3 Vector  
pCDFDuet-1 was a generous gift from Professor Gabriel Waksmann, Birkbeck, 
University of London, UK. This vector is used for the recombinant expression of two 
target open reading frames (ORFs). The vector contains two multiple cloning sites 
(MCS) each of which is preceded by a T7 lac promoter and ribosome binding site. 
The vector also carries lac I and a streptomycin resistance gene. Rv3712 was 
cloned in MCS1 by digesting with EcoR I and Hind III. The Tig A (Rv2462c) gene 
from M. tuberculosis was cloned in MCS 2 in between Nde I and Xho I restriction 
endonuclease sites (Fig. 4.1).  
 
Figure 4.1 Plasmid pCDFDuet-1 
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4.6.4 Bacterial growth media  
25 g of Luria-Bertani broth (LB) was dissolved in 1 L of double distilled water. Prior 
to use, the broth was sterilised by autoclaving at 121 °C and 1.1 bar pressure for 15 
min. Once sterilised the medium was stored in a dry, cool area. 
4.6.5 Methods 
4.6.5.1 Stock solutions for SDS-Page gel electrophoresis 
10X Running Buffer: 30 g of Tris base and 144 g of glycine were dissolved in 1 L of 
ddH2O and stored in a dry place.  
1X Running Buffer: 100 mL of 10X stock and 10 mL of 10% SDS were made up to 
1000 mL with ddH2O. 
Resolving/Separating Gel Buffer (1.5 M Tris-HCl, 0.5% (w/v) SDS at pH 8.8):  
90.85 g of Tris base and 2.5 g of SDS were dissolved in 350 mL of water and the pH 
adjusted to 8.8 with 1 N HCl. The volume was made up to 500 mL with ddH2O and 
stored in a dry place.  
Stacking Gel Buffer (0.5 M Tris-HCl, 0.5% (w/v) SDS at pH 6.8): 30.28 g of Tris 
base and 2.5 g of SDS were dissolved in 350 mL of water and the pH adjusted to 
6.8 with 1 N HCl. The volume was made up to 500 mL with ddH2O and stored in a 
dry place.  
Acrylamide 40% contains acrylamide and bis-acrylamide in a 29:1 ratio. Acrylamide 
can autopolymerise when dissolved in water and addition of free radicals speeds up 
this process. Bis-acrylamide serves as a cross-linking agent for the gel formation. 
1% Ammonium Persulphate (APS): 0.1 g of ammonium persulphate was dissolved 
in 10 mL of sterile dH2O. It was prepared freshly and stored at 4 °C. It serves as 
source of free radicals and initiates polymerisation. 
Tetramethylethylenediamine (TEMED): 99% TEMED was used to initiate 
polymerisation.  
5X Sample Preparation Buffer contains 10 mL of stacking buffer, 5 mL of glycerol, 
2 g of SDS, 5 mg of bromophenol blue and 5 mL of β-mercaptoethanol. The 
components were dissolved and stored at 4 °C in a dark tube as β-mercaptoethanol 
is light sensitive.  
Gel stain (order of addition): 7.5 g of Coomassie brilliant blue (CBB) R250, 910 mL 
methanol, 725 mL ddH2O, 375 mL glacial acetic acid.  
Destaining Buffer: 250 mL methanol and 375 mL acetic acid were made up to 
5000 mL with ddH2O.  
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12% Resolving Gel was prepared by mixing 1.376 mL deionised water, 0.866 mL 
separating buffer, 1.043 mL acrylamide, 0.188 mL 1% APS and 7.5 μL TEMED. 
Stacking Gel was prepared by mixing 0.713 mL deionised water, 0.313 mL stacking 
buffer, 0.188 acrylamide, 0.038 mL 1% APS and 5 μL TEMED. 
4.6.5.2 Buffer solutions for protein expression and purification 
1 M Tris-HCl (pH 7.4):  
60.57 g of Tris base was dissolved in 400 mL of ddH2O and adjusted pH to 7.4 with 
1 N HCl, then made up the volume with ddH2O to 500 mL and stored at room 
temperature in a dry place. 
Lysis Buffer consisted of 20 mM Tris-HCl (pH = 8) and 300 mM NaCl. 
1 M Imidazole (pH 8): 34.04 g of imidazole was dissolved in 400 mL of ddH2O, 
adjusted with 1 N HCl to pH = 8 and made up to 500 mL. The solution was stored in 
a dry place at room temperature.  
Elution Buffer consisted of 20 mM Tris-HCl, 300mM NaCl and 10-250 mM 
imidazole.  
1 M IPTG (isopropylthio-β-D-galactoside): 2.3 g of IPTG in was dissolved in 10 
mL of ddH2O and sterilised by passing it through a 0.20 μm filter (Sartorius Stedim 
Biotech, Appleton Woods, Birmingham, UK). The solution was dispensed into 1 mL 
aliquots and stored at -20 °C.  
Bovine Serum Albumin (BSA): 2 mg/mL stock concentration was diluted to 0.1 
μg/μL with water. 
4.6.5.3 Stock solutions 
Streptomycin (50 mg/mL): 500 mg streptomycin was dissolved in 10 mL of ddH2O, 
sterilised by passing it through a 0.20 μm single use mini start filter (Sartorius 
Stedim Biotech, Appleton Woods, Birmingham, UK), then dispensed into 1 mL 
aliquots and stored at -20 °C.  
Chloramphenicol (34 mg/mL): 340 mg chloramphenicol was dissolved in 10 mL of 
100% ethanol, then dispensed into 1 mL aliquots and stored at -20 °C.  
25X EDTA-free Protease Inhibitor: One complete Mini protease inhibitor cocktail 
tablet (Roche Diagnostics GmBH, Basel, Switzerland) was completely dissolved in 2 
mL of sterile water, divided in 500 μL aliquots and stored at -20 °C. 
1X EDTA-free Protease Inhibitor: 400 μL of the 25X stock was added to 10 mL of 
lysis buffer. 
4.6.5.4 Western Blot 
Transfer Buffer consisted of 24 mM Tris, 192 mM glycine and 20% methanol. 
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TBST (Tris-Buffered Saline with Tween) consisted of 50 mM Tris HCl pH 7.4, 150 
mM NaCl and 0.05% Tween 20. 
TBS (Tris-Buffered Saline) consisted of 50 mM Tris HCl pH 7.4, 150 mM NaCl. 
4.6.5.5 Bacterial transformation  
The competent cells were kept on ice. 50 μL of competent cells and 1 μL of purified 
plasmid was added into a sterile, ice-cold 12 mL PP-tube (Greiner® Bio-one) and 
incubated for 10 min on ice. The tube was kept for 40 s in a water bath at 42 °C to 
provide a heat shock. The cells were then put immediately on ice for an additional 2 
min. 900 μL of LB medium was then added to the tubes and the cells incubated at 
37 °C for 1 h at 180 rpm. 100 μL of incubated culture was spread on the LB-agar 
plates containing the appropriate antibiotic (either streptomycin alone or in 
combination with chloramphenicol). The plates were allowed to dry and incubated at 
37 °C for 18 h. 
4.6.5.6 Seed cultures  
4.6.5.6.1 E.coli for heterologous expression 
Seed cultures of E. coli were prepared in sterile conditions with 10 mL of sterile LB 
broth in a 50 mL Falcon tube containing the appropriate antibiotic (streptomycin 50 
μg/mL and/or chloramphenicol 34 μg/mL), and inoculated with one colony from a 
solid agar culture or a small amount from a 50% glycerol stock using a sterile 
disposable loop. The culture was then incubated at 37 °C, 180 rpm for 18 h.  
4.6.5.6.2 Mycobacterial species for SPOTi 
M. aurum (NC 10437), M. smegmatis mc2155 and M. bovis BCG Pasteur cultures 
were prepared in sterile conditions with 10 mL Difco Middlebrook 7H9 broth 
(containing 0.02% glycerol and 0.05% Tween 80) supplemented with 10% ADC and 
inoculated with a small amount from a 50% glycerol stock. The culture was 
incubated at 35 °C, for M. aurum and smegmatis, at 37 °C for M. bovis BCG, with 
180 rpm shaking.  
Growth of cultures was monitored by measuring the turbidity of the culture 
suspension (as optical density, OD) at 600 nm in a cell density meter (WPA Biowave 
CO 8000). When the cultures reached mid-exponential phase they were passaged 
twice into fresh medium. Once OD reached 0.8, dilutions were carried out in fresh 
medium to obtain 10-3 dilutions, (10-2 in the case of M. aurum), prior to their use for 
SPOTi. The undiluted bacterial cultures were cryopreserved as stated in Chapter 
4.6.5.9. 
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4.6.5.6.3 E.coli for SPOTi 
E. coli DH5α cultures were initiated from glycerol stocks in 10 mL Luria Broth 
medium using 1% inoculum and grown at 37 °C at 180 rpm overnight. The culture 
was passaged once before the experiment. Once OD reached 0.8, dilutions were 
carried out in fresh LB medium to obtain 10-3 dilution prior to use for the SPOTi 
assay.  
4.6.5.7 Long-term preservation of bacterial cultures 
50 % (v/v) glycerol stocks were used for long-term storage of all bacterial cultures. 
500 μL of sterile glycerol was mixed in a cryovial (Corning®) with 500 μL of seed 
culture and the mixture inverted 10 times. The cryovial was stored in a -80 °C 
freezer. 
4.6.5.8 Heterologous expression of proteins in E. coli 
4 mL of seed culture was inoculated in 400 mL LB medium supplemented with 50 
μg/mL of streptomycin and 34 μg/mL of chloramphenicol and incubated at 37 °C at 
180 rpm constant rotation until OD600 = 0.5. 
1 M IPTG was added, reaching a final 0.5 mM concentration, to induce protein 
expression and the culture was incubated for 18 h at 18 °C with 180 rpm constant 
rotation. IPTG was not added to one culture that was kept as a control (uninduced). 
After incubation the cells were harvested at 4 °C at 9000 rpm for 15 min (Beckmann 
Coulter® JLA 10.25). The supernatant was discarded, the pellet thoroughly 
resuspended in ice-chilled lysis buffer containing 1X protease inhibitor (5 mL for 
each 400 mL culture) and sonicated (Soniprep® 150) at 10 microns amplitude for 5 
cycles (30 s active sonication followed by 1 min break) while keeping the tube 
immersed in a water-ice mixture. A small sample was then kept for the estimation of 
the whole protein content. A further centrifugation cycle of 45 minutes at 20 000 rpm 
at 4 °C (Beckmann Coulter® JA 25.5) followed. The supernatant containing the 
soluble proteins was filtered and divided into 1 mL aliquots. Cell pellet and lysate 
contents were compared to those of the total protein and uninduced sample through 
SDS-PAGE gel electrophoresis. The cell lysate was then carried forward to the 
purification step.  
4.6.5.9 SDS-PAGE gel electrophoresis  
Unless otherwise specified, all the samples loaded on the SDS-PAGE gels were 
prepared with 16 μL of sample and 4 μL of 5X sample preparation buffer mixed in an 
Eppendorf tube by 15 s centrifugation. The samples were then heated to 100 °C for 
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10 min and centrifuged for 15 s. 18 μL was loaded on the gel, next to a 5 μL load of 
PageRuler® Ladder or, if preparing for a western blot, with Spectra Multicolor® 
Ladder. The gel was run at 200 V (Bio-Rad Powerpac 300) for 45-60 min until the 
dye front ran out of the bottom of the gel. Following the run, the gel was stained in 
Coomassie staining solution for 5 min, then washed with water for 5 min and 
destained overnight with destaining solution on a Mini orbital shaker SO5 (Stuart 
Scientific, Stone, UK). 
4.6.5.10 Purification of Rv3712 with Ni-NTA resin 
This type of purification uses affinity chromatography columns. In this case, the 
molecule that needs to be isolated has been designed to express 6 consecutive His 
residues. The resin consists of nickel-charged nitrilotriacetic acid chelate 
immobilised on 6% cross-linked agarose. The metal has a high affinity for His. 
The procedure involved used a gravity-flow column containing 4 mL of resin. The 
supernatant containing the soluble proteins was loaded on the column after a 10 
column-volume (CV) pre-equilibration with lysis buffer. Fractions containing unbound 
proteins were collected. Subsequently 10 CV of 10 mM imidazole in elution buffer 
was loaded and fractions collected. Finally sequential 1 CV of increasing imidazole 
dilutions was used to elute the protein which was collected in fractions. 
Recombinant proteins were eluted with 250 mM imidazole. The collected fractions 
were analysed through 12% SDS-PAGE electrophoresis gels.  
Regeneration of the column involved sequential washes with 3 CV of deionised 
water, 3 CV of 0.5 M NaOH, 2 CV of deionised water and 3 CV of lysis buffer. The 
column was then stored at 4 °C. In the case of long-term storage, an additional 3 CV 
wash with 70% ethanolwas required.  
4.6.5.11 Bradford Assay 
This colorimetric assay is utilised to estimate the concentration of protein in a 
sample. Bovine serum albumin (BSA) is used as the protein standard dilution of 
which allows the construction of a calibration curve. 
The Bradford reagent essentially consists of Coomassie Blue G-250.  
The assay is carried out on a 96-well plate as outlined in Table 3.1. The 
concentration of each sample was determined by comparison of the measured value 
with those from the BSA calibration curve. Absorbances were measured using a 
fluorimeter at 595 nm (Fluostar Optima®, BMG Labtech). 
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Well 
 
BSA 
(µL) 
 
Water 
(µL) 
 
Protein 
(µL) 
Sample Final 
Concentration 
(µg/µL) 
Bradford 
Reagent 
(µL) 
A 0 150 - 0.000 150 
B 10 140 - 0.007 150 
C 20 130 - 0.013 150 
D 30 120 - 0.020 150 
E 40 110 - 0.027 150 
F 50 100 - 0.033 150 
G - 148 2 sample 150 
Table 4.1 Bradford assay plate set-up 
4.6.5.12 Western blot 
A 10% SDS-PAGE gel was prepared and loaded with the appropriate marker, as 
described in Chapter 4.6.5.9. After the run, the gel was passed briefly in water twice 
and left for 15 min in transfer buffer. 
One nitrocellulose membrane, cut to fit the size of the gel, was immersed for 30 s in 
methanol, 1 min in ddH2O and finally left for 15 min in transfer buffer. 
Six 3mm Whatman® blotting papers, cut to fit the size of the gel, were left for 15 min 
in transfer buffer. 
The different layers were assembled inside a Bio-Rad® Trans-Blot SD Semi-Dry 
Transfer Cell in the following order, from bottom to top: 3 filter papers, the 
membrane, the gel, 3 filter papers. The cell was closed and a 15 V potential 
difference applied across the system for 1 h. 
The membrane was then removed from the cell and immersed in 5% fat-free milk in 
TBST at -4 °C for 16 h. It was then transferred to 3% fat-free milk in TBST solution 
three times for 10 min, followed by 1 h immersion in a solution of 6x-HIS Epitope 
Tag Monoclonal Antibodies in 3% fat-free milk in TBST.  The membrane was then 
washed three times for 10 min in 3% fat-free milk in TBST, then once in TBST for 10 
min and once in TBS for 10 min. Finally a SIGMAFAST™ Protease Inhibitor Cocktail 
Tablet, EDTA-free solution was poured onto the membrane and left until the bands 
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started appearing. The membrane was then removed and stored in between two 
filter papers.  
4.6.5.13 High-throughput spot culture growth inhibition assay (HT-SPOTi) 
HT-SPOTi was a spot culture assay used to screen the antibacterial properties of a 
compound against a population of bacterial cells (191). The semi-automated assay 
was conducted in a 96-well plate. The peptides were dissolved in H2O and diluted to 
a 50 mg/mL concentration. 20 μL of solution was used to prepare a series of two-
fold dilutions, 2 μL of which were then dispensed into each well of a 96-well plate to 
which 200 μL of agar, kept at 55 °C, was added (Middlebrook 7H10 agar, 
supplemented with 0.05% (v/v) glycerol and 10% (v/v) OADC for mycobacteria, LB 
agar for E. coli). The highest concentration used was 500 μg/mL. Wells with no 
compound (H2O only) and INH were used as experimental controls. To all the plates, 
2 μL of early to mid-log bacterial culture was spotted in the middle of each well and 
the plates were incubated (M. aurum 35 °C for five days, M. smegmatis 35 °C for 
three days, M. bovis BCG 37 °C for fourteen days, E. coli 37 °C overnight). The 
assay result was evaluated by direct eye observation of the appearance of spots 
(191). 
4.7 Synthetic methods 
H-Ala-D-Glu(Lys-D-Ala-D-Ala-OH)-OH (53). Pentapeptide 53 was synthesised 
starting from Fmoc-D-Ala-Wang resin. The synthesis was carried out both 
automatically (0.080 mmol) and manually (0.160 mmol) as described in the general 
methods. Lys was introduced as its side chain Boc-protected derivative. Fmoc-D-
Glu-OtBu was coupled to the Lys α-amino group via its side chain γ-carboxyl group. 
The two crude samples were combined for purification via RP-HPLC to afford the 
title compound as an amorphous white solid (50 mg, 43%). ESI-MS (C20H36N6O8) 
488.26 m/z (%): 977.40 [2M+H]+ (100). RP-HPLC: Rt = 7.39 min. 
1H NMR (H2O + 
D2O): δ = 1.34 (d, 3H, J = 7.2, D-Ala CH3), 1.34-1.47 (m, 2H, Lys δCH2), 1.39 (d, 3H, 
J = 7.3, D-Ala CH3), 1.51 (d, 3H, J = 7.1, L-Ala CH3), 1.64 (m, 2H, Lys εCH2), 1.71-
1.79 (m,  2H, D-Glu βCH), 1.97 (m, 1H, Lys βCHa), 2.16 (m, 1H, Lys βCHb), 2.36 (m, 
2H, Lys γCH2), 2.95 (t, 2H, J = 5.15, D-Glu γCH2), 4.09 (q, 1H, J = 6.95 – 14.0, L-Ala 
αCH), 4.21 (q, 1H, J = 6.7 – 14.1, D-Glu αCH), 4.28-4.34 (m, 3H, Lys and 2 x D-Ala 
αCH), 8.26 (d, 1H, J = 6.0, NH), 8.32 (d, 1H, J = 7.3, NH), 8.42 (d, 1H, J = 6.5, NH), 
8.68 (d, 1H, J = 7.4, NH). 
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H-Ala-D-Glu(Lys-OH)-OH (54) Tripeptide 54 was synthesised automatically on 
0.080 mmol scale using Fmoc-Lys(Boc)-Wang resin as described in the general 
methods. The manual synthesis was conducted on a 0.132 mmol scale as specified 
in the general methods.  
The two crude samples were combined for purification via RP-HPLC to afford the 
title compound as a white solid (30 mg, 41%). ESI-MS (C14H26N4O6) 346.19 m/z (%): 
347.4 [M+H]+ (55). RP-HPLC: Rt = 4.74 min. 
1H NMR (H2O + D2O): δ = 1.44 (m, 2H, 
Lys δCH2) 1.50 (d, 3H, J = 6.5, L-Ala CH3), 1.65 m, 2H, Lys εCH2), 1.72 (m,  1H, D-
Glu βCHa), 1.86 (m, 1H, D-Glu βCHb), 2.00 (m, 1H, Lys βCHa), 2.18 (m, 1H, Lys 
βCHb), 2.38 (m, 2H, Lys γCH2), 2.95 (t, 2H, J = 5.65, D-Glu γCH2), 4.08 (q, 1H, J = 
7.0 – 14.0, L-Ala αCH), 4.28-4.36 (m, 2H, D-Glu αCH and Lys αCH), 8.32 (d, 1H, J = 
7.2, NH), 8.70 (d, 1H, J = 7.4, NH).  
H-Ala-D-Glu(Lys-D-Ala-OH)-OH (55). Tetrapeptide 55 was synthesised starting 
from Fmoc-D-Ala-Wang resin. The synthesis was carried out both automatically 
(0.080 mmol) and manually (0.160 mmol) as described in the general methods. Lys 
and D-Glu were introduced as described for 53. 
The two crude samples were combined for purification via RP-HPLC to afford the 
title compound as an amorphous white solid (20 mg, 20%). ESI-MS (C17H31N2O7) 
417.19 m/z (%): 222.1 [M+2H+Na]2+ (55), 417.9 [M+H]+ (20). RP-HPLC: Rt = 7.22 
min. 1H NMR (90% H2O/D2O): δ = 1.37 (d, 3H, J = 7.3, D-Ala CH3), 1.44 (m, 2H, Lys 
δCH2), 1.52 (d, 3H, J = 7.0, L-Ala CH3), 1.65 (m, 2H, Lys εCH2), 1.72 (m, 1H, D-Glu 
βCHa), 1.78 (m, 1H, D-Glu βCHb), 1.99 (m, 1H, Lys βCHa), 2.18 (m, 1H, Lys βCHb), 
2.39 (m, 2H, Lys γCH2), 2.96 (t, 2H, J = 5.7, D-Glu γCH2), 4.09 (q, 1H, J = 7.0 - 14.0, 
L-Ala αCH), 4.28 (q, 1H, J = 7.0 – 13.5, D-Glu αCH), 4.33 (q, 2H, J = 7.3 – 14.0, Lys 
and D-Ala αCH), 8.24 (d, 1H, J = 6.9, D-Glu NH), 8.37 (d, 1H, J = 10.5, Lys NH), 
8.67 (d, 1H, J = 7.4, D-Ala NH). 
H-Ala-D-Glu-OH (56). Both manual and automated syntheses were initially 
attempted starting from Fmoc-D-Glu(OtBu)-Wang resin on 0.080 mmol scale using 
the procedures described in the general methods but unfortunately preparative RP-
HPLC did not result in the isolation of the desired dipeptide. 
Subsequently, Fmoc-D-Glu(OtBu)-OH 59 (0.25 g, 0.60 mmol, 1.1 equiv) was loaded 
on 2-chlorotrityl chloride resin (0.41 g, 1.33 mmol g-1 substitution, 0.54 mmol). Both 
the resin and the amino acid were dried for 3 days in a desiccator prior to loading. 
The resin was then allowed to swell in 1 mL of freshly distilled dry CH2Cl2 under an 
N2 atmosphere. The amino acid was dissolved in a minimal amount of dry CH2Cl2 
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and DIEA (0.41 mL, 2.38 mmol, 4.4 equiv) was added. The mixture was added to 
the resin and the suspension stirred at room temperature for 2 h. The resin was then 
transferred to a solid phase reaction vessel and washed 3 times with 
CH2Cl2/MeOH/DIEA (17:2:1), 3 times with CH2Cl2, twice with DMF and twice with 
CH2Cl2. It was then drained and dried in a desiccator overnight. The dipeptide 
sequence was completed using the standard deprotection and coupling (Fmoc-Ala-
OH) procedures, followed by cleavage and isolation, described in the general 
methods, The product was freeze-dried overnight and purified. RP-HPLC yielded the 
title peptide as an amorphous white solid (77 mg, 47%). ESI-MS (C8H14N2O5) 218.09 
m/z (%): 219.01 [M+H]+ (100). RP-HPLC: Rt = 6.01 min. 
1H NMR (H2O + D2O): δ = 
1.48 (d, 3H, J = 7.1, L-Ala CH3), 1.94 (m, 1H, D-Glu βCHa), 2.15 (m, 1H, D-Glu βCHb), 
2.40 (t, 2H, J = 7.4, D-Glu γCH2), 4.06 (q, 1H, J = 7.1 – 14.1, L-Ala αCH), 4.31 (q, 1H, 
J = 8.1 – 16.1, D-Glu αCH), 8.55 (d, 1H, J = 7.5, L-Ala NH). 
Leu-enkephalin (61). The sample used for generation of the calibration curve was 
synthesised manually as described in the general methods, on 0.210 mmol scale 
starting from Fmoc-Leu-Wang resin. Purification lead to the isolation of the title 
compound as an amorphous white solid (43 mg, 37%). ESI-MS (C28H37N5O7) 555.27 
m/z (%): 1111.50 [2M+H]+ (100), 578.30 [M+Na]+ (50). RP-HPLC: Rt = 13.11 min. 
The calibration curve (Fig. 4.1) was obtained starting from a stock solution made by 
dissolving 2 mg of the pure sample in 1 mL of water. Five two-fold serial dilutions of 
the stock solution were prepared and the six samples analysed in triplicate by HPLC. 
The mean AUC of the desired peak was plotted for each concentration of standard 
solution to generate the calibration curve.  
 
Figure 4.2 Calibration curve for Syro I optimisation using Leu-enkephalin 
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The syntheses for the automated coupling protocol evaluation using the gravimetric 
method were carried out in quadruplicate, while those analysed using the calibration 
curve interpolation were performed in triplicate. The crude samples were obtained 
starting from 100 mg of Fmoc-Leu-Wang resin (0.069 mmol). SPPS, work-up and 
cleavage proceeded largely as described in the general methods and according to 
the protocol being examined (Tables 2.2 and 2.3).  
The resin was swelled in 1 mL of DMF for 1 hour (excluding Table 2.3 entry #9, 
which omitted the swelling step). Nα-Fmoc deprotection was achieved as described 
in the general methods by treatment with 40% piperidine in DMF for 3 min and with 
20% piperidine for 12 min, followed by washing with DMF. Automated couplings 
used variable excesses (refer to Tables 2.2. and 2.3) of amino acid residue, 
activated using an equimolar amount of HBTU and a two-fold excess (over activated 
amino acid) of DIEA. Couplings were allowed to proceed for the appropriate amount 
of time for the selected protocol. The resins were then washed with DMF and the 
reagents replaced for a second and third coupling if required. After final deprotection 
and washing (DMF), the resins were finally washed three times with a 1:1 mixture of 
CH2Cl2 and methanol. The resins were placed in a desiccator for 2 h. The peptides 
were removed from the resins by acidolysis using TFA. The peptide-resin was 
treated with 0.25% v/v TIS and 0.25% v/v water in TFA, stirring for 2 h. The mixture 
was then filtered and the resin beads washed once with TFA. The TFA was 
removed under a stream of nitrogen gas and the crude peptide precipitated from 
cold diethyl ether, extracted into 95% aqueous ethanoic acid and lyophilised.  
Analysis of the samples was achieved via RP-HPLC. Sample absorbance was 
recorded at 214 or 254 nm. The crude sample was diluted in 10 mL of Solvent A and 
2 mL of Solvent B. The value of the AUC of the peak of interest was taken and 
substituted into the equation of the line of best fit of the calibration curve. The 
calculated concentration of the pure peptide present in the crude sample  was 
multiplied by 555.6 g mol-1 (molecular weight of Leu-enkephalin) and the mass of 
the pure peptide present in the entire sample was obtained. These masses were 
used to calculate the yield of each protocol evaluated. The results were compared 
and examined for statistical significance using a one-way ANOVA test, performed 
using GraphPad Prism 7.  
ACP 65-74 (62). The peptide was synthesised automatically starting from 400 mg of 
Fmoc-Gly-Wang (0.78 mmol/g) and cleaved as described in the general synthetic 
procedure (Chapter 4.3) to yield a crude mass of 0.137 g. 64 mg of the crude 
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material was purified via preparative HPLC to yield 4.6 mg (1.4% yield) of pure 
product as an amorphous white solid. ESI-MS (C47H74N12O16) 1062.53 m/z (%): 
1085.55 [M+Na]+ (90). RP-HPLC: Rt = 9.803 min. 
 
Figure 4.3 Calibration curve for Syro I optimisation using ACP 65-74 
The calibration curve (Fig. 4.2) was obtained starting from a stock solution made by 
dissolving 4.6 mg of pure 62 in 1 mL of water. Four two-fold serial dilutions of the 
stock solution were prepared and the five samples analysed in triplicate by HPLC. 
The mean AUC of the desired peak was plotted for each concentration of standard 
solution to generate the calibration curve.  
The syntheses for the automated protocol evaluation were carried out in triplicate 
starting from 50 mg of Fmoc-Gly-Wang (0.039 mmol). SPPS, work-up and cleavage 
proceeded as described in the general methods and according to the protocol being 
examined (Table 2.4).  
The resin was swelled in 1 mL of DMF for 1 hour (excluding Table 2.4 entry #9, 
which omitted the swelling step). Nα-Fmoc deprotection was achieved as described 
in the general methods by treatment with 40% piperidine in DMF for 3 min and with 
20% piperidine for 12 min, followed by washing with DMF. Automated couplings 
used variable excesses (refer to Table 2.4) of amino acid residue, activated using an 
equimolar amount of HBTU and a two-fold excess (over activated amino acid) of 
DIEA. For the protocol in Table 2.4 entry #10, 2.5 equiv of HOBt was added to the 
coupling mixture. Couplings were allowed to proceed for the appropriate amount of 
time for the selected protocol. The resins were then washed with DMF and the 
reagents replaced for a second and third coupling if required. After final deprotection 
and washing (DMF), the resins were finally washed three times with a 1:1 mixture of 
CH2Cl2 and methanol. The resins were placed in a desiccator for 2 h. The peptides 
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were removed from the resins by acidolysis using TFA. The peptide-resin was 
treated with 0.25% v/v TIS and 0.25% v/v water in TFA, stirring for 2 h. The mixture 
was then filtered and the resin beads washed once with TFA. The TFA was 
removed under a stream of nitrogen gas and the crude peptide precipitated from 
cold diethyl ether, extracted into 95% aqueous ethanoic acid and lyophilised.  
Analysis of the samples was achieved via RP-HPLC. Sample absorbance was 
recorded at 214 or 254 nm. The crude sample was diluted in 5 mL of Solvent A and 
1 mL of Solvent B. The mean of the AUC values measured for ACP 65-74 peak for 
each protocol repetition was taken and substituted into the equation of the line of 
best fit of the calibration curve. The calculated concentration of the pure peptide 
present in the crude sample was multiplied by 1063.16 g mol-1 (molecular weight of 
ACP 65-74) and the mass of the pure peptide present in the entire sample was 
determined. These masses were used to calculate the yield of each protocol 
evaluated 
The results were compared and examined for statistical significance using a one-
way ANOVA test, performed using GraphPad Prism 7.  
H-Val-D-Glu(Lys-OH)-OH (63). Tripeptide 63 was obtained automatically on 0.025 
mmol scale, starting from Fmoc-Lys(Boc)-Wang resin, as described in the general 
methods. HPLC analysis of the crude peptide (white amorphous solid, 7.7 mg, 82%) 
indicated only a single major product. The crude product was used for biological 
evaluation without further purification.  ESI-MS (C16H30N4O6) 374.22 m/z (%): 373.30 
[M-H]- (100). RP-HPLC: Rt = 7.84 min.  
H-Leu-D-Glu(Lys-OH)-OH (64). Tripeptide 64 was obtained automatically on 0.025 
mmol scale, starting from Fmoc-Lys(Boc)-Wang resin, as described in the general 
methods. HPLC analysis of the crude peptide (white amorphous solid, 7.0 mg, 72%) 
indicated only a single major product. The crude product was used for biological 
evaluation without further purification.. ESI-MS (C17H32N4O6) 388.23 m/z (%): 411.2 
[M+Na]+ (100), 389.20 [M+H]+ (14). RP-HPLC: Rt = 8.39 min. 
H-Ile-D-Glu(Lys-OH)-OH (65). Tripeptide 65 was obtained automatically on 0.025 
mmol scale, starting from Fmoc-Lys(Boc)-Wang resin, as described in the general 
methods. HPLC analysis of the crude peptide (white amorphous solid, 7.7 mg, 79%) 
indicated only a single major product. The crude product was used for biological 
evaluation without further purification. ESI-MS (C17H32N4O6) 388.23 m/z (%): 411.3 
[M+Na]+ (100), 389.20 [M+H]+ (12). RP-HPLC: Rt = 8.38 min. 
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H-Ala-D-Glu(Arg-OH)-OH (66). Tripeptide 66 was obtained automatically on 0.025 
mmol scale, starting from Fmoc-Arg(Pbf)-Wang resin, as described in the general 
methods. HPLC analysis of the crude peptide (white amorphous solid, 8.1 mg, 86%) 
indicated only a single major product. The crude product was used for biological 
evaluation without further purification. ESI-MS (C14H26N6O6) 374.19 m/z (%): 375.20 
[M+H]+ (100). RP-HPLC: Rt = 7.51 min. 
H-Ala-D-Glu(Lys-Gly-Gly-OH)-OH (67). Pentapeptide 67 was obtained 
automatically as on 0.025 mmol scale, starting from Fmoc-Gly-Wang resin, 
described in the general methods. HPLC analysis of the crude peptide (white 
amorphous solid, 7.8 mg, 68%) indicated only a single major product. The crude 
product was used for biological evaluation without further purification. ESI-MS 
(C18H32N6O8) 460.23 m/z (%): 921.40 [2M+H]
+ (100), 943.40 [2M+Na]+ (15). RP-
HPLC: Rt = 7.35 min. 
Diethyl-2-acetamido-2-allylmalonate (108). Sodium metal (5.3 g, 0.230 mol) was 
dissolved in 250 mL of absolute ethanol and diethylacetamidomalonate (50.0 g, 
0.230 mol, 1 equiv) was added in one portion, stirring to ensure complete dissolution. 
Allyl bromide (28.87 mL, 0.316 mol, 1.4 equiv) was then added and the reaction 
mixture was stirred under reflux for 48 h at 110 °C. The mixture was cooled to room 
temperature and the mixture was concentrated under reduced pressure. Water (200 
mL) was added to the residue followed by extraction with chloroform (200 mL). The 
aqueous layer was extracted twice more with 100 mL of fresh chloroform. The 
combined organic layers were washed with 300 mL of brine, dried with MgSO4, 
filtered and evaporated to obtain a yellow oil. The product was taken up in 20 mL of 
ethanol and poured into 300 mL of ice-water, then stirred until a waxy white 
precipitate formed. The precipitate was filtered and washed several times with ice 
water, and dried in a desiccator overnight to yield the title compound as a white solid 
(typically 31-50%). HRMS (ESI) m/z: Calcd for C12H20NO5 [M+H]
+ 258.1342; found 
258.1343. 1H NMR (CDCl3): δ = 1.24 (t, 6H, J = 7.1, 2 x CH2CH3), 2.01 (s, 3H, 
NHCOCH3), 3.05 (d, 2H, J = 7.4, βCH2), 4.22 (q, 4H, J = 7.1, 2 x  CH2CH3), 5.07 (s, 
1H, δCHa), 5.10 (d, 1H, J = 3.36, δCHb), 5.55 (m, 1H, γCH), 6.72 (s, 1H, NH); 
13C 
NMR (CDCl3): δ = 14.1 (CH2CH3), 23.1 (NHCOCH3), 37.1 (βC), 62.7 (CH2CH3), 66.3 
(αC), 119.9 (δC), 131.4 (γCH), 167.8 (COOCH2CH3), 169.0 (COCH3).  
2-Acetamidopent-4-enoic acid (113). NaOH (4.19 g, 0.105 mol, 1.1 equiv) was 
added in one portion to a solution of 108 (24.45 g, 0.095 mol) in 200 mL of 50% v/v 
ethanol in water. The mixture was stirred under reflux for 16 h at a 110 °C. After 
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cooling the mixture to room temperature, the ethanol was evaporated under reduced 
pressure and the remaining aqueous solution was washed with an equal volume of 
diethyl ether. The aqueous layer was acidified with 2 M HCl to pH 1.5 and extracted 
3 times with 250 mL of ethyl acetate. The combined organic layers were dried over 
MgSO4, filtered and evaporated to yield the title compound as a white solid (typically 
60-78%). HRMS (ESI) m/z: Calcd for C7H12NO3 [M+H]
+ 158.0817; found 158.0816. 
1H NMR (CD3OD): δ = 1.97 (s, 3H, CH3), 2.44 (m, 1H, βCHa), 2.59 (m, 1H, βCHb), 
4.45 (m, 1H, αCH), 4.98 (s, 1H, OH), 5.11 (m, 2H, δCH2), 5.78 (m, 1H, γCH); 
13C 
NMR (CD3OD): δ = 22.4 (CH3), 37.0 (βCH2), 53.5 (αCH), 118.6 (δCH2), 134.6 (γCH), 
173.3 (COCH3), 174.7 (COOH).  
(S)-2-Aminopent-4-enoic acid (115) (192). 113 (12.00 g, 76.40 mmol) was 
dissolved in 500 mL of distilled water. The solution was brought to pH 7.5 with 2 M 
LiOH. Acylase I from Aspergillus melleus (440 mg, 8.3 U/mmol of acyl-L-aa) was 
added and the solution left to stir at room temperature for 7 days maintaining pH 7.5. 
2 M HCl was then added to bring the pH to 5 and 1.5 g of activated charcoal was 
added. The mixture was stirred while heating it to 60 °C, then filtered through a 
Celite® pad and brought to pH 1.5 with conc. HCl. The filtrate was extracted 4 times 
with equal volumes of ethyl acetate. The organic phases were combined and 
reserved for the isolation of 114 (below). The aqueous layer volume was reduced 
under vacuum and extracted once more with 1.5 volumes of ethyl acetate. The 
aqueous phase was then evaporated and the residue washed three times with hot 
ethanol. The ethanol filtrate was evaporated, taken up in water, then freeze dried 
and stored. FDAA derivatisation (see general methods) and HPLC analysis at 340 
nm showed an R:S enantiomeric ratio of 3:97. Rf = 0.55 (nBuOH/CH3COOH/H2O 
2:1:1). 1H NMR (CD3OD): δ = 2.58 (m, 1H, βCHa), 2.69 (m, 1H, βCHb), 3.61 (m, 1H, 
αCH), 5.23 (m, 2H, δCH2), 5.82 (m, 1H, γCH), identical to the NMR spectra reported 
in literature.  
(R)-2-Acetamidopent-4-enoic acid (114) (192). The reserved organic phases were 
dried with MgSO4, filtered and evaporated to give an oil. The oil was dissolved in 
acetone and evaporated under reduced pressure to give the title compound as white 
solid (5.11 g, 85%).  [α]D = +20.0° for a 78:22 ratio (similar to what expected given 
the published [α]D = +35.0° for the enantiomeric pure molecule (154)). Rf = 0.75 
(nBuOH/AcOH/H2O 2:1:1). 
1H NMR (CD3OD): δ = 1.97 (s, 3H, COCH3), 2.43 (m, 1H, 
βCHa), 2.58 (m, 1H, βCHb), 4.44 (q, 1H, J = 5.0, αCH), 5.11 (m, 2H, δCH2), 5.76 (m, 
1H, γCH). 
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(R)-2-Aminopent-4-enoic acid (116) (192). 2.5 M NaOH (101.4 mL, 253.50 mmol) 
was added to 114 (5.11 g, 32.50 mmol) and the solution stirred under reflux for 24 h 
at 110 °C. After cooling to room temperature, 5 M HCl was added until pH 7 and 
precipitation occurred. The precipitate was filtered and washed twice with hot 
ethanol. The filtrate was then evaporated under reduced pressure to yield the title 
compound as a white solid (1.02 g, 27%). FDAA derivatisation (see general 
methods) and HPLC analysis at 340 nm showed an R:S enantiomeric ratio of 80:20. 
Rf = 0.56 (nBuOH/AcOH/H2O 2:1:1). 
1H NMR (D2O): δ = 2.73 (m, 2H, βCH2), 3.98 (q, 
1H, J = 12.1, αCH), 5.37 (m, 2H, δCH2), 5.82 (m, 1H, γCH). 
13C NMR (D2O): δ = 
34.7 (αCH), 53.6 (βCH2), 120.8 (γCH), 131.2 (δCH2). 
(R)-2-((tert-Butoxycarbonyl)amino)pent-4-enoic acid (119) (193). Nα-Boc-D-
allylglycine · DCHA (100 mg, 0.25 mmol) was taken up in 10 mL of EtOAc and 
washed 2 × 10 mL of 0.5 M KHSO4. The organic layer was dried over MgSO4, 
filtered and evaporated. The free acid was used as required without further 
purification. 
(R)-tert-Butyl 2-((tert-butoxycarbonyl)amino)pent-4-enoate (49) (193). Nα-Boc-D-
allylglycine (1.00 g, 4.64 mmol) was dissolved in dry CH2Cl2 (20 mL) followed by the 
addition of DIC (0.78 mL, 5.10 mmol, 1.1 equiv), DMAP (0.17 g, 1.39 mmol, 0.3 
equiv) and tert-butanol (2.22 mL, 23.2 mmol, 5 equiv). The reaction mixture was 
allowed to stir at room temperature under an argon atmosphere for 18 h. The 
mixture was then filtered and the residue washed with CH2Cl2 (2 × 25 mL). The 
filtrate was washed with 0.5 M KHSO4 (2 × 25 mL) and the organic layer dried over 
MgSO4, filtered and evaporated. The resulting crude oil was subjected to flash 
chromatography (petroleum ether/EtOAc 19:1) to yield the title product as a white 
solid (0.74 g, 60%). RP-HPLC: Rt = 19.82 min. 
1H NMR (CDCl3): δ = 1.43 (s, 9H, 3 x 
tBu CH3), 1.45 (s, 9H, 3 x Boc CH3), 2.48 (m, 2H, βCH2), 4.24 (q, 1H, J = 6.4, αCH), 
5.03 (d, 1H, J = 4.8, NH), 5.11 (m, 2H, δCH2), 5.67 (m, 1H, γCH) identical to the 
NMR spectra reported in literature. 13C NMR (CDCl3): δ = 28.0 (tBu 3 x CH3), 28.3 
(Boc 3 x CH3), 37.0 (βCH2), 53.3 (αCH), 79.4 (tBu CCH3), 82.5 (Boc CCH3), 118.8 
(δCH2), 132.5 (γCH), 155.7 (COOCCH3), 171.9 (COOCH3).(S)-1-Benzyl 5-tert-
butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino) pentanedioate (126). A 
solution of 125 (6 g, 14.10 mmol) in methanol (120 mL) was cooled to 0 °C. A 
solution of Cs2CO3 (2.30 g, 7.06 mmol, 0.5 equiv) in methanol was added dropwise, 
while keeping the temperature constant at 0 °C. The mixture was allowed to stir at 
25 °C for 20 min, then was evaporated to dryness and co-evaporated sequentially 
with toluene, benzene and hexane. The residue was taken up in dry DMF (30 mL), 
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benzyl bromide (2 mL, 16.92 mmol, 1.2 equiv) was added and the solution was 
allowed to stir at room temperature for 18 h under an argon atmosphere. The 
volume was reduced under reduced pressure and the residue taken up in CHCl3 
and washed with water (1*10 mL) and 0.5 M KHSO4 (10 mL). The combined organic 
layers were dried over MgSO4, filtered and evaporated to yield the title compound as 
a white solid (6.73 g, 93%). Rf = 0.48 (hexane/EtOAc 2:1). ESI-MS (C31H33NO6) 
515.23 m/z (%): 538.10 [M+Na]+ (100), 1054.40 [2M+Na]+ (95). 1H NMR (CDCl3): δ 
= 1.44 (s, 9H, 3 x CH3), 1.97 (m, 1H, βCHa), 2.19 (m, 1H, βCHb), 2.31 (m, 2H, γCH2), 
4.21 (t, 1H, J = 13.9, Fmoc CH), 4.34-4.47 (m, 3H, αCH and Fmoc CH), 5.19 (s, 2H, 
OCH2Ph), 5.49 (d, 1H, J = 8.0, NH), 7.29-7.42 (m, 9H, Fmoc and benzyl CHAr), 7.59 
(d, 2H, J = 7.3, Fmoc CHAr), 7.76 (d, 2H, J = 7.5, Fmoc CHAr). 13C NMR (CDCl3): δ 
= 27.5 (βCH2), 28.1 (3 x CH3), 31.4 (γCH2), 47.2 (Fmoc CH), 53.6 (αCH), 67.1 
(OCH2Ph), 67.3 (Fmoc CH2), 120.0 (Fmoc CHAr), 125.1 (Fmoc CHAr), 127.1-128.6 
(Fmoc and benzyl CHAr). 
(S)-4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(benzyloxy)-5-oxopentan-
oic acid (124). A solution of 126 (2.62 g, 5.08 mmol) in 50% v/v TFA in CH2Cl2 (25 
mL) was allowed to stir for 2 h under an argon atmosphere and then evaporated. 
The residue was taken up in ethyl acetate and washed with sat. aq. NaHCO3 (20 
mL), 5% HCl (20 mL), sat. aq. NaCl (20 mL). The organic layer was dried over 
MgSO4, filtered and evaporated to yield the title compound as a colourless oil (2.02 
g, 87%).Rf = 0.12 (hexane/EtOAc 2:1). 
1H NMR (CDCl3): δ = 1.98 (m, 1H, βCH2a), 
2.23 (m, 1H, βCH2b), 2.41 (m, 2H,  γCH2), 4.20 (t, 1H, J = 13.4, Fmoc CH), 4.41 (d, 
2H, J = 7.2, Fmoc CH2), 4.46 (m, 1H, αCH), 5.18 (s, 2H, OCH2Ph), 5.45 (d, 1H, J = 
7.8, NH), 7.28-7.41 (m, 9H, Fmoc and benzyl CHAr), 7.58 (d, 2H, J = 7.2, Fmoc 
CHAr), 7.75 (d, 2H, J = 2.5, Fmoc CHAr). 13C NMR (CDCl3): δ = 27.5 (βCH2), 29.7 
(γCH2), 47.2 (Fmoc CH), 53.3 (αCH), 67.1 (OCH2Ph), 67.5 (Fmoc CH2), 120.0 
(Fmoc CHAr), 125.1 (Fmoc CHAr), 127.1-128.7 (Fmoc and benzyl CHAr), 135.0 
(PhC), 141.3 (COOCH2Ph), 143.7 (Fmoc Ca), 143.8 (Fmoc Cb), 156.0 (CONH), 
177.31 (COOH). 
 
(S)-Benzyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)but-3-enoate (50). 
Method A: Fmoc-Glu-OBn (2.0 g, 4.35 mmol) was suspended in benzene (100 mL). 
Copper (II) acetate monohydrate (0.22 g, 1.10 mmol, 0.25 equivl) was added and 
the mixture was stirred under argon for 1 h at room temperature. Lead tetraacetate 
(3.86 g, 8.70 mmol, 2 equiv) was added to the suspension and the mixture stirred 
under argon for 1 h at room temperature, before refluxing at 85 °C for 42 h. The 
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mixture was filtered through a Celite® pad, the filtrate diluted with ethyl acetate, then 
washed three times with water and once with brine. The organic phase was dried 
over MgSO4, filtered and evaporated to yield a yellow syrup. The crude product was 
purified via flash column chromatography (petroleum ether/EtOAc 19:1) to yield the 
title compound as a white solid (4.1 mg, 2%). Rf = 0.58 (petroleum ether/EtOAc 1:1). 
ESI-MS (C26H23NO4) 413.16 m/z (%): 621.05 [M+Pb]
+ (100). 1H NMR (CDCl3): δ = 
4.16 (t, 1H, J = 6.8, Fmoc CH), 4.34 (d, 2H, J = 6.8, Fmoc CH2), 4.92 (t, 1H, J = 4.4, 
αCH), 5.13 (s, 2H, benzyl CH2), 5.23 (m, 2H, γCH2), 5.41 (d, 1H, J = 7.3, NH), 5.85 
(m, 1H, βCH), 7.19-7.38 (m, 9H, Fmoc and benzyl CHAr), 7.52 (d, 2H, J = 7.2, Fmoc 
CHAr), 7.69 (d, 2H, J = 7.5, Fmoc CHAr). 13C NMR (CDCl3): δ = 47.2 (Fmoc CH), 
56.2 (αCH), 67.2 Fmoc CH2), 67.5 (OCH2Ph), 117.9 (γCH2), 120.0 (Fmoc CHAr), 
125.1 (Fmoc CHAr), 128.6-127.1 (Fmoc and benzyl CHAr), 132.3 (βCH).  
Method B: A solution of Fmoc-hSer-OBn (133) (1.46 g, 3.39 mmol) and oNO2SeCN 
(0.65 g, 3.73 mmol, 1.1 equiv) in dry THF (17 mL) was cooled to 0 °C. PBu3 (0.94 
mL, 3.73 mmol, 1.1 equiv) was added dropwise over 20 min and the solution was 
stirred 2 h at 25 °C. H2O2 (1.92 mL, 30%) was added at 0 °C and the reaction was 
left to stir for 16 h at 25 °C. The mixture was poured onto sat. aq. NaCl (25 mL) and 
extracted with ethyl acetate (3 × 25 mL). The organic layers were combined, 
washed with fresh sat. aq. NaCl (25 mL), dried over MgSO4, filtered and evaporated 
to give a brown oil. The crude product was purified by flash chromatography 
(petroleum ether/EtOAc 17:3) to yield the title compound as a yellow solid (0.64 g, 
45%). Rf = 0.61 (hexane/EtOAc 1:1). ESI-MS (C26H23NO4) 413.16 m/z (%): 436.1 
[M+Na]+ (100). RP-HPLC: Rt = 21.51 min.
 1H NMR (CDCl3): δ = 4.23 (t, 1H, J = 6.8, 
Fmoc CH), 4.43 (d, 2H, J = 6.8, Fmoc CH2), 5.01 (t, 1H, J = 4.3, αCH), 5.21 (s, 2H, 
benzyl CH2), 5.30 (m, 2H, γCH2), 5.52 (d, 1H, J = 7.2, NH), 5.94 (m, 1H, βCH), 7.29-
7.49 (m, 9H, Fmoc and benzyl CHAr), 7.60 (d, 2H, J = 7.2, Fmoc CHAr), 7.77 (d, 2H, 
J = 7.3, Fmoc CHAr). 
(S)-4-tert-Butyl 1-phenyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino) 
succinate (131). A solution of Fmoc-Asp(OtBu)-OH (130) (5.00 g, 12.1 mmol) in 
methanol (100 mL) was cooled to 0 °C. A solution of Cs2CO3 (1.97 g, 6.05 mmol, 0.5 
equiv) in methanol (40 mL) was added dropwise and stirred for 20 min at 25 °C. The 
volume was reduced by vacuum and the solution co-evaporated once with 
toluene,once with benzene and once with hexane. The residue was taken up in dry 
DMF (25 mL) and benzyl bromide (1.72 mL, 14.5 mmol, 1.2 equiv) was added and 
stirred overnight under argon atmosphere, at 25 °C. The volume was reduced under 
reduced pressure, the residue taken up in CHCl3 and washed once with H2O and 
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once with 0.5 M KHSO4. The organic phase was dried over MgSO4, filtered and 
evaporated to give the title compound as a white solid (6.01 g, 99%). Rf = 0.62 
(hexane/EtOAc 2:1). ESI-MS (C30H31NO6) 501.22 m/z (%): 1025.35 [2M+Na]
+ (100), 
524.25 [M+Na]+ (25). 1H NMR (CDCl3): δ = 1.42 (s, 9H,  3 x CH3), 2.79 (d, 1H, J = 
17.2, βCHa), 2.98 (d, 1H, J = 16.9, βCHb), 4.23 (t, 1H, J = 7.2, Fmoc CH), 4.37 (m, 
2H, Fmoc CH2), 4.65 (m, 1H, αCH), 5.21 (m, 2H, OCH2Ph), 5.84 (d, 1H, J = 8.5, NH), 
7.28-7.42 (m, 9H, Fmoc and benzyl CHAr), 7.59 (d, 2H, J = 7.3, Fmoc CHAr), 7.76 
(d, 2H, J = 7.5, Fmoc CHAr). 13C NMR (CDCl3): δ = 28.0 (3xCH3 tBu), 37.8 (βCH2), 
47.1 (Fmoc CH), 50.7 (αCH), 67.3 (Fmoc CH2), 67.4 (OCH2Ph), 119.9 (Fmoc CHAr), 
125.2 (Fmoc CHAr), 128.5-127.1 (Fmoc and benzyl CHAr). 
(S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-oxo-4-phenoxybutanoic 
acid (132). A solution of 131 (6.01 g, 12.00 mmol) in 50% CH2Cl2 in TFA (50 mL) 
was stirred for 2 h under argon atmosphere and then evaporated to give a yellow oil. 
The residue was taken up in ethyl acetate and washed with sat. aq. NaHCO3  (40 
mL), 5% HCl (40 mL) and sat. aq. NaCl (40 mL). The organic layer was dried over 
MgSO4, filtered and evaporated to give the title compound as a white solid (5.05 g, 
94%). Rf = 0.16 (hexane/EtOAc 2:1). ESI-MS (C26H23NO6) 445.15 m/z (%): 443.80 
[M-H]- (90). 
(S)-Benzyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-hydroxybutanoate 
(133). A solution of 132 (2.43 g, 5.46 mmol) in dry THF (15 mL) was cooled 
to -10 °C, treated with N-methylmorpholine (634 μL, 5.77 mmol, 1.05 equiv) and 
stirred for 5 min under argon atmosphere at -10 °C. Isobutyl chloroformate (754 μL, 
5.77 mmol, 1.05 equiv) was added dropwise and the mixture stirred for 30 min under 
an argon atmosphere at -10 °C. The mixture was filtered through a Celite® pad, 
washing thoroughly with THF, and the filtrate was collected and cooled to -10 °C. 
NaBH4 (0.312 g, 8.25 mmol, 1.5 equiv), pre-dissolved in H2O (4 mL), was added 
dropwise. The mixture was then stirred for 1 h at 0 °C and 1 h at 25 °C. The 
suspension was diluted with EtOAc and washed once with 1 M KHSO4, once with 
sat. aq. NaHCO3 and once with sat. aq. NaCl. The organic layer was dried over 
MgSO4, filtered and evaporated and the crude product was purified by flash 
chromatography (petroleum ether/EtOAc 1:1) to yield the title compound as a white 
solid (1.16 g, 50%). Rf = 0.25 (petroleum ether/EtOAc 1:1). ESI-MS (C26H25NO5) 
431.17 m/z (%): 430.70 [M-H]- (25), 296.10 (100). 1H NMR (CDCl3): δ = 1.73 (m, 1H, 
βCH2a), 2.18 (m, 1H, βCH2b), 2.71 (m, 1H, OH), 3.56-3.72 (m, 2H, γCH2), 4.22 (t, 1H, 
J = 6.28, Fmoc CH), 4.43 (m, 2H, Fmoc CH2), 4.59 (m, 1H, αCH), 5.20 (dd, 2H, J = 
12.24, 16.36, OCH2Ph), 5.70 (d, 1H, J = 7.8, NH), 7.41-7.29 (m, 9H, Fmoc and 
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benzyl CHAr), 7.59 (d, 2H, J = 7.4, Fmoc CHAr), 7.76 (d, 2H, J = 7.5, Fmoc CHAr). 
13C NMR (CDCl3): δ = 35.6 (βCH2), 47.2 Fmoc CH), 51.3 (αCH), 58.3 (γCH2), 62.1 
(Fmoc CH2), 67.3 (OCH2Ph), 120.0 Fmoc CHAr), 125.0 (Fmoc CHAr), 12.7-127.1 
(Fmoc and benzyl CHAr). 
(2R,7R)-Di-tert-butyl 2,7-bis((tert-butoxycarbonyl)amino)oct-4-enedioate (136). 
10 mg (0.037 mmol) of Nα-Boc D-allylglycine tert-butyl ester (49) and 1.56 mg (0.002 
mmol, 5 mol %) of Grubbs 2nd generation catalyst were transferred and sealed into a 
microwave vial. Using a needle the vial was evacuated and then filled with N2. 300 
μL of dry CH2Cl2 was injected into the vial and the mixture stirred for 30 s before 
placing the vial in the microwave. The sample was irradiated for 10 min at a target 
temperature of 40 °C, then 10 min at 65 °C, 10 min at 120 °C and 10 min at 130 °C. 
Each time a TLC sample was taken for comparison. Rf = 0.13 (petroleum 
ether/EtOAc 9:1). 
(2S,6R)-1-Benzyl 7-tert-butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-6-
((tert-butoxycarbonyl)amino)hept-3-enedioate (105). 0.024 g (0.088 mmol) of Nα-
Boc D-allylglycine tert-butyl ester (49), 0.065 g (0.157 mmol, 1.8 equiv) of Nα-Fmoc 
vinylglycine benzyl ester 50 and 3.64 mg (4.28 mol, 5%) of Grubbs 2nd generation 
catalyst were transferred and sealed into a microwave vial. Using a needle the vial 
was evacuated and then filled with N2. 1.95 mL of dry CH2Cl2 was injected into the 
vial and the mixture stirred for 30 s before placing the vial in the microwave. The 
sample was irradiated for 1 h at a target temperature of 55 °C. The sample was 
evaporated to dryness to yield a brown liquid (0.082 g). The crude product was 
purified via preparative HPLC (System P2) to give the title compound as a white 
solid (4.7 mg, 8%). ESI-MS (C38H44N2O8) 656.31 m/z (%): 679.4 [M+Na]
+ (100). RP-
HPLC: Rt = 23.62 min. 
1H NMR (CDCl3) δ = 1.44 (s, 18H, Boc 3 x CH3, tBu 3 x CH3), 
2.44-2.55 (m, 2H, δCH2), 4.22-4.25 (m, 2H,εCH and Fmoc CH), 4.37-4.46 (m, 2H, 
Fmoc CH2), 4.95 (m, 1H, CH), 5.19 (d, 1H, J = 6.0, Boc NH), 5.24 (m, 2H, Bn CH2), 
5.51 (t, 1H, J = 8.4, Fmoc NH), 5.63-5.71 (m, 2H, βCH and γCH), 7.31-7.44 (m, 9H, 
Fmoc and Bn CHAr), 7.62 (2H, d, J = 7.2, Fmoc CHAr), 7.78 (2H, d, J = 7.6, Fmoc 
CHAr) identical to the NMR spectra reported in literature (147). 13C NMR (CDCl3 ): δ 
= 28.0-28.3 (2 x C(CH3)3), 35.7 (δCH2), 47.12 (εCH and Fmoc CH), 55.5 (αCH), 
67.2-67.6 (Fmoc CH2), 82.2 (tBu C(CH3)3), 120.0-128.0 (Fmoc and Bn CHAr),  128.3 
(γCH), 128.6 (βCH) 135.0 (Bn CAr), 141.3 (Fmoc 2 x CAr), 143.7 (Fmoc 2 x Car 
ortho). 
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(2S,6R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-7-(tert-butoxy)-6-((tert-
butoxycarbon-yl)amino)-7-oxoheptanoic acid  (51). 40 mg (0.062 mmol) of 
alkene 105 was dissolved in 11 mL of 9:1:1 mixture of MeOH, H2O and CH2Cl2 and 
3% dry Pt/C (0.020 g) was added. The mixture was stirred under a hydrogen 
atmosphere (balloons) at room temperature, monitoring the reaction via TLC. The 
reaction was complete after 30 h and the mixture was then filtered through a Celite® 
pad, washed with MeOH and evaporated to dryness. The residue was taken up with 
hexane and evaporated three times, followed by the addition of MeCN and freeze-
drying to yield the title compound as an amorphous white solid (35.0 mg, 72%). 
HRMS (ESI) m/z. Calcd for C31H40N2NaO8 [M+Na]
+ 591.2682; found  591.2673. RP-
HPLC: Rt = 20.11 min. 
1H NMR (CD3OD): δ = 1.32-1.35 (m, 20 H, 3xCH3 Boc,  
3xCH3 tBu, γCH2), 1.47-1.75 (m, 4H, βCH2 δCH2), 3.85 (m, 1H, εCH), 4.04 (m, 1H, 
CH), 4.13 (t, 1H, J = 6.8, Fmoc CH), 4.26 (m, 2H, Fmoc CH2), 7.21 (t, 2H, J = 7.6, 
Fmoc CHAr),-7.29 (t, 2H, J = 7.2, Fmoc CHAr), 7.58 (t, 2H, J = 6.4, Fmoc CHAr), 
7,69 (d, 2H, J = 7.2, Fmoc CHAr). 13C NMR (CD3OD): δ = 28.3-28.7 (Boc CH3 and 
tBu CH3), 32.4 (γCH2), 48.0 (Fmoc CH), 55.0 (CH), 55.8 (εCH), 68.0 (Fmoc CH2) 
80.1, 82.6 (Boc C(CH3)3 and tBu C(CH3)3), 120.09 (Fmoc CHAr), 126.3 (Fmoc 
CHAr), 128.2 (Fmoc CHAr), 128.8 (Fmoc CHAr), 142,6 (Fmoc CAr), 145.4 (Fmoc 
CAr ortho). 
H-Ala-D-Glu(mDAP-OH)-OH (52). 0.044 g of 2-ClTrt resin (0.072 mmol) was left to 
swell in dry CH2Cl2 in a sealed vessel under Ar atmosphere for 30 min. 0.020 g of 
Fmoc-mDAP(Boc,OtBu)-OH (51) (0.043 mmol, 0.6 equiv based on the 
manufacturer’s resin substitution) was dissolved in 0.44 mL (10 mL per g of resin) of 
dry CH2Cl2 in a sealed vessel under an Ar atmosphere, followed by the addition of 
0.029 mL (0.172 mmol, 4 equiv) of DIEA. The mDAP-containing solution was then 
transferred by syringe into the flask containing the resin and the mixture allowed to 
shake for 2 h. The resin was drained and washed three times with dry CH2Cl2, three 
times with 17:2:1 (v/v/v) CH2Cl2:MeOH:DIEA and shaken for 1 h in the same mixture. 
Finally the resin was washed three times with CH2Cl2 and three times with DMF. 
52 was manually synthesised, cleaved and isolated as described in the general 
methods. Purification via RP-HPLC (System P3) led to the isolation of the desired 
peptide (contaminated by a closely-eluting by-product) as an amorphous white solid 
(4.7 mg, 28%). ESI-MS (C15H26N4O8) 390.18 m/z (%): 389.14 [M-H]
- (100), 412.1 [M-
H+Na]- (75), 445.1 [M+tBu-H]- (60), 467.0 [M+tBu-2H+Na]2- (35). RP-HPLC: Rt = 
2.61 min (by-product Rt = 3.72 min). 
1H NMR (D2O+H2O): δ = 1.32 (m, 2H, mDAP 
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γCH2), 1.42 (d, 3H, J = 7.5, Ala βCH3), 1.61 (m, 1H, mDAP βCHa), 1.69-1.84 (m, 3H, 
mDAP βCHb and δCH2), 1.90 (m, 1H, Glu βCHa), 2.04 (m, 1H, Glu βCHb), 2.26 (t, 2H, 
J = 8.0, Glu γCH2), 4.01 (q, 1H, J = 7.5, 15.0, Ala αCH), 4.06 (m, 1H, mDAP αCH), 
4.11 (q, 1H, J = 5.5, 15.0, Glu αCH), 3.63 (t, 1H, J = 7.0, mDAP εCH), 7.86 (d, 1H, J 
= 7.5, mDAP NH), 8.37 (d, 1H, J = 7.0, Glu NH). 
Linear lariatin A analogue (141). 100 mg (0.085 mmol) of H-Pro-2-ClTrt resin (0.85 
mmol/g) was used for the automated synthesis of the lariatin A sequence, in which 
Glu8 was replaced with Gln8, as described in the general methods. The resin-bound 
peptide was washed thoroughly with DMF and three times with CH2Cl2:MeOH (1:1), 
dried and desiccated overnight. The peptide was cleaved and isolated according to 
the procedure described in the general methods. Purification via RP-HPLC (System 
P4) afforded the title compound as an amorphous white solid (2.8 mg, 5%). ESI-MS 
(C94H146N28O25) 2068.7 m/z (%): 1034.9 [M+2H]
2+ (40), 273.3 (100), 294.9 (97). RP-
HPLC: Rt = 9.65 min.  
Linear lariatin B analogue (142). 100 mg (0.085 mmol) of H-Pro-2-ClTrt resin (0.85 
mmol/g) was used for the automated synthesis of the lariatin B sequence, in which 
Glu8 was replaced by Gln8, as described in the general methods. The resin-bound 
peptide was washed thoroughly with DMF and three times with CH2Cl2:MeOH (1:1), 
dried and desiccated overnight. The peptide was cleaved and isolated according to 
the procedure described in the general methods. Purification via RP-HPLC (System 
P4) afforded the title compound as a white solid (8.1 mg, 4%). ESI-MS 
(C101H156N30O27) 2222.4 m/z (%): 1145.2 [M+H+3Na]
2+ (100), 1134.9 [M+2Na]2+ (77), 
1112.1 [M+2H]2+ (58). RP-HPLC: Rt = 9.59 min.  
N-Terminally truncated pyroglutamate derivative of lariatin A (via ODmab side 
chain protection strategy) (139). 100 mg (0.085 mmol) of H-Pro-2-ClTrt resin (0.85 
mmol/g) was used for the attempted automated synthesis of the cyclic lariatin A 
peptide sequence as described in the general methods. Glu8 was coupled as its 
ODmab side chain protected derivative. After the final Fmoc deprotection and 
thorough washing with DMF, the resin was transferred to SPPS a vessel for the 
manual cyclisation. This step was preceded by Dmab removal. 2% hydrazine 
monohydrate in DMF (ca. 2 mL) was added to the resin and the mixture shaken for 
3 min, followed by draining and washing with DMF. This deprotection step was 
repeated four more times. The resin was then treated with solution of 5% v/v DIEA 
in DMF (3 × 2 min). After a positive Kaiser test, the resin was washed thoroughly 
with DMF. The cyclisation was attempted by adding a solution of 34.71 mg HOAt (3 
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equiv, 0.255 mmol) and 39.5 μL DIC (3 equiv, 0.255 mmol) in DMF to the resin, 
followed by shaking for 24 h. This step was repeated three times until the Kaiser test 
provided a negative result. The resin-bound peptide was then thoroughly washed 
with DMF, washed three times with CH2Cl2:MeOH (1:1), dried and desiccated 
overnight. The peptide was cleaved and isolated according to the protocol described 
in the general methods to afford a crude mass of 0.072 g. Purification via RP-HPLC 
(System P4) resulted in the isolation of a single compound as an amorphous white 
solid (1.9 mg, 1.8%) consistent with the truncated pyroglutamyl-peptide. ESI-MS 
(C58H86N16O15) 1246.69 m/z (%): 1291.8 [M-H+2Na]
+ (100), 1247.8 [M+H]+ (70). RP-
HPLC: Rt = 10.08 min.  
N-Terminally truncated pyroglutamate derivative of lariatin B (via ODmab side 
chain protection strategy) (140). 100 mg (0.085 mmol) of H-Pro-ClTrt resin (0.85 
mmol/g) was used for the attempted automated synthesis of the cyclic lariatin B 
peptide sequence as described in the general methods. Glu8 was coupled as its 
ODmab side chain protected derivative. After the final Fmoc deprotection and 
following thorough washing with DMF, the resin was transferred to a vessel for the 
manual cyclisation. This step was preceded by Dmab removal: 2% hydrazine 
monohydrate in DMF (ca. 2 mL) was added to the resin and the mixture shaken for 
3 min, followed by draining and washing with DMF. This deprotection step was 
repeated four more times. The resin was then treated with a solution of 5% DIEA in 
DMF (3 × 2 min). After a positive result of the Kaiser test, the resin was washed 
thoroughly with DMF. The cyclisation was attempted by adding a solution of 34.7 mg 
HOAt (3 equiv, 0.255 mmol) and 39.5 μL DIC (3 equiv, 0.255 mmol) in DMF to the 
resin, followed by shaking for 24 h. This step was repeated three times, until the 
Kaiser test provided a negative result. The resin-bound peptide was then thoroughly 
washed with DMF, washed three times with CH2Cl2:MeOH (1:1), dried and 
desiccated overnight. The peptide was cleaved and isolated according to the 
protocol described in the general methods to afford a crude mass of 0.055 g. 
Purification via RP-HPLC (system P4) resulted in the isolation of a single compound 
as an amorphous white solid (3.7 mg, 3%) consistent with the truncated 
pyroglutamyl-peptide. ESI-MS (C65H96N18O17) 1440.7 m/z (%): 1423.9 [M+Na]
+ (75), 
1401.8 [M+H]+ (70), 1447.8 [M+2H+2Na]2+ (5). RP-HPLC: Rt = 10.03 min.  
Linear Asn8 free acid lassomycin analogue (143). 200 mg (0.138 mmol) of 
Fmoc-Ile-Wang (0.69 mmol/g) was used for the automated synthesis of the 
lassomycin sequence, in which Asp8 was replaced with Asn8, as described in the 
general methods. The resin-bound peptide was thoroughly washed with DMF and 
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three times with CH2Cl2:MeOH (1:1), then dried and desiccated overnight. The 
peptide was cleaved and isolated according to the procedure described in the 
general methods to yield a crude mass of 0.225 g. 90 mg of crude product was 
subjected to purification via RP-HPLC (System P5) to afford the title peptide as an 
amorphous white solid (23.0 mg, 25%). ESI-MS (C82H143N31O20) 1882.1 m/z (%): 
942.6 [M+2H]2+ (100), 472.0 [M+3H]3+ (82), 628.8 [M+4H]4+ (21). RP-HPLC: Rt = 
9.60 min.  
Linear Asn8 lassomycin methyl ester analogue (144). To 10 mg (5.00 mol) of 
143 were added 1 mL of MeOH and 1 mL of 4 M HCl in dioxane. The mixture was 
stirred at room temperature for 4 h, monitoring the reaction by HPLC. The mixture 
was poured into a mixture of 4 mL of water and 3 mL of diethyl ether. The organic 
layer was washed three times with 2 mL of water and the aqueous phases 
combined and freeze-dried. The crude product was purified using semi-preparative 
HPLC (System P6) to afford the title compound as an amorphous white solid (5.0 
mg, 45%). ESI-MS (C83H145N31O20) 1896.1 m/z (%): 475.4 [M+4H]
4+ (100), 949.4 
[M+2H]2+ (16). RP-HPLC: Rt = 10.02 min. 
Cyclic lassomycin synthesis (via ODmab side chain protection strategy) (148). 
First attempt: 200 mg (0.138 mmol) of Fmoc-Ile-Wang (0.69 mmol/g) was used for 
the automated synthesis of the peptide following the protocol of two couplings with 
2.5 equiv of activated amino acid for 30 min each time. Asp8 was coupled as its side 
chain ODmab protected derivative. The final residue was not Fmoc deprotected. 
The resin-bound peptide was thoroughly washed with DMF and three times with 
CH2Cl2:MeOH (1:1) then was transferred to a manual synthesis vessel and washed 
thoroughly with DMF. Five treatments of 3 min with 2% hydrazine monohydrate in 
DMF were performed followed by five washes with DMF. The product was treated 
three times for 2 min with 5% DIEA in DMF and then washed five times with DMF. 
After a positive Kaiser test result, a 24 h cyclisation was attempted using 64 μL (3 
equiv, 0.414 mmol) of DIC and 56.4 mg (3 equiv, 0.414 mmol) of HOAt dissolved in 
minimal DMF. The following Kaiser test was positive, therefore this step was 
repeated. After a further positive result, cyclisation of 6 h duration was attempted 
twice, using a mixture of 0.359 g (5 equiv, 0.690 mmol) of PyBOP and 0.094 g (5 
equiv, 0.690 mmol) of HOAt dissolved in DMF, and 235 μL (10 equiv, 1.38 mmol) of 
DIEA. After these treatment the Kaiser test result improved, therefore the resin was 
washed thoroughly in DMF, and three times with CH2Cl2:MeOH (1:1) and desiccated 
overnight. The resin was then cleaved and the product isolated as described in the 
general methods to yield a crude mass of 0.181 g. The crude product was subjected 
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to purification via RP-HPLC (system P7) to afford a product consistent with the 
molecular weight of the desired product (or the aspartimide adduct of the linear 
sequence, see Discussion) as a white solid (10.0 mg, 3.9%).  
Second attempt: the synthesis was repeated starting from 80 mg (0.055 mmol) of 
Fmoc-Ile-Wang (0.69 mmol/g) and the steps were carried out as described for the 
earlier attempt. As before, 24 h cyclisation with DIC and HOAt failed to give a 
negative Kaiser test therefore the peptide was treated with 5 mM NaOH in 
MeOH:H2O (1:1) for 3 h. The Kaiser test result was once more positive therefore the 
cyclisation step was repeated. After a further positive result, the same cyclisation 
reaction was attempted once again for 6 h. After this treatment the Kaiser test result 
improved, therefore the resin was washed thoroughly in DMF, and three times with 
CH2Cl2:MeOH (1:1) and desiccated overnight. The resin was then cleaved and the 
product isolated as described in the general methods to yield a crude mass of   
0.081 g.  
Third attempt: an analogous synthesis starting from 80 mg of resin was also 
performed, omitting the NaOH treatment and performing 3 DIC/HOAt cyclisation’s 
reactions of 24 h each, finally obtaining a negative Kaiser test. The crude product 
obtained (0.074 g) was combined with that of the previous attempt and subjected to 
purification via RP-HPLC (system P7) to afford a product consistent with the 
molecular weight of the desired product (or the aspartimide adduct of the linear 
sequence, see Discussion, as an amorphous white solid (3.0 mg, 1.5%). HRMS 
(ESI) m/z. Calcd for C82H140N30O20 [M+3H]
3+ 622.7032; found 622.7047. RP-HPLC: 
Rt = 9.10 min. 
Cyclic lariatin A (via OAll side chain protection strategy) (31). 
Manual SPPS 
200 mg (0.164 mmol) of H-Pro-ClTrt resin (0.82 mmol/g) was used for the manual 
synthesis of the peptide as described in the general methods. Glu8 was coupled as 
its side chain OAll protected derivative. The final residue coupled was not Fmoc 
deprotected. The peptide-resin was thoroughly washed with DMF, washed three 
times with CH2Cl2:MeOH (1:1), dried briefly under suction and desiccated overnight. 
The SPPS vessel was then sealed with a septum, the air removed and replaced with 
Ar using a balloon to maintain dry conditions. Dry CH2Cl2 was added using a syringe 
and the resin left to swell for 30 min. After removal of the CH2Cl2 via positive 
pressure of Ar, 0.019 g (2 equiv, 0.328 mmol) of dimethylamineborane, previously 
dissolved in dry CH2Cl2 (4 mL), was added to the resin in the sealed vessel and 
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allowed to stand for 30 min. Afterwards 0.189 g (1 equiv, 0.164 mmol) of Pd(PPh3)4 
was quickly and carefully added and the vessel was shaken for 1 h. The resin was 
washed four times with CH2Cl2 and four times with DMF, followed by two Fmoc 
deprotection steps of 15 min with 20% piperidine in DMF. After confirmation of the 
Fmoc removal using the Kaiser test, the resin-bound peptide was washed once with 
5% DIEA in DMF to remove any residual piperidine, followed by a thorough wash 
with DMF. One 24 h cyclisation step was performed, using 0.076 mL of DIC (3 equiv, 
0.492 mmol) and 0.067 g of HOAt (3 equiv, 0.492 mmol) in minimal DMF. Following 
a negative Kaiser test, the peptide-bound resin was thoroughly washed with DMF, 
washed three times with CH2Cl2:MeOH (1:1), dried and desiccated overnight. The 
peptide was cleaved and isolated according to the procedure described in the 
general methods to afford a crude mass of 0.217 g.  
Automated 
200 mg (0.164 mmol) of H-Pro-ClTrt resin (0.82 mmol/g) was used for the 
automated synthesis of the peptide following the protocol of two couplings with 2.5 
equiv of activated amino acid for 30 min each time. Glu8 was coupled as its side 
chain OAll protected derivative.The final residue was not Fmoc deprotected. The 
resin-bound peptide was thoroughly washed with DMF, washed three times with 
CH2Cl2:MeOH (1:1), dried briefly under suction and desiccated overnight. The resin 
was then transferred to a manual SPPS vessel. OAll deprotection, Fmoc 
deprotection and cyclisation were carried out as described for the manual procedure 
above. The resin-bound peptide was thoroughly washed with DMF, washed three 
times with CH2Cl2:MeOH (1:1), dried and desiccated overnight. The resin was 
cleaved isolated according to the procedure described in the general methods, to 
afford a crude mass of 0.235 g. 
The crude products of the manual and automated syntheses were combined and 
purified by RP-HPLC (System P4) to yield the desired lariatin A as an amorphous 
white solid (9.0 mg; 1.5%). ESI-MS (C94H143N27O25) 2051.2 m/z (%): 1026.6 
[M+2H]2+ (100), 684.7 [M+3H]3+ (70). RP-HPLC: Rt = 10.58 min.   
 
Cyclic lariatin B (via OAll side chain protection strategy) (32). 200 mg (0.164 
mmol) of H-Pro-ClTrt resin (0.82 mmol/g) was used for the automated synthesis of 
the peptide following the protocol of two couplings with 2.5 equiv of activated amino 
acid for 30 min each time. Glu8 was coupled as its side chain OAll protected 
derivative. The final residue was not Fmoc deprotected. The resin-bound peptide 
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was thoroughly washed with DMF, washed three times with CH2Cl2:MeOH (1:1), 
dried briefly under suction and desiccated overnight. The resin was then transferred 
to a manual SPPS vessel which was sealed with a septum and maintained under an 
Ar atmosphere using a balloon. Dry CH2Cl2 was added using a syringe and the resin 
left to swell for 1 h. After removal of the CH2Cl2 via positive pressure of Ar, OAll 
removal was achieved using the method described above for 31 above. After 
confirmation of the Fmoc removal using the Kaiser test, the resin-bound peptide was 
washed once with 5% DIEA in DMF to remove any residual piperidine, followed by a 
thorough wash with DMF. One 24 h cyclisation step was performed, using 0.076 mL 
of DIC (3 equiv, 0.492 mmol) and 0.067 g of HOAt (3 equiv, 0.492 mmol) in minimal 
DMF. Following a negative Kaiser test, the peptide-bound resin was thoroughly 
washed with DMF, washed three times with CH2Cl2:MeOH (1:1), dried and 
desiccated overnight. The resin was cleaved and isolated as described in the 
general methods to afford a crude mass of 0.210 g. 0.100 g of crude product was 
purified via RP-HPLC (System P4) and, after combination of the fractions, resulted 
in the isolation of a single compound as an amorphous white solid (3.1 mg, 1.8%) 
consistent with the desired product. ESI-MS (C101H153N29O27) 2205.2 m/z (%): 736.1 
[M+3H]3+ (100), 1103.1 [M+2H]2+ (15). RP-HPLC: Rt =10.40 min.   
Cyclic free acid lassomycin (via OAll side chain protection strategy) (148). 236 
mg (0.164 mmol) of Fmoc-Ile-Wang resin (0.69 mmol/g) was used for the automated 
synthesis of the peptide following the protocol of two couplings with 2.5 equiv of 
amino acid for 30 min each time. Asp8 was coupled as its side chain OAll protected 
derivative. The final residue was not Fmoc deprotected and the resin-bound peptide 
was thoroughly washed in DMF, washed three times with CH2Cl2:MeOH (1:1), dried 
briefly and desiccated overnight. The resin was then transferred to a manual SPPS 
vessel which was sealed with a septum then mantained under an Ar atmosphere 
using a balloon. Dry CH2Cl2 was added using a syringe and the resin left to swell the 
resin for 30 min.  After removal of CH2Cl2 via positive pressure of Ar, 0.019 g (2 
equiv, 0.328 mmol) of dimethylamineborane, previously dissolved in dry CH2Cl2 
(4mL), was added to the resin in the sealed vessel and allowed to stand for 30 min. 
Afterwards 0.189 g (1 equiv, 0.164 mmol) of Pd(PPh3)4 was quickly and carefully 
added and the vessel was shaken for 1 h. The resin was washed four times with 
CH2Cl2 and four times with DMF, followed by two Fmoc deprotection steps of 15 min 
with 20% piperidine in DMF. After confirmation of the Fmoc removal, using the 
Kaiser test, the resin-bound peptide was washed once with 5% DIEA in DMF to 
remove any residual piperidine, followed by a thorough wash with DMF.. A 24 h 
cyclisation step was performed, using 0.076 mL of DIC (3 equiv, 0.492 mmol) and 
175 
 
0.067 g of HOAt (3 equiv, 0.492 mmol) dissolved in minimal DMF. After a positive 
Kaiser test, the resin was washed in DMF and the 24 h cyclisation was repeated 
twice more. Unfortunately the Kaiser test remained weakly positive. The peptide-
bound resin was thoroughly washed with DMF, washed three times with 
CH2Cl2:MeOH (1:1) dried briefly under suction and then desiccated overnight. The 
resin was cleaved and the resulting peptide processed as described in the general 
methods, to afford a crude mass of 0.28 g. 70 mg of crude product were purified via 
RP-HPLC and, after combination of the fractions, resulted in the isolation of a single 
compound as an amorphous white solid (3.0 mg, 3.9%) consistent with the 
molecular weight of the desired product (or the aspartimide adduct of the linear 
sequence, see Discussion). ESI-MS (C82H140N30O20) 1865.1 m/z (%): 933.9 
[M+2H]2+ (100), 622.8 [M+3H]3+ (95), 467.45 [M+4H]4+ (20). RP-HPLC: Rt = 9.92 min.  
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4.7.1 List of compounds 
Below is a table which shows the compound number in bold and where it appears in 
the experimental section. 
Compound Nr Page  Compound Nr Page 
31 169  113 158 
32 170  114 159 
49 160  115 159 
50 161  116 159 
51 164  119 160 
52 165  124 161 
53 152  126 160 
54 153  131 162 
55 153  132 163 
56 153  133 163 
61 154  136 164 
62 155  139 166 
63 157  140 167 
64 157  141 166 
65 157  142 166 
66 158  143 167 
67 158  144 168 
105 164  148 (ODmab) 168 
108 158  148 (OAll) 171 
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